date generated: 2022-08-23
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## 5_8S_rRNA 13.3741078
## 7SK 8.2273400
## A1BG 6.5685508
## A1BG-AS1 2.0363758
## A1CF -0.3352928
## A2M -19.6839168
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2512 |
num_genes_in_profile | 26163 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8997 |
num_profile_genes_not_in_sets | 17166 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2512 |
num_genesets_excluded | 1033 |
num_genesets_included | 1479 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.68e-07 | -0.853 | 6.07e-06 |
Cohesin Loading onto Chromatin | 10 | 3.04e-06 | -0.852 | 1.63e-05 |
Laminin interactions | 23 | 4.40e-11 | -0.793 | 5.87e-10 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
Signaling by CTNNB1 phospho-site mutants | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
Signaling by GSK3beta mutants | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783 | 1.16e-06 |
Signaling by Hippo | 20 | 1.64e-09 | -0.779 | 1.78e-08 |
Syndecan interactions | 20 | 1.76e-09 | -0.777 | 1.88e-08 |
MET activates RAP1 and RAC1 | 11 | 8.89e-06 | -0.773 | 4.31e-05 |
APC truncation mutants have impaired AXIN binding | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
AXIN missense mutants destabilize the destruction complex | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
Signaling by AMER1 mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
Signaling by APC mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
Signaling by AXIN mutants | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
Truncations of AMER1 destabilize the destruction complex | 14 | 6.48e-07 | -0.768 | 4.24e-06 |
ERKs are inactivated | 13 | 1.68e-06 | -0.767 | 9.67e-06 |
MET activates PTK2 signaling | 18 | 2.19e-08 | -0.762 | 2.01e-07 |
Establishment of Sister Chromatid Cohesion | 11 | 1.50e-05 | -0.754 | 6.74e-05 |
MET promotes cell motility | 29 | 5.60e-12 | -0.739 | 8.81e-11 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 4.77e-06 | -0.733 | 2.44e-05 |
Defective EXT2 causes exostoses 2 | 13 | 4.77e-06 | -0.733 | 2.44e-05 |
tRNA processing in the mitochondrion | 20 | 1.43e-08 | 0.732 | 1.35e-07 |
Synthesis of PIPs at the early endosome membrane | 16 | 4.19e-07 | -0.730 | 2.92e-06 |
Complex I biogenesis | 57 | 1.31e-21 | 0.730 | 5.88e-20 |
Beta-catenin phosphorylation cascade | 17 | 1.86e-07 | -0.730 | 1.37e-06 |
Signaling by PDGFRA extracellular domain mutants | 12 | 1.41e-05 | -0.724 | 6.37e-05 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.41e-05 | -0.724 | 6.37e-05 |
Non-integrin membrane-ECM interactions | 42 | 8.66e-16 | -0.717 | 2.00e-14 |
Viral mRNA Translation | 87 | 6.88e-31 | 0.716 | 8.48e-29 |
Peptide chain elongation | 87 | 7.93e-31 | 0.715 | 9.02e-29 |
Signaling by PDGFR in disease | 19 | 8.03e-08 | -0.711 | 6.49e-07 |
DCC mediated attractive signaling | 14 | 4.24e-06 | -0.710 | 2.22e-05 |
Activation of RAC1 | 13 | 9.42e-06 | -0.709 | 4.53e-05 |
FOXO-mediated transcription of cell cycle genes | 15 | 2.13e-06 | -0.707 | 1.19e-05 |
HDMs demethylate histones | 22 | 1.56e-08 | -0.696 | 1.46e-07 |
Adenylate cyclase inhibitory pathway | 12 | 3.89e-05 | -0.686 | 1.58e-04 |
Eukaryotic Translation Termination | 91 | 1.29e-29 | 0.684 | 1.27e-27 |
Synthesis of PIPs at the late endosome membrane | 11 | 8.49e-05 | -0.684 | 3.19e-04 |
ERK/MAPK targets | 22 | 2.97e-08 | -0.682 | 2.66e-07 |
Selenocysteine synthesis | 91 | 3.21e-29 | 0.680 | 2.97e-27 |
Eukaryotic Translation Elongation | 92 | 5.39e-29 | 0.673 | 4.43e-27 |
Platelet sensitization by LDL | 15 | 6.79e-06 | -0.671 | 3.36e-05 |
rRNA processing in the mitochondrion | 24 | 1.27e-08 | 0.671 | 1.21e-07 |
Signaling by FLT3 fusion proteins | 19 | 4.21e-07 | -0.670 | 2.92e-06 |
Signaling by FGFR3 fusions in cancer | 10 | 2.58e-04 | -0.667 | 8.89e-04 |
Defective B4GALT7 causes EDS, progeroid type | 18 | 1.16e-06 | -0.662 | 7.07e-06 |
ALK mutants bind TKIs | 12 | 7.86e-05 | -0.658 | 2.99e-04 |
Interleukin-6 signaling | 11 | 1.74e-04 | -0.654 | 6.20e-04 |
Cell-extracellular matrix interactions | 16 | 6.27e-06 | -0.652 | 3.11e-05 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.68e-07 | -0.853000 | 6.07e-06 |
Cohesin Loading onto Chromatin | 10 | 3.04e-06 | -0.852000 | 1.63e-05 |
Laminin interactions | 23 | 4.40e-11 | -0.793000 | 5.87e-10 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
Signaling by CTNNB1 phospho-site mutants | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
Signaling by GSK3beta mutants | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.53e-07 | -0.783000 | 1.16e-06 |
Signaling by Hippo | 20 | 1.64e-09 | -0.779000 | 1.78e-08 |
Syndecan interactions | 20 | 1.76e-09 | -0.777000 | 1.88e-08 |
MET activates RAP1 and RAC1 | 11 | 8.89e-06 | -0.773000 | 4.31e-05 |
APC truncation mutants have impaired AXIN binding | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
AXIN missense mutants destabilize the destruction complex | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
Signaling by AMER1 mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
Signaling by APC mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
Signaling by AXIN mutants | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
Truncations of AMER1 destabilize the destruction complex | 14 | 6.48e-07 | -0.768000 | 4.24e-06 |
ERKs are inactivated | 13 | 1.68e-06 | -0.767000 | 9.67e-06 |
MET activates PTK2 signaling | 18 | 2.19e-08 | -0.762000 | 2.01e-07 |
Establishment of Sister Chromatid Cohesion | 11 | 1.50e-05 | -0.754000 | 6.74e-05 |
MET promotes cell motility | 29 | 5.60e-12 | -0.739000 | 8.81e-11 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 4.77e-06 | -0.733000 | 2.44e-05 |
Defective EXT2 causes exostoses 2 | 13 | 4.77e-06 | -0.733000 | 2.44e-05 |
tRNA processing in the mitochondrion | 20 | 1.43e-08 | 0.732000 | 1.35e-07 |
Synthesis of PIPs at the early endosome membrane | 16 | 4.19e-07 | -0.730000 | 2.92e-06 |
Complex I biogenesis | 57 | 1.31e-21 | 0.730000 | 5.88e-20 |
Beta-catenin phosphorylation cascade | 17 | 1.86e-07 | -0.730000 | 1.37e-06 |
Signaling by PDGFRA extracellular domain mutants | 12 | 1.41e-05 | -0.724000 | 6.37e-05 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.41e-05 | -0.724000 | 6.37e-05 |
Non-integrin membrane-ECM interactions | 42 | 8.66e-16 | -0.717000 | 2.00e-14 |
Viral mRNA Translation | 87 | 6.88e-31 | 0.716000 | 8.48e-29 |
Peptide chain elongation | 87 | 7.93e-31 | 0.715000 | 9.02e-29 |
Signaling by PDGFR in disease | 19 | 8.03e-08 | -0.711000 | 6.49e-07 |
DCC mediated attractive signaling | 14 | 4.24e-06 | -0.710000 | 2.22e-05 |
Activation of RAC1 | 13 | 9.42e-06 | -0.709000 | 4.53e-05 |
FOXO-mediated transcription of cell cycle genes | 15 | 2.13e-06 | -0.707000 | 1.19e-05 |
HDMs demethylate histones | 22 | 1.56e-08 | -0.696000 | 1.46e-07 |
Adenylate cyclase inhibitory pathway | 12 | 3.89e-05 | -0.686000 | 1.58e-04 |
Eukaryotic Translation Termination | 91 | 1.29e-29 | 0.684000 | 1.27e-27 |
Synthesis of PIPs at the late endosome membrane | 11 | 8.49e-05 | -0.684000 | 3.19e-04 |
ERK/MAPK targets | 22 | 2.97e-08 | -0.682000 | 2.66e-07 |
Selenocysteine synthesis | 91 | 3.21e-29 | 0.680000 | 2.97e-27 |
Eukaryotic Translation Elongation | 92 | 5.39e-29 | 0.673000 | 4.43e-27 |
Platelet sensitization by LDL | 15 | 6.79e-06 | -0.671000 | 3.36e-05 |
rRNA processing in the mitochondrion | 24 | 1.27e-08 | 0.671000 | 1.21e-07 |
Signaling by FLT3 fusion proteins | 19 | 4.21e-07 | -0.670000 | 2.92e-06 |
Signaling by FGFR3 fusions in cancer | 10 | 2.58e-04 | -0.667000 | 8.89e-04 |
Defective B4GALT7 causes EDS, progeroid type | 18 | 1.16e-06 | -0.662000 | 7.07e-06 |
ALK mutants bind TKIs | 12 | 7.86e-05 | -0.658000 | 2.99e-04 |
Interleukin-6 signaling | 11 | 1.74e-04 | -0.654000 | 6.20e-04 |
Cell-extracellular matrix interactions | 16 | 6.27e-06 | -0.652000 | 3.11e-05 |
RORA activates gene expression | 18 | 1.70e-06 | -0.651000 | 9.74e-06 |
Formation of a pool of free 40S subunits | 99 | 3.75e-29 | 0.651000 | 3.26e-27 |
PKA-mediated phosphorylation of CREB | 18 | 1.74e-06 | -0.651000 | 9.94e-06 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 1.02e-04 | -0.648000 | 3.79e-04 |
Caspase activation via Dependence Receptors in the absence of ligand | 10 | 4.06e-04 | -0.646000 | 1.34e-03 |
PKA activation | 16 | 7.79e-06 | -0.645000 | 3.82e-05 |
Synthesis of PIPs at the Golgi membrane | 15 | 1.95e-05 | -0.637000 | 8.56e-05 |
Regulation of gene expression by Hypoxia-inducible Factor | 11 | 2.82e-04 | -0.632000 | 9.58e-04 |
Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 8.04e-05 | -0.632000 | 3.05e-04 |
Regulation of signaling by CBL | 18 | 3.88e-06 | -0.629000 | 2.06e-05 |
RHOV GTPase cycle | 37 | 3.62e-11 | -0.628000 | 4.92e-10 |
Interleukin-15 signaling | 14 | 5.26e-05 | -0.624000 | 2.08e-04 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 6.34e-27 | 0.624000 | 4.26e-25 |
Formation of ATP by chemiosmotic coupling | 18 | 4.70e-06 | 0.623000 | 2.42e-05 |
Downstream signal transduction | 29 | 7.03e-09 | -0.621000 | 6.93e-08 |
VEGFR2 mediated cell proliferation | 19 | 2.97e-06 | -0.619000 | 1.60e-05 |
RHOU GTPase cycle | 40 | 1.43e-11 | -0.617000 | 2.16e-10 |
Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 1.07e-05 | -0.617000 | 5.02e-05 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 7.64e-25 | 0.617000 | 4.71e-23 |
CTLA4 inhibitory signaling | 18 | 6.23e-06 | -0.615000 | 3.10e-05 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 7.61e-04 | -0.615000 | 2.31e-03 |
Signaling by KIT in disease | 20 | 1.97e-06 | -0.614000 | 1.10e-05 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 1.97e-06 | -0.614000 | 1.10e-05 |
Prolonged ERK activation events | 14 | 6.92e-05 | -0.614000 | 2.65e-04 |
Nephrin family interactions | 20 | 2.46e-06 | -0.608000 | 1.35e-05 |
Other semaphorin interactions | 15 | 4.86e-05 | -0.606000 | 1.93e-04 |
RHOF GTPase cycle | 41 | 2.03e-11 | -0.605000 | 2.94e-10 |
STAT5 activation downstream of FLT3 ITD mutants | 10 | 9.72e-04 | -0.602000 | 2.89e-03 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 125 | 3.41e-31 | 0.601000 | 5.04e-29 |
Signal transduction by L1 | 21 | 2.24e-06 | -0.596000 | 1.23e-05 |
Defective B3GAT3 causes JDSSDHD | 18 | 1.24e-05 | -0.595000 | 5.64e-05 |
Miscellaneous transport and binding events | 24 | 5.25e-07 | -0.591000 | 3.57e-06 |
Signaling by FLT3 ITD and TKD mutants | 16 | 4.68e-05 | -0.588000 | 1.86e-04 |
Signaling by Leptin | 10 | 1.29e-03 | -0.588000 | 3.62e-03 |
Respiratory electron transport | 103 | 6.97e-25 | 0.587000 | 4.48e-23 |
Ephrin signaling | 19 | 9.77e-06 | -0.586000 | 4.63e-05 |
RHOJ GTPase cycle | 54 | 9.18e-14 | -0.586000 | 1.81e-12 |
MECP2 regulates neuronal receptors and channels | 17 | 2.93e-05 | -0.585000 | 1.23e-04 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 1.71e-05 | -0.585000 | 7.58e-05 |
Frs2-mediated activation | 12 | 4.55e-04 | -0.584000 | 1.48e-03 |
HS-GAG biosynthesis | 27 | 1.71e-07 | -0.581000 | 1.26e-06 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 25 | 5.03e-07 | -0.580000 | 3.46e-06 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 5.35e-04 | -0.577000 | 1.71e-03 |
RAF-independent MAPK1/3 activation | 22 | 2.81e-06 | -0.577000 | 1.52e-05 |
Insulin processing | 25 | 6.05e-07 | -0.576000 | 4.07e-06 |
Signal regulatory protein family interactions | 11 | 9.87e-04 | -0.574000 | 2.93e-03 |
Regulation of PTEN mRNA translation | 12 | 5.99e-04 | -0.572000 | 1.88e-03 |
RHO GTPases activate KTN1 | 11 | 1.02e-03 | -0.572000 | 2.98e-03 |
RHOH GTPase cycle | 36 | 3.18e-09 | -0.570000 | 3.33e-08 |
RHO GTPases Activate WASPs and WAVEs | 36 | 3.45e-09 | -0.569000 | 3.55e-08 |
Netrin-1 signaling | 45 | 4.65e-11 | -0.567000 | 6.14e-10 |
RHOQ GTPase cycle | 58 | 9.01e-14 | -0.565000 | 1.80e-12 |
Mitotic Telophase/Cytokinesis | 13 | 4.35e-04 | -0.563000 | 1.42e-03 |
Regulation of RUNX1 Expression and Activity | 18 | 3.60e-05 | -0.562000 | 1.48e-04 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 6.92e-08 | -0.559000 | 5.81e-07 |
Signaling by WNT in cancer | 33 | 2.94e-08 | -0.557000 | 2.66e-07 |
Regulation of localization of FOXO transcription factors | 12 | 8.36e-04 | -0.557000 | 2.50e-03 |
Heme signaling | 43 | 2.62e-10 | -0.557000 | 3.07e-09 |
Growth hormone receptor signaling | 20 | 1.63e-05 | -0.557000 | 7.30e-05 |
RAC2 GTPase cycle | 86 | 5.35e-19 | -0.555000 | 1.61e-17 |
Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 2.45e-03 | -0.553000 | 6.38e-03 |
RAC3 GTPase cycle | 90 | 1.13e-19 | -0.553000 | 3.72e-18 |
Recycling pathway of L1 | 27 | 6.63e-07 | -0.553000 | 4.28e-06 |
RHOC GTPase cycle | 72 | 4.88e-16 | -0.553000 | 1.16e-14 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 1.51e-03 | -0.552000 | 4.17e-03 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 1.79e-11 | -0.549000 | 2.63e-10 |
Mitochondrial translation elongation | 90 | 2.79e-19 | 0.547000 | 8.77e-18 |
Apoptotic cleavage of cellular proteins | 34 | 3.90e-08 | -0.544000 | 3.43e-07 |
STAT3 nuclear events downstream of ALK signaling | 10 | 2.88e-03 | -0.544000 | 7.34e-03 |
RUNX3 regulates NOTCH signaling | 14 | 4.24e-04 | -0.544000 | 1.39e-03 |
Mitochondrial translation initiation | 90 | 4.60e-19 | 0.543000 | 1.42e-17 |
FCGR3A-mediated phagocytosis | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
Leishmania phagocytosis | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
Parasite infection | 56 | 1.99e-12 | -0.543000 | 3.43e-11 |
Deadenylation of mRNA | 22 | 1.09e-05 | -0.542000 | 5.07e-05 |
Mitochondrial translation termination | 90 | 2.10e-18 | 0.533000 | 6.09e-17 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 9.28e-05 | -0.532000 | 3.48e-04 |
Uptake and function of anthrax toxins | 11 | 2.25e-03 | -0.532000 | 5.93e-03 |
G-protein mediated events | 48 | 1.87e-10 | -0.531000 | 2.25e-09 |
SRP-dependent cotranslational protein targeting to membrane | 110 | 5.68e-22 | 0.531000 | 2.71e-20 |
MET receptor recycling | 10 | 3.64e-03 | -0.531000 | 9.11e-03 |
Formation of the ternary complex, and subsequently, the 43S complex | 50 | 8.27e-11 | 0.531000 | 1.05e-09 |
RHOG GTPase cycle | 74 | 2.98e-15 | -0.530000 | 6.56e-14 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 28 | 1.20e-06 | -0.530000 | 7.29e-06 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 5.30e-07 | -0.529000 | 3.60e-06 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 1.00e-21 | 0.528000 | 4.62e-20 |
RND1 GTPase cycle | 42 | 3.35e-09 | -0.527000 | 3.49e-08 |
FCGR3A-mediated IL10 synthesis | 32 | 2.49e-07 | -0.527000 | 1.78e-06 |
L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 3.49e-21 | 0.523000 | 1.26e-19 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 26 | 4.00e-06 | -0.522000 | 2.11e-05 |
DAG and IP3 signaling | 37 | 3.87e-08 | -0.522000 | 3.43e-07 |
Ca-dependent events | 33 | 2.09e-07 | -0.522000 | 1.52e-06 |
Synthesis of PIPs at the plasma membrane | 50 | 1.68e-10 | -0.522000 | 2.03e-09 |
Signaling by ALK fusions and activated point mutants | 55 | 2.20e-11 | -0.521000 | 3.10e-10 |
Signaling by ALK in cancer | 55 | 2.20e-11 | -0.521000 | 3.10e-10 |
CD209 (DC-SIGN) signaling | 20 | 5.67e-05 | -0.520000 | 2.22e-04 |
PLC beta mediated events | 44 | 2.46e-09 | -0.519000 | 2.62e-08 |
FCERI mediated Ca+2 mobilization | 28 | 2.08e-06 | -0.518000 | 1.16e-05 |
PKA activation in glucagon signalling | 15 | 5.35e-04 | -0.516000 | 1.71e-03 |
Reduction of cytosolic Ca++ levels | 12 | 2.03e-03 | -0.514000 | 5.44e-03 |
Selenoamino acid metabolism | 115 | 1.53e-21 | 0.514000 | 6.66e-20 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 4.23e-11 | -0.514000 | 5.68e-10 |
VEGFA-VEGFR2 Pathway | 92 | 1.61e-17 | -0.513000 | 4.19e-16 |
Mitochondrial translation | 96 | 3.34e-18 | 0.513000 | 9.32e-17 |
Circadian Clock | 67 | 4.34e-13 | -0.511000 | 8.13e-12 |
Activated NTRK2 signals through FRS2 and FRS3 | 11 | 3.49e-03 | -0.508000 | 8.79e-03 |
Aflatoxin activation and detoxification | 15 | 6.75e-04 | 0.507000 | 2.08e-03 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 3.61e-03 | -0.507000 | 9.04e-03 |
Cap-dependent Translation Initiation | 117 | 2.75e-21 | 0.506000 | 1.04e-19 |
Eukaryotic Translation Initiation | 117 | 2.75e-21 | 0.506000 | 1.04e-19 |
Signaling by VEGF | 101 | 1.64e-18 | -0.505000 | 4.86e-17 |
Signaling by FGFR4 in disease | 11 | 3.77e-03 | -0.504000 | 9.39e-03 |
Interleukin-27 signaling | 10 | 5.81e-03 | -0.504000 | 1.35e-02 |
RHOB GTPase cycle | 69 | 4.94e-13 | -0.503000 | 9.13e-12 |
MET activates RAS signaling | 11 | 3.94e-03 | -0.502000 | 9.77e-03 |
Cargo concentration in the ER | 31 | 1.38e-06 | -0.501000 | 8.29e-06 |
RHOD GTPase cycle | 52 | 4.36e-10 | -0.500000 | 4.94e-09 |
Signaling by BMP | 23 | 3.61e-05 | -0.498000 | 1.48e-04 |
Diseases associated with glycosaminoglycan metabolism | 35 | 3.53e-07 | -0.497000 | 2.48e-06 |
Signaling by Erythropoietin | 25 | 1.69e-05 | -0.497000 | 7.49e-05 |
CaM pathway | 31 | 1.66e-06 | -0.497000 | 9.61e-06 |
Calmodulin induced events | 31 | 1.66e-06 | -0.497000 | 9.61e-06 |
Signaling by MET | 66 | 3.00e-12 | -0.496000 | 5.04e-11 |
RAF activation | 33 | 8.43e-07 | -0.495000 | 5.35e-06 |
Signaling by SCF-KIT | 42 | 2.78e-08 | -0.495000 | 2.52e-07 |
Regulated proteolysis of p75NTR | 11 | 4.52e-03 | -0.494000 | 1.09e-02 |
Tie2 Signaling | 17 | 4.23e-04 | -0.494000 | 1.39e-03 |
VEGFR2 mediated vascular permeability | 27 | 9.78e-06 | -0.492000 | 4.63e-05 |
PI Metabolism | 77 | 8.57e-14 | -0.491000 | 1.74e-12 |
RND3 GTPase cycle | 41 | 5.54e-08 | -0.490000 | 4.74e-07 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 7.44e-03 | -0.489000 | 1.69e-02 |
Sema3A PAK dependent Axon repulsion | 16 | 7.40e-04 | -0.487000 | 2.26e-03 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 3.52e-03 | -0.487000 | 8.83e-03 |
Zinc transporters | 15 | 1.13e-03 | -0.486000 | 3.24e-03 |
Response to metal ions | 10 | 7.88e-03 | 0.485000 | 1.76e-02 |
A tetrasaccharide linker sequence is required for GAG synthesis | 24 | 3.92e-05 | -0.485000 | 1.59e-04 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 2.79e-05 | -0.484000 | 1.18e-04 |
MAPK3 (ERK1) activation | 10 | 8.13e-03 | -0.483000 | 1.81e-02 |
Erythropoietin activates RAS | 14 | 1.81e-03 | -0.482000 | 4.87e-03 |
L1CAM interactions | 93 | 1.10e-15 | -0.480000 | 2.51e-14 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 4.78e-05 | 0.479000 | 1.90e-04 |
COPI-independent Golgi-to-ER retrograde traffic | 33 | 1.89e-06 | -0.479000 | 1.06e-05 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 38 | 3.30e-07 | -0.478000 | 2.34e-06 |
PECAM1 interactions | 12 | 4.20e-03 | -0.477000 | 1.03e-02 |
The activation of arylsulfatases | 10 | 9.05e-03 | -0.477000 | 1.98e-02 |
Regulation of actin dynamics for phagocytic cup formation | 58 | 3.36e-10 | -0.477000 | 3.91e-09 |
Keratan sulfate biosynthesis | 24 | 5.58e-05 | -0.475000 | 2.19e-04 |
COPI-mediated anterograde transport | 79 | 2.88e-13 | -0.475000 | 5.47e-12 |
Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 1.10e-13 | -0.474000 | 2.15e-12 |
RAC1 GTPase cycle | 177 | 1.18e-27 | -0.474000 | 9.15e-26 |
Unwinding of DNA | 12 | 4.50e-03 | 0.474000 | 1.08e-02 |
Signaling by PDGF | 52 | 3.62e-09 | -0.473000 | 3.70e-08 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 6.66e-03 | -0.472000 | 1.53e-02 |
Interleukin receptor SHC signaling | 21 | 1.84e-04 | -0.471000 | 6.52e-04 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 2.45e-03 | -0.468000 | 6.38e-03 |
Activation of gene expression by SREBF (SREBP) | 42 | 1.58e-07 | -0.467000 | 1.19e-06 |
RUNX2 regulates osteoblast differentiation | 23 | 1.06e-04 | -0.467000 | 3.94e-04 |
Cristae formation | 31 | 6.98e-06 | 0.466000 | 3.44e-05 |
Molecules associated with elastic fibres | 26 | 3.85e-05 | -0.466000 | 1.57e-04 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 1.05e-06 | -0.464000 | 6.48e-06 |
RHO GTPases activate IQGAPs | 11 | 7.75e-03 | -0.464000 | 1.74e-02 |
VxPx cargo-targeting to cilium | 19 | 4.77e-04 | -0.463000 | 1.54e-03 |
CDC42 GTPase cycle | 153 | 5.00e-23 | -0.462000 | 2.64e-21 |
Elastic fibre formation | 36 | 1.58e-06 | -0.462000 | 9.33e-06 |
Regulation of KIT signaling | 16 | 1.39e-03 | -0.462000 | 3.87e-03 |
Signaling by NTRK3 (TRKC) | 16 | 1.42e-03 | -0.461000 | 3.94e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 2.83e-17 | 0.460000 | 6.98e-16 |
Nonsense-Mediated Decay (NMD) | 113 | 2.83e-17 | 0.460000 | 6.98e-16 |
Signaling by ALK | 26 | 5.03e-05 | -0.459000 | 1.99e-04 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 4.21e-03 | 0.458000 | 1.03e-02 |
NOTCH2 intracellular domain regulates transcription | 11 | 8.66e-03 | -0.457000 | 1.91e-02 |
HS-GAG degradation | 19 | 5.71e-04 | -0.456000 | 1.80e-03 |
Interleukin-7 signaling | 23 | 1.52e-04 | -0.456000 | 5.50e-04 |
GAB1 signalosome | 17 | 1.15e-03 | -0.455000 | 3.28e-03 |
CD28 co-stimulation | 30 | 1.61e-05 | -0.455000 | 7.23e-05 |
Oncogenic MAPK signaling | 77 | 5.03e-12 | -0.455000 | 8.09e-11 |
RHOA GTPase cycle | 146 | 3.46e-21 | -0.452000 | 1.26e-19 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 24 | 1.30e-04 | -0.451000 | 4.74e-04 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 17 | 1.31e-03 | -0.450000 | 3.67e-03 |
Keratan sulfate/keratin metabolism | 29 | 2.70e-05 | -0.450000 | 1.16e-04 |
RET signaling | 37 | 2.18e-06 | -0.450000 | 1.21e-05 |
NOTCH3 Intracellular Domain Regulates Transcription | 22 | 2.60e-04 | -0.450000 | 8.94e-04 |
Myogenesis | 25 | 1.11e-04 | -0.446000 | 4.09e-04 |
Extra-nuclear estrogen signaling | 68 | 1.93e-10 | -0.446000 | 2.31e-09 |
Integrin signaling | 26 | 8.32e-05 | -0.446000 | 3.13e-04 |
Activation of BAD and translocation to mitochondria | 15 | 2.82e-03 | -0.445000 | 7.24e-03 |
Chondroitin sulfate biosynthesis | 19 | 7.97e-04 | -0.444000 | 2.39e-03 |
Dermatan sulfate biosynthesis | 10 | 1.50e-02 | -0.444000 | 3.12e-02 |
Post NMDA receptor activation events | 56 | 8.91e-09 | -0.444000 | 8.67e-08 |
N-Glycan antennae elongation | 14 | 4.09e-03 | -0.443000 | 1.01e-02 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 14 | 4.11e-03 | -0.443000 | 1.01e-02 |
Platelet calcium homeostasis | 25 | 1.34e-04 | -0.441000 | 4.85e-04 |
VLDLR internalisation and degradation | 11 | 1.13e-02 | -0.441000 | 2.41e-02 |
Regulation of expression of SLITs and ROBOs | 166 | 1.06e-22 | 0.440000 | 5.42e-21 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 28 | 5.54e-05 | -0.440000 | 2.18e-04 |
Retrograde transport at the Trans-Golgi-Network | 49 | 1.01e-07 | -0.440000 | 8.05e-07 |
Cell-Cell communication | 108 | 3.01e-15 | -0.439000 | 6.56e-14 |
Notch-HLH transcription pathway | 28 | 5.99e-05 | -0.438000 | 2.34e-04 |
ER to Golgi Anterograde Transport | 131 | 5.69e-18 | -0.437000 | 1.56e-16 |
Metal ion SLC transporters | 23 | 3.06e-04 | -0.435000 | 1.03e-03 |
Transport to the Golgi and subsequent modification | 161 | 2.05e-21 | -0.433000 | 8.53e-20 |
RUNX2 regulates bone development | 30 | 4.03e-05 | -0.433000 | 1.63e-04 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 1.67e-23 | -0.432000 | 9.14e-22 |
DARPP-32 events | 23 | 3.40e-04 | -0.431000 | 1.14e-03 |
MAP kinase activation | 62 | 4.35e-09 | -0.431000 | 4.38e-08 |
Signaling by ERBB2 ECD mutants | 16 | 2.88e-03 | -0.430000 | 7.34e-03 |
rRNA processing | 214 | 1.94e-27 | 0.430000 | 1.37e-25 |
Constitutive Signaling by EGFRvIII | 15 | 4.03e-03 | -0.429000 | 9.96e-03 |
Signaling by EGFRvIII in Cancer | 15 | 4.03e-03 | -0.429000 | 9.96e-03 |
Signalling to ERKs | 33 | 2.12e-05 | -0.428000 | 9.26e-05 |
Intra-Golgi traffic | 43 | 1.25e-06 | -0.427000 | 7.52e-06 |
Activation of NMDA receptors and postsynaptic events | 69 | 8.31e-10 | -0.427000 | 9.18e-09 |
Glutathione conjugation | 29 | 6.85e-05 | 0.427000 | 2.62e-04 |
Signaling by Activin | 15 | 4.19e-03 | -0.427000 | 1.03e-02 |
RHO GTPase cycle | 435 | 8.83e-53 | -0.426000 | 3.27e-50 |
RND2 GTPase cycle | 41 | 2.53e-06 | -0.425000 | 1.38e-05 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 1.83e-04 | -0.424000 | 6.52e-04 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 6.06e-03 | -0.424000 | 1.40e-02 |
Opioid Signalling | 78 | 9.71e-11 | -0.424000 | 1.22e-09 |
Ca2+ pathway | 56 | 4.24e-08 | -0.423000 | 3.69e-07 |
Interleukin-2 signaling | 10 | 2.11e-02 | -0.421000 | 4.17e-02 |
Golgi Associated Vesicle Biogenesis | 55 | 7.07e-08 | -0.420000 | 5.90e-07 |
Gap junction degradation | 10 | 2.20e-02 | -0.418000 | 4.33e-02 |
GPVI-mediated activation cascade | 31 | 6.12e-05 | -0.416000 | 2.37e-04 |
Signaling by EGFR | 50 | 3.71e-07 | -0.415000 | 2.60e-06 |
Gap junction trafficking and regulation | 21 | 1.00e-03 | -0.415000 | 2.94e-03 |
Heparan sulfate/heparin (HS-GAG) metabolism | 48 | 6.81e-07 | -0.414000 | 4.38e-06 |
EPHB-mediated forward signaling | 34 | 2.93e-05 | -0.414000 | 1.23e-04 |
Interleukin-35 Signalling | 12 | 1.30e-02 | -0.414000 | 2.73e-02 |
Regulation of MECP2 expression and activity | 29 | 1.15e-04 | -0.414000 | 4.22e-04 |
p130Cas linkage to MAPK signaling for integrins | 14 | 7.66e-03 | -0.412000 | 1.73e-02 |
Signaling by NODAL | 19 | 1.89e-03 | -0.412000 | 5.10e-03 |
Glycosaminoglycan metabolism | 109 | 1.16e-13 | -0.411000 | 2.23e-12 |
Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 2.08e-21 | 0.410000 | 8.53e-20 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 1.05e-02 | -0.410000 | 2.26e-02 |
Glutamate and glutamine metabolism | 13 | 1.05e-02 | -0.410000 | 2.26e-02 |
Sodium/Calcium exchangers | 10 | 2.48e-02 | -0.410000 | 4.76e-02 |
CRMPs in Sema3A signaling | 16 | 4.56e-03 | -0.410000 | 1.09e-02 |
Signaling by TGF-beta Receptor Complex | 74 | 1.66e-09 | -0.405000 | 1.79e-08 |
Glycolysis | 67 | 9.95e-09 | -0.405000 | 9.62e-08 |
Signaling by BRAF and RAF1 fusions | 60 | 6.37e-08 | -0.403000 | 5.38e-07 |
FLT3 signaling in disease | 28 | 2.34e-04 | -0.402000 | 8.16e-04 |
G alpha (z) signalling events | 40 | 1.12e-05 | -0.401000 | 5.19e-05 |
Membrane Trafficking | 581 | 9.61e-62 | -0.401000 | 7.11e-59 |
Cellular response to starvation | 150 | 2.52e-17 | 0.400000 | 6.43e-16 |
COPII-mediated vesicle transport | 66 | 1.94e-08 | -0.400000 | 1.81e-07 |
Regulation of IFNA signaling | 12 | 1.66e-02 | -0.399000 | 3.38e-02 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 4.23e-04 | -0.399000 | 1.39e-03 |
rRNA processing in the nucleus and cytosol | 190 | 2.56e-21 | 0.398000 | 1.02e-19 |
Receptor-type tyrosine-protein phosphatases | 18 | 3.46e-03 | -0.398000 | 8.72e-03 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 94 | 2.72e-11 | -0.397000 | 3.80e-10 |
Negative regulation of the PI3K/AKT network | 101 | 5.32e-12 | -0.397000 | 8.47e-11 |
Signaling by NTRK2 (TRKB) | 24 | 7.68e-04 | -0.397000 | 2.32e-03 |
Role of phospholipids in phagocytosis | 22 | 1.28e-03 | -0.397000 | 3.61e-03 |
EPHA-mediated growth cone collapse | 15 | 7.88e-03 | -0.396000 | 1.76e-02 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 45 | 4.36e-06 | -0.396000 | 2.27e-05 |
Influenza Viral RNA Transcription and Replication | 134 | 2.70e-15 | 0.395000 | 6.05e-14 |
FGFR1 mutant receptor activation | 29 | 2.34e-04 | -0.395000 | 8.16e-04 |
ECM proteoglycans | 45 | 4.85e-06 | -0.394000 | 2.46e-05 |
Sphingolipid de novo biosynthesis | 42 | 1.16e-05 | -0.391000 | 5.34e-05 |
FCERI mediated MAPK activation | 29 | 2.71e-04 | -0.391000 | 9.25e-04 |
Interleukin-2 family signaling | 35 | 6.45e-05 | -0.390000 | 2.48e-04 |
IRE1alpha activates chaperones | 50 | 1.82e-06 | -0.390000 | 1.03e-05 |
Signal amplification | 28 | 3.54e-04 | -0.390000 | 1.18e-03 |
Prolactin receptor signaling | 11 | 2.52e-02 | -0.390000 | 4.81e-02 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 1.53e-02 | -0.388000 | 3.16e-02 |
Signaling by NOTCH1 | 72 | 1.25e-08 | -0.388000 | 1.20e-07 |
Transcriptional activation of mitochondrial biogenesis | 53 | 1.09e-06 | -0.387000 | 6.72e-06 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 6.16e-05 | -0.386000 | 2.38e-04 |
Signaling by FGFR1 in disease | 36 | 6.20e-05 | -0.386000 | 2.39e-04 |
DAP12 interactions | 34 | 9.97e-05 | -0.386000 | 3.72e-04 |
AKT phosphorylates targets in the cytosol | 14 | 1.26e-02 | -0.385000 | 2.67e-02 |
SUMOylation of intracellular receptors | 27 | 5.39e-04 | -0.385000 | 1.72e-03 |
Apoptotic execution phase | 47 | 5.08e-06 | -0.384000 | 2.58e-05 |
Carnitine metabolism | 11 | 2.73e-02 | -0.384000 | 5.15e-02 |
Gap junction assembly | 10 | 3.54e-02 | -0.384000 | 6.44e-02 |
The citric acid (TCA) cycle and respiratory electron transport | 173 | 2.57e-18 | 0.384000 | 7.31e-17 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 2.76e-02 | -0.384000 | 5.19e-02 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.74e-04 | -0.383000 | 6.21e-04 |
Signaling by TGFB family members | 98 | 5.31e-11 | -0.383000 | 6.83e-10 |
Cell junction organization | 78 | 5.27e-09 | -0.382000 | 5.23e-08 |
Golgi-to-ER retrograde transport | 111 | 3.55e-12 | -0.382000 | 5.90e-11 |
FLT3 Signaling | 37 | 6.07e-05 | -0.381000 | 2.36e-04 |
Vesicle-mediated transport | 612 | 1.01e-58 | -0.381000 | 4.99e-56 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 5.93e-07 | 0.379000 | 4.01e-06 |
SHC1 events in ERBB2 signaling | 21 | 2.67e-03 | -0.379000 | 6.89e-03 |
XBP1(S) activates chaperone genes | 48 | 5.81e-06 | -0.378000 | 2.93e-05 |
EPH-ephrin mediated repulsion of cells | 48 | 5.97e-06 | -0.378000 | 2.98e-05 |
Interleukin-17 signaling | 67 | 9.22e-08 | -0.377000 | 7.41e-07 |
Signaling by NTRKs | 133 | 5.83e-14 | -0.377000 | 1.23e-12 |
Negative regulation of MAPK pathway | 42 | 2.38e-05 | -0.377000 | 1.03e-04 |
Dissolution of Fibrin Clot | 12 | 2.40e-02 | -0.376000 | 4.63e-02 |
Fatty acyl-CoA biosynthesis | 35 | 1.18e-04 | -0.376000 | 4.31e-04 |
activated TAK1 mediates p38 MAPK activation | 18 | 5.92e-03 | -0.375000 | 1.37e-02 |
Elevation of cytosolic Ca2+ levels | 13 | 1.98e-02 | -0.373000 | 3.95e-02 |
NOTCH1 Intracellular Domain Regulates Transcription | 47 | 9.66e-06 | -0.373000 | 4.62e-05 |
Chondroitin sulfate/dermatan sulfate metabolism | 48 | 8.15e-06 | -0.372000 | 3.98e-05 |
WNT ligand biogenesis and trafficking | 24 | 1.61e-03 | -0.372000 | 4.42e-03 |
Signaling by NTRK1 (TRKA) | 115 | 6.18e-12 | -0.371000 | 9.53e-11 |
Gap junction trafficking | 19 | 5.15e-03 | -0.371000 | 1.22e-02 |
Ribosomal scanning and start codon recognition | 57 | 1.28e-06 | 0.371000 | 7.71e-06 |
EPH-Ephrin signaling | 91 | 9.82e-10 | -0.370000 | 1.08e-08 |
Effects of PIP2 hydrolysis | 24 | 1.71e-03 | -0.370000 | 4.63e-03 |
Translation initiation complex formation | 57 | 1.40e-06 | 0.369000 | 8.33e-06 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 1.07e-02 | 0.368000 | 2.31e-02 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 4.42e-02 | -0.368000 | 7.82e-02 |
CD28 dependent PI3K/Akt signaling | 19 | 5.59e-03 | -0.367000 | 1.31e-02 |
TBC/RABGAPs | 43 | 3.20e-05 | -0.366000 | 1.34e-04 |
Spry regulation of FGF signaling | 16 | 1.13e-02 | -0.366000 | 2.42e-02 |
ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 1.26e-03 | 0.365000 | 3.58e-03 |
Semaphorin interactions | 60 | 9.93e-07 | -0.365000 | 6.17e-06 |
DAP12 signaling | 27 | 1.04e-03 | -0.365000 | 3.03e-03 |
Disorders of Developmental Biology | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
Disorders of Nervous System Development | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
Loss of function of MECP2 in Rett syndrome | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
Pervasive developmental disorders | 13 | 2.37e-02 | -0.362000 | 4.58e-02 |
Phosphorylation of the APC/C | 20 | 5.05e-03 | 0.362000 | 1.20e-02 |
AKT phosphorylates targets in the nucleus | 10 | 4.77e-02 | -0.362000 | 8.39e-02 |
WNT5A-dependent internalization of FZD4 | 15 | 1.54e-02 | -0.361000 | 3.16e-02 |
N-glycan antennae elongation in the medial/trans-Golgi | 25 | 1.77e-03 | -0.361000 | 4.79e-03 |
NRAGE signals death through JNK | 59 | 1.60e-06 | -0.361000 | 9.36e-06 |
trans-Golgi Network Vesicle Budding | 71 | 1.66e-07 | -0.359000 | 1.24e-06 |
DNA strand elongation | 32 | 4.65e-04 | 0.357000 | 1.51e-03 |
Asparagine N-linked glycosylation | 278 | 9.61e-25 | -0.357000 | 5.68e-23 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 15 | 1.69e-02 | -0.356000 | 3.44e-02 |
Downregulation of TGF-beta receptor signaling | 26 | 1.67e-03 | -0.356000 | 4.56e-03 |
Transport of the SLBP independent Mature mRNA | 35 | 2.75e-04 | -0.355000 | 9.36e-04 |
Interactions of Vpr with host cellular proteins | 37 | 1.85e-04 | -0.355000 | 6.55e-04 |
TRAF3-dependent IRF activation pathway | 14 | 2.15e-02 | -0.355000 | 4.25e-02 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 2.19e-02 | -0.354000 | 4.31e-02 |
PPARA activates gene expression | 110 | 1.65e-10 | -0.352000 | 2.02e-09 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 9.81e-03 | -0.352000 | 2.13e-02 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 5.87e-04 | -0.351000 | 1.85e-03 |
Vpr-mediated nuclear import of PICs | 34 | 3.96e-04 | -0.351000 | 1.31e-03 |
Insulin receptor signalling cascade | 50 | 1.78e-05 | -0.351000 | 7.84e-05 |
PI3K/AKT Signaling in Cancer | 94 | 4.15e-09 | -0.351000 | 4.20e-08 |
Lewis blood group biosynthesis | 15 | 1.89e-02 | -0.350000 | 3.78e-02 |
Retrograde neurotrophin signalling | 14 | 2.36e-02 | -0.349000 | 4.58e-02 |
Adherens junctions interactions | 29 | 1.14e-03 | -0.349000 | 3.26e-03 |
RAB GEFs exchange GTP for GDP on RABs | 88 | 1.49e-08 | -0.349000 | 1.41e-07 |
NOTCH4 Intracellular Domain Regulates Transcription | 19 | 8.55e-03 | -0.348000 | 1.88e-02 |
Signaling by RAF1 mutants | 37 | 2.48e-04 | -0.348000 | 8.58e-04 |
Transport of the SLBP Dependant Mature mRNA | 36 | 3.04e-04 | -0.348000 | 1.03e-03 |
MyD88 cascade initiated on plasma membrane | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
Toll Like Receptor 10 (TLR10) Cascade | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
Toll Like Receptor 5 (TLR5) Cascade | 80 | 7.51e-08 | -0.348000 | 6.17e-07 |
Regulation of lipid metabolism by PPARalpha | 112 | 2.21e-10 | -0.347000 | 2.62e-09 |
Ovarian tumor domain proteases | 37 | 2.69e-04 | -0.346000 | 9.22e-04 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 5.87e-04 | -0.346000 | 1.85e-03 |
Platelet Aggregation (Plug Formation) | 32 | 7.13e-04 | -0.346000 | 2.19e-03 |
Synaptic adhesion-like molecules | 21 | 6.16e-03 | -0.345000 | 1.42e-02 |
Cytosolic iron-sulfur cluster assembly | 13 | 3.12e-02 | 0.345000 | 5.81e-02 |
Synthesis of very long-chain fatty acyl-CoAs | 22 | 5.11e-03 | -0.345000 | 1.21e-02 |
Endosomal/Vacuolar pathway | 12 | 3.89e-02 | -0.344000 | 6.97e-02 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 11 | 4.87e-02 | -0.343000 | 8.54e-02 |
Attenuation phase | 23 | 4.44e-03 | -0.343000 | 1.07e-02 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 2.52e-03 | 0.342000 | 6.56e-03 |
APC/C:Cdc20 mediated degradation of Securin | 66 | 1.56e-06 | 0.342000 | 9.25e-06 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 35 | 4.73e-04 | -0.341000 | 1.54e-03 |
Toll Like Receptor 3 (TLR3) Cascade | 89 | 2.71e-08 | -0.341000 | 2.47e-07 |
LDL clearance | 16 | 1.84e-02 | -0.340000 | 3.69e-02 |
COPI-dependent Golgi-to-ER retrograde traffic | 78 | 2.14e-07 | -0.339000 | 1.55e-06 |
Nucleotide biosynthesis | 12 | 4.24e-02 | -0.338000 | 7.56e-02 |
Citric acid cycle (TCA cycle) | 22 | 6.13e-03 | -0.338000 | 1.41e-02 |
G alpha (12/13) signalling events | 75 | 4.33e-07 | -0.337000 | 2.99e-06 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 1.00e-03 | -0.336000 | 2.94e-03 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 1.00e-03 | -0.336000 | 2.94e-03 |
Translocation of ZAP-70 to Immunological synapse | 15 | 2.43e-02 | 0.336000 | 4.68e-02 |
SARS-CoV-2 Infection | 71 | 9.85e-07 | -0.336000 | 6.15e-06 |
RNA Polymerase I Promoter Opening | 25 | 3.68e-03 | 0.336000 | 9.18e-03 |
Pre-NOTCH Processing in Golgi | 18 | 1.38e-02 | -0.335000 | 2.87e-02 |
Signaling by Receptor Tyrosine Kinases | 480 | 1.62e-36 | -0.335000 | 2.66e-34 |
Toll Like Receptor 9 (TLR9) Cascade | 90 | 4.31e-08 | -0.334000 | 3.71e-07 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 3.87e-03 | -0.334000 | 9.62e-03 |
Signaling by Rho GTPases | 629 | 1.15e-46 | -0.334000 | 2.43e-44 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 4.18e-06 | 0.332000 | 2.20e-05 |
Diseases of signal transduction by growth factor receptors and second messengers | 411 | 4.45e-31 | -0.332000 | 5.99e-29 |
RHOBTB GTPase Cycle | 35 | 6.65e-04 | -0.332000 | 2.06e-03 |
Deactivation of the beta-catenin transactivating complex | 41 | 2.34e-04 | -0.332000 | 8.16e-04 |
Glucagon signaling in metabolic regulation | 26 | 3.41e-03 | -0.332000 | 8.61e-03 |
Transcriptional Regulation by MECP2 | 55 | 2.10e-05 | -0.331000 | 9.18e-05 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 645 | 3.62e-47 | -0.331000 | 8.93e-45 |
Extracellular matrix organization | 256 | 7.37e-20 | -0.331000 | 2.48e-18 |
HSF1-dependent transactivation | 31 | 1.48e-03 | -0.330000 | 4.10e-03 |
DNA methylation | 27 | 3.01e-03 | 0.330000 | 7.67e-03 |
Interleukin-20 family signaling | 19 | 1.29e-02 | -0.330000 | 2.70e-02 |
Rab regulation of trafficking | 120 | 4.34e-10 | -0.330000 | 4.94e-09 |
Integrin cell surface interactions | 60 | 1.03e-05 | -0.329000 | 4.85e-05 |
Clathrin-mediated endocytosis | 138 | 2.98e-11 | -0.327000 | 4.11e-10 |
Initial triggering of complement | 15 | 2.81e-02 | 0.327000 | 5.29e-02 |
Glycogen breakdown (glycogenolysis) | 15 | 2.83e-02 | -0.327000 | 5.32e-02 |
IGF1R signaling cascade | 49 | 7.55e-05 | -0.327000 | 2.88e-04 |
Platelet activation, signaling and aggregation | 230 | 1.57e-17 | -0.326000 | 4.15e-16 |
Rap1 signalling | 15 | 2.93e-02 | -0.325000 | 5.49e-02 |
Constitutive Signaling by Aberrant PI3K in Cancer | 67 | 4.37e-06 | -0.324000 | 2.27e-05 |
Platelet homeostasis | 73 | 1.65e-06 | -0.324000 | 9.61e-06 |
Translesion synthesis by POLI | 17 | 2.07e-02 | 0.324000 | 4.09e-02 |
Diseases associated with visual transduction | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
Diseases of the neuronal system | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
Retinoid cycle disease events | 10 | 7.60e-02 | 0.324000 | 1.26e-01 |
RAB geranylgeranylation | 62 | 1.07e-05 | -0.323000 | 5.04e-05 |
MyD88-independent TLR4 cascade | 93 | 7.64e-08 | -0.322000 | 6.20e-07 |
TRIF(TICAM1)-mediated TLR4 signaling | 93 | 7.64e-08 | -0.322000 | 6.20e-07 |
Processing and activation of SUMO | 10 | 7.80e-02 | -0.322000 | 1.29e-01 |
p75 NTR receptor-mediated signalling | 95 | 5.94e-08 | -0.322000 | 5.05e-07 |
Transport of bile salts and organic acids, metal ions and amine compounds | 61 | 1.40e-05 | -0.321000 | 6.36e-05 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 85 | 3.01e-07 | -0.321000 | 2.14e-06 |
TGF-beta receptor signaling activates SMADs | 32 | 1.67e-03 | -0.321000 | 4.56e-03 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 2.59e-06 | 0.320000 | 1.41e-05 |
SUMOylation of SUMOylation proteins | 35 | 1.04e-03 | -0.320000 | 3.03e-03 |
Translation | 293 | 4.91e-21 | 0.319000 | 1.73e-19 |
ADP signalling through P2Y purinoceptor 1 | 21 | 1.16e-02 | -0.318000 | 2.47e-02 |
Sialic acid metabolism | 31 | 2.18e-03 | -0.318000 | 5.78e-03 |
Mitochondrial protein import | 64 | 1.09e-05 | 0.318000 | 5.08e-05 |
Cargo recognition for clathrin-mediated endocytosis | 100 | 4.03e-08 | -0.317000 | 3.53e-07 |
Thrombin signalling through proteinase activated receptors (PARs) | 27 | 4.31e-03 | -0.317000 | 1.05e-02 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
p53-Independent DNA Damage Response | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
p53-Independent G1/S DNA damage checkpoint | 50 | 1.08e-04 | 0.316000 | 3.98e-04 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
Signaling by NOTCH1 in Cancer | 57 | 3.59e-05 | -0.316000 | 1.48e-04 |
CDT1 association with the CDC6:ORC:origin complex | 57 | 3.62e-05 | 0.316000 | 1.48e-04 |
Influenza Infection | 153 | 1.44e-11 | 0.316000 | 2.16e-10 |
Nuclear Receptor transcription pathway | 46 | 2.08e-04 | -0.316000 | 7.29e-04 |
SUMOylation of ubiquitinylation proteins | 39 | 6.42e-04 | -0.316000 | 1.99e-03 |
IRS-related events triggered by IGF1R | 48 | 1.55e-04 | -0.316000 | 5.57e-04 |
Signaling by ERBB2 in Cancer | 25 | 6.33e-03 | -0.315000 | 1.46e-02 |
mRNA Splicing - Minor Pathway | 52 | 8.30e-05 | 0.315000 | 3.13e-04 |
The role of Nef in HIV-1 replication and disease pathogenesis | 24 | 7.48e-03 | -0.315000 | 1.70e-02 |
Fanconi Anemia Pathway | 36 | 1.10e-03 | 0.314000 | 3.16e-03 |
Transcriptional regulation of white adipocyte differentiation | 81 | 1.13e-06 | -0.313000 | 6.93e-06 |
Repression of WNT target genes | 14 | 4.34e-02 | -0.312000 | 7.70e-02 |
Integration of energy metabolism | 93 | 2.04e-07 | -0.312000 | 1.50e-06 |
PI3K events in ERBB2 signaling | 15 | 3.75e-02 | -0.310000 | 6.78e-02 |
MyD88 dependent cascade initiated on endosome | 86 | 6.62e-07 | -0.310000 | 4.28e-06 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 86 | 6.62e-07 | -0.310000 | 4.28e-06 |
Assembly and cell surface presentation of NMDA receptors | 23 | 1.02e-02 | -0.310000 | 2.20e-02 |
Vif-mediated degradation of APOBEC3G | 52 | 1.15e-04 | 0.309000 | 4.23e-04 |
Blood group systems biosynthesis | 19 | 1.98e-02 | -0.309000 | 3.95e-02 |
Cellular response to heat stress | 94 | 2.34e-07 | -0.308000 | 1.68e-06 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 50 | 1.64e-04 | -0.308000 | 5.90e-04 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 4.62e-06 | 0.308000 | 2.39e-05 |
SHC1 events in EGFR signaling | 14 | 4.62e-02 | -0.308000 | 8.16e-02 |
Metabolism of carbohydrates | 263 | 8.02e-18 | -0.307000 | 2.16e-16 |
NR1H2 and NR1H3-mediated signaling | 43 | 4.88e-04 | -0.307000 | 1.58e-03 |
Regulation of TP53 Activity through Acetylation | 29 | 4.38e-03 | -0.306000 | 1.06e-02 |
Vasopressin regulates renal water homeostasis via Aquaporins | 35 | 1.78e-03 | -0.305000 | 4.82e-03 |
Signaling by high-kinase activity BRAF mutants | 33 | 2.42e-03 | -0.305000 | 6.35e-03 |
Biotin transport and metabolism | 11 | 8.03e-02 | -0.304000 | 1.33e-01 |
SARS-CoV Infections | 151 | 1.03e-10 | -0.304000 | 1.28e-09 |
Sphingolipid metabolism | 84 | 1.44e-06 | -0.304000 | 8.55e-06 |
Cell surface interactions at the vascular wall | 100 | 1.56e-07 | -0.303000 | 1.17e-06 |
Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 2.42e-04 | 0.303000 | 8.40e-04 |
PI-3K cascade:FGFR3 | 16 | 3.59e-02 | -0.303000 | 6.52e-02 |
Translesion synthesis by REV1 | 16 | 3.62e-02 | 0.303000 | 6.55e-02 |
Sensory processing of sound by outer hair cells of the cochlea | 44 | 5.20e-04 | -0.302000 | 1.67e-03 |
Signaling by FGFR3 | 38 | 1.26e-03 | -0.302000 | 3.58e-03 |
NS1 Mediated Effects on Host Pathways | 40 | 9.45e-04 | -0.302000 | 2.82e-03 |
Costimulation by the CD28 family | 59 | 6.23e-05 | -0.301000 | 2.40e-04 |
Nuclear Events (kinase and transcription factor activation) | 62 | 4.24e-05 | -0.301000 | 1.70e-04 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 19 | 2.34e-02 | -0.300000 | 4.57e-02 |
Ras activation upon Ca2+ influx through NMDA receptor | 18 | 2.75e-02 | -0.300000 | 5.19e-02 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 8.50e-02 | -0.300000 | 1.38e-01 |
Nuclear Envelope Breakdown | 53 | 1.62e-04 | -0.299000 | 5.82e-04 |
Leishmania infection | 189 | 1.23e-12 | -0.299000 | 2.20e-11 |
DSCAM interactions | 10 | 1.02e-01 | -0.299000 | 1.61e-01 |
Signaling by FGFR1 | 47 | 3.94e-04 | -0.299000 | 1.30e-03 |
Digestion and absorption | 11 | 8.69e-02 | 0.298000 | 1.41e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 76 | 7.25e-06 | -0.297000 | 3.56e-05 |
IRS-mediated signalling | 45 | 5.59e-04 | -0.297000 | 1.77e-03 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
Signaling by RAS mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
Signaling by moderate kinase activity BRAF mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
Signaling downstream of RAS mutants | 41 | 1.00e-03 | -0.297000 | 2.94e-03 |
Protein-protein interactions at synapses | 78 | 5.93e-06 | -0.296000 | 2.98e-05 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 1.05e-01 | 0.296000 | 1.65e-01 |
Assembly of active LPL and LIPC lipase complexes | 13 | 6.45e-02 | -0.296000 | 1.09e-01 |
Hemostasis | 495 | 1.11e-29 | -0.296000 | 1.17e-27 |
Negative regulation of MET activity | 21 | 1.88e-02 | -0.296000 | 3.77e-02 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 34 | 2.82e-03 | -0.296000 | 7.24e-03 |
PI-3K cascade:FGFR1 | 19 | 2.56e-02 | -0.296000 | 4.90e-02 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 9.42e-06 | 0.296000 | 4.53e-05 |
TNFR1-induced proapoptotic signaling | 13 | 6.50e-02 | -0.296000 | 1.10e-01 |
Synthesis of DNA | 118 | 3.07e-08 | 0.295000 | 2.73e-07 |
Inositol phosphate metabolism | 45 | 6.37e-04 | -0.294000 | 1.98e-03 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 27 | 8.32e-03 | -0.293000 | 1.85e-02 |
Trafficking of AMPA receptors | 27 | 8.32e-03 | -0.293000 | 1.85e-02 |
ISG15 antiviral mechanism | 72 | 1.67e-05 | -0.293000 | 7.45e-05 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 2.32e-02 | 0.293000 | 4.55e-02 |
Class I peroxisomal membrane protein import | 19 | 2.71e-02 | -0.293000 | 5.13e-02 |
Diseases associated with glycosylation precursor biosynthesis | 18 | 3.15e-02 | -0.293000 | 5.83e-02 |
Long-term potentiation | 20 | 2.34e-02 | -0.293000 | 4.57e-02 |
Death Receptor Signalling | 138 | 2.90e-09 | -0.292000 | 3.07e-08 |
SHC1 events in ERBB4 signaling | 13 | 6.86e-02 | -0.292000 | 1.15e-01 |
Downstream signaling of activated FGFR3 | 23 | 1.55e-02 | -0.292000 | 3.18e-02 |
DNA Replication | 151 | 6.63e-10 | 0.291000 | 7.37e-09 |
Signaling by ERBB2 KD Mutants | 24 | 1.37e-02 | -0.291000 | 2.86e-02 |
Listeria monocytogenes entry into host cells | 20 | 2.45e-02 | -0.290000 | 4.72e-02 |
Physiological factors | 10 | 1.12e-01 | -0.290000 | 1.75e-01 |
Glucose metabolism | 84 | 4.31e-06 | -0.290000 | 2.25e-05 |
Assembly of the pre-replicative complex | 91 | 1.76e-06 | 0.290000 | 1.00e-05 |
TRAF6 mediated IRF7 activation | 16 | 4.50e-02 | -0.290000 | 7.95e-02 |
Deposition of new CENPA-containing nucleosomes at the centromere | 45 | 7.88e-04 | 0.289000 | 2.37e-03 |
Nucleosome assembly | 45 | 7.88e-04 | 0.289000 | 2.37e-03 |
FOXO-mediated transcription | 59 | 1.22e-04 | -0.289000 | 4.45e-04 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 2.21e-05 | 0.289000 | 9.63e-05 |
CDK-mediated phosphorylation and removal of Cdc6 | 71 | 2.58e-05 | 0.289000 | 1.11e-04 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 2.79e-03 | -0.288000 | 7.18e-03 |
DNA Replication Pre-Initiation | 108 | 2.32e-07 | 0.288000 | 1.67e-06 |
Lagging Strand Synthesis | 20 | 2.61e-02 | 0.287000 | 4.97e-02 |
EGFR downregulation | 31 | 5.65e-03 | -0.287000 | 1.32e-02 |
ESR-mediated signaling | 174 | 6.10e-11 | -0.287000 | 7.78e-10 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 5.92e-04 | 0.287000 | 1.86e-03 |
Antiviral mechanism by IFN-stimulated genes | 80 | 9.39e-06 | -0.286000 | 4.53e-05 |
PI3K Cascade | 41 | 1.52e-03 | -0.286000 | 4.17e-03 |
Formation of the cornified envelope | 22 | 2.02e-02 | -0.286000 | 3.99e-02 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 3.39e-03 | -0.286000 | 8.58e-03 |
Activation of the pre-replicative complex | 33 | 4.49e-03 | 0.286000 | 1.08e-02 |
Lysosphingolipid and LPA receptors | 11 | 1.01e-01 | -0.286000 | 1.60e-01 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 1.35e-03 | -0.286000 | 3.78e-03 |
CDC6 association with the ORC:origin complex | 11 | 1.01e-01 | 0.286000 | 1.60e-01 |
Negative regulation of NOTCH4 signaling | 54 | 2.80e-04 | 0.286000 | 9.53e-04 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 3.18e-05 | 0.285000 | 1.33e-04 |
Depolymerisation of the Nuclear Lamina | 15 | 5.57e-02 | -0.285000 | 9.63e-02 |
Cargo trafficking to the periciliary membrane | 47 | 7.15e-04 | -0.285000 | 2.19e-03 |
Stabilization of p53 | 53 | 3.29e-04 | 0.285000 | 1.11e-03 |
Nuclear import of Rev protein | 34 | 4.03e-03 | -0.285000 | 9.96e-03 |
Interleukin-6 family signaling | 23 | 1.83e-02 | -0.284000 | 3.68e-02 |
SUMOylation of transcription cofactors | 44 | 1.11e-03 | -0.284000 | 3.21e-03 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 4.27e-02 | 0.284000 | 7.60e-02 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 8.95e-02 | -0.283000 | 1.44e-01 |
alpha-linolenic acid (ALA) metabolism | 12 | 8.95e-02 | -0.283000 | 1.44e-01 |
Cell-cell junction organization | 53 | 3.70e-04 | -0.283000 | 1.23e-03 |
Neurexins and neuroligins | 49 | 6.34e-04 | -0.282000 | 1.98e-03 |
Activated NOTCH1 Transmits Signal to the Nucleus | 30 | 7.62e-03 | -0.281000 | 1.72e-02 |
PKMTs methylate histone lysines | 45 | 1.09e-03 | -0.281000 | 3.14e-03 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 1.42e-03 | -0.281000 | 3.96e-03 |
Phospholipid metabolism | 192 | 1.80e-11 | -0.281000 | 2.63e-10 |
Amine ligand-binding receptors | 23 | 1.99e-02 | -0.280000 | 3.95e-02 |
Rev-mediated nuclear export of HIV RNA | 35 | 4.09e-03 | -0.280000 | 1.01e-02 |
RHO GTPases activate PAKs | 21 | 2.65e-02 | -0.280000 | 5.04e-02 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.66e-02 | 0.279000 | 5.05e-02 |
Leading Strand Synthesis | 14 | 7.02e-02 | 0.279000 | 1.18e-01 |
Polymerase switching | 14 | 7.02e-02 | 0.279000 | 1.18e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 37 | 3.27e-03 | -0.279000 | 8.32e-03 |
Potential therapeutics for SARS | 82 | 1.23e-05 | -0.279000 | 5.63e-05 |
Signal Transduction | 2189 | 0.00e+00 | -0.279000 | 0.00e+00 |
Downstream signaling of activated FGFR1 | 29 | 9.57e-03 | -0.278000 | 2.09e-02 |
Signaling by ERBB2 | 49 | 7.72e-04 | -0.278000 | 2.33e-03 |
Processive synthesis on the lagging strand | 15 | 6.28e-02 | 0.277000 | 1.07e-01 |
Aquaporin-mediated transport | 39 | 2.72e-03 | -0.277000 | 7.01e-03 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.27e-02 | -0.277000 | 2.68e-02 |
FOXO-mediated transcription of cell death genes | 15 | 6.32e-02 | -0.277000 | 1.07e-01 |
Receptor Mediated Mitophagy | 11 | 1.13e-01 | -0.276000 | 1.76e-01 |
Uptake and actions of bacterial toxins | 29 | 1.02e-02 | -0.276000 | 2.20e-02 |
Metabolism of fat-soluble vitamins | 36 | 4.26e-03 | -0.275000 | 1.04e-02 |
Defective pyroptosis | 35 | 4.86e-03 | 0.275000 | 1.16e-02 |
Intracellular signaling by second messengers | 292 | 6.06e-16 | -0.275000 | 1.42e-14 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 6.64e-02 | -0.274000 | 1.12e-01 |
HSF1 activation | 26 | 1.59e-02 | -0.273000 | 3.26e-02 |
Ion homeostasis | 45 | 1.53e-03 | -0.273000 | 4.21e-03 |
RHO GTPases activate CIT | 19 | 3.96e-02 | -0.273000 | 7.09e-02 |
Condensation of Prometaphase Chromosomes | 11 | 1.17e-01 | 0.273000 | 1.81e-01 |
O-linked glycosylation of mucins | 52 | 6.75e-04 | -0.272000 | 2.08e-03 |
RHOBTB1 GTPase cycle | 23 | 2.38e-02 | -0.272000 | 4.60e-02 |
Defects in vitamin and cofactor metabolism | 21 | 3.12e-02 | -0.271000 | 5.81e-02 |
Mucopolysaccharidoses | 11 | 1.20e-01 | -0.271000 | 1.83e-01 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 3.72e-04 | 0.270000 | 1.23e-03 |
GRB2 events in ERBB2 signaling | 15 | 7.04e-02 | -0.270000 | 1.18e-01 |
Regulation of HSF1-mediated heat shock response | 78 | 3.98e-05 | -0.269000 | 1.61e-04 |
Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 1.24e-01 | -0.268000 | 1.89e-01 |
G-protein beta:gamma signalling | 27 | 1.59e-02 | -0.268000 | 3.25e-02 |
Ion transport by P-type ATPases | 47 | 1.50e-03 | -0.268000 | 4.13e-03 |
Switching of origins to a post-replicative state | 89 | 1.27e-05 | 0.268000 | 5.77e-05 |
Signaling by Non-Receptor Tyrosine Kinases | 53 | 7.49e-04 | -0.268000 | 2.28e-03 |
Signaling by PTK6 | 53 | 7.49e-04 | -0.268000 | 2.28e-03 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 3.83e-02 | 0.267000 | 6.91e-02 |
Vpu mediated degradation of CD4 | 50 | 1.08e-03 | 0.267000 | 3.12e-03 |
Regulation of insulin secretion | 65 | 1.99e-04 | -0.267000 | 7.01e-04 |
Synthesis of IP2, IP, and Ins in the cytosol | 14 | 8.41e-02 | -0.267000 | 1.37e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 3.47e-02 | 0.266000 | 6.35e-02 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 3.47e-02 | 0.266000 | 6.35e-02 |
ER Quality Control Compartment (ERQC) | 21 | 3.52e-02 | -0.265000 | 6.43e-02 |
Defective GALNT12 causes CRCS1 | 12 | 1.11e-01 | 0.265000 | 1.74e-01 |
GRB2 events in EGFR signaling | 13 | 9.79e-02 | -0.265000 | 1.56e-01 |
Ubiquitin-dependent degradation of Cyclin D | 50 | 1.20e-03 | 0.265000 | 3.42e-03 |
Interactions of Rev with host cellular proteins | 37 | 5.41e-03 | -0.264000 | 1.27e-02 |
SUMOylation of chromatin organization proteins | 57 | 5.59e-04 | -0.264000 | 1.77e-03 |
Lysosome Vesicle Biogenesis | 34 | 7.70e-03 | -0.264000 | 1.73e-02 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 2.27e-02 | 0.263000 | 4.46e-02 |
Thromboxane signalling through TP receptor | 20 | 4.20e-02 | -0.263000 | 7.51e-02 |
eNOS activation | 11 | 1.33e-01 | -0.262000 | 2.01e-01 |
Factors involved in megakaryocyte development and platelet production | 116 | 1.10e-06 | -0.262000 | 6.78e-06 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 1.33e-01 | 0.262000 | 2.01e-01 |
SUMOylation of transcription factors | 19 | 4.85e-02 | -0.261000 | 8.52e-02 |
Neurotransmitter receptors and postsynaptic signal transmission | 155 | 2.06e-08 | -0.261000 | 1.91e-07 |
Autophagy | 125 | 5.14e-07 | -0.260000 | 3.52e-06 |
MHC class II antigen presentation | 98 | 8.80e-06 | -0.260000 | 4.28e-05 |
Toll Like Receptor 4 (TLR4) Cascade | 122 | 7.93e-07 | -0.259000 | 5.08e-06 |
Toll-like Receptor Cascades | 140 | 1.26e-07 | -0.259000 | 9.91e-07 |
Regulation of TP53 Expression and Degradation | 36 | 7.41e-03 | -0.258000 | 1.69e-02 |
The NLRP3 inflammasome | 15 | 8.48e-02 | -0.257000 | 1.38e-01 |
Interleukin-4 and Interleukin-13 signaling | 97 | 1.21e-05 | -0.257000 | 5.55e-05 |
Regulation of beta-cell development | 31 | 1.34e-02 | -0.256000 | 2.82e-02 |
Activation of the AP-1 family of transcription factors | 10 | 1.60e-01 | -0.256000 | 2.35e-01 |
Glutathione synthesis and recycling | 12 | 1.24e-01 | 0.256000 | 1.90e-01 |
Collagen degradation | 35 | 8.75e-03 | -0.256000 | 1.92e-02 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 1.32e-03 | 0.255000 | 3.70e-03 |
Retinoid metabolism and transport | 32 | 1.27e-02 | -0.254000 | 2.68e-02 |
CS/DS degradation | 13 | 1.12e-01 | -0.254000 | 1.75e-01 |
Endogenous sterols | 22 | 3.91e-02 | -0.254000 | 7.01e-02 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 1.49e-02 | -0.253000 | 3.10e-02 |
Response to elevated platelet cytosolic Ca2+ | 117 | 2.35e-06 | -0.252000 | 1.29e-05 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 1.49e-03 | 0.252000 | 4.12e-03 |
Regulation of TLR by endogenous ligand | 15 | 9.18e-02 | 0.251000 | 1.47e-01 |
MAPK family signaling cascades | 299 | 7.30e-14 | -0.251000 | 1.52e-12 |
Macroautophagy | 111 | 4.80e-06 | -0.251000 | 2.45e-05 |
Trafficking of GluR2-containing AMPA receptors | 16 | 8.35e-02 | -0.250000 | 1.37e-01 |
SUMOylation of DNA damage response and repair proteins | 76 | 1.65e-04 | -0.250000 | 5.90e-04 |
Activation of BH3-only proteins | 29 | 1.99e-02 | -0.250000 | 3.95e-02 |
Synthesis of IP3 and IP4 in the cytosol | 24 | 3.43e-02 | -0.250000 | 6.29e-02 |
Signaling by FGFR4 | 38 | 7.75e-03 | -0.250000 | 1.74e-02 |
Signalling to RAS | 20 | 5.35e-02 | -0.249000 | 9.31e-02 |
SCF-beta-TrCP mediated degradation of Emi1 | 53 | 1.69e-03 | 0.249000 | 4.61e-03 |
Calnexin/calreticulin cycle | 26 | 2.79e-02 | -0.249000 | 5.24e-02 |
Regulation of Apoptosis | 51 | 2.08e-03 | 0.249000 | 5.55e-03 |
Sulfur amino acid metabolism | 25 | 3.13e-02 | 0.249000 | 5.81e-02 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
Toll Like Receptor 2 (TLR2) Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
Toll Like Receptor TLR1:TLR2 Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
Toll Like Receptor TLR6:TLR2 Cascade | 95 | 2.76e-05 | -0.249000 | 1.17e-04 |
Post-translational protein modification | 1270 | 6.68e-51 | -0.249000 | 1.98e-48 |
Orc1 removal from chromatin | 69 | 3.62e-04 | 0.248000 | 1.20e-03 |
O-linked glycosylation | 99 | 1.97e-05 | -0.248000 | 8.64e-05 |
NCAM signaling for neurite out-growth | 55 | 1.46e-03 | -0.248000 | 4.06e-03 |
Glycogen synthesis | 15 | 9.67e-02 | -0.248000 | 1.54e-01 |
Platelet degranulation | 112 | 5.95e-06 | -0.248000 | 2.98e-05 |
SARS-CoV-1 Infection | 50 | 2.62e-03 | -0.246000 | 6.79e-03 |
RHO GTPases Activate ROCKs | 19 | 6.38e-02 | -0.246000 | 1.08e-01 |
IRAK1 recruits IKK complex | 10 | 1.79e-01 | -0.245000 | 2.59e-01 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 1.79e-01 | -0.245000 | 2.59e-01 |
Platelet Adhesion to exposed collagen | 11 | 1.59e-01 | -0.245000 | 2.34e-01 |
Synthesis of substrates in N-glycan biosythesis | 61 | 9.39e-04 | -0.245000 | 2.81e-03 |
Signaling by NOTCH2 | 32 | 1.65e-02 | -0.245000 | 3.37e-02 |
G beta:gamma signalling through PI3Kgamma | 21 | 5.25e-02 | -0.244000 | 9.15e-02 |
Cross-presentation of soluble exogenous antigens (endosomes) | 45 | 4.55e-03 | 0.244000 | 1.09e-02 |
ERBB2 Regulates Cell Motility | 14 | 1.14e-01 | -0.244000 | 1.76e-01 |
Degradation of the extracellular matrix | 94 | 4.30e-05 | -0.244000 | 1.72e-04 |
Mitochondrial Fatty Acid Beta-Oxidation | 34 | 1.39e-02 | 0.244000 | 2.90e-02 |
Signaling by ERBB4 | 52 | 2.45e-03 | -0.243000 | 6.38e-03 |
Unblocking of NMDA receptors, glutamate binding and activation | 18 | 7.48e-02 | -0.243000 | 1.25e-01 |
Translesion synthesis by POLK | 17 | 8.34e-02 | 0.242000 | 1.37e-01 |
Resolution of D-Loop Structures | 33 | 1.61e-02 | 0.242000 | 3.30e-02 |
MAP2K and MAPK activation | 37 | 1.12e-02 | -0.241000 | 2.40e-02 |
Signaling by FGFR3 in disease | 20 | 6.26e-02 | -0.240000 | 1.07e-01 |
Signaling by FGFR3 point mutants in cancer | 20 | 6.26e-02 | -0.240000 | 1.07e-01 |
PIP3 activates AKT signaling | 256 | 3.63e-11 | -0.240000 | 4.92e-10 |
FGFRL1 modulation of FGFR1 signaling | 12 | 1.51e-01 | -0.239000 | 2.23e-01 |
G beta:gamma signalling through CDC42 | 16 | 9.74e-02 | -0.239000 | 1.55e-01 |
ADP signalling through P2Y purinoceptor 12 | 17 | 8.80e-02 | -0.239000 | 1.42e-01 |
Negative regulation of FGFR1 signaling | 30 | 2.35e-02 | -0.239000 | 4.57e-02 |
Regulation of TP53 Degradation | 35 | 1.47e-02 | -0.238000 | 3.05e-02 |
Negative regulators of DDX58/IFIH1 signaling | 35 | 1.52e-02 | -0.237000 | 3.15e-02 |
Negative regulation of FGFR3 signaling | 27 | 3.32e-02 | -0.237000 | 6.09e-02 |
Signaling by NOTCH3 | 46 | 5.52e-03 | -0.236000 | 1.29e-02 |
Hh mutants are degraded by ERAD | 54 | 2.66e-03 | 0.236000 | 6.87e-03 |
Downstream signaling of activated FGFR2 | 27 | 3.41e-02 | -0.236000 | 6.25e-02 |
Signaling by WNT | 277 | 1.44e-11 | -0.235000 | 2.16e-10 |
FRS-mediated FGFR1 signaling | 21 | 6.24e-02 | -0.235000 | 1.07e-01 |
Kinesins | 39 | 1.15e-02 | -0.234000 | 2.44e-02 |
Anti-inflammatory response favouring Leishmania parasite infection | 108 | 2.71e-05 | -0.234000 | 1.16e-04 |
Leishmania parasite growth and survival | 108 | 2.71e-05 | -0.234000 | 1.16e-04 |
Signaling by Nuclear Receptors | 240 | 4.50e-10 | -0.233000 | 5.04e-09 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 13 | 1.46e-01 | -0.233000 | 2.17e-01 |
Phase 4 - resting membrane potential | 16 | 1.07e-01 | -0.233000 | 1.69e-01 |
SUMOylation | 170 | 1.63e-07 | -0.233000 | 1.22e-06 |
APC/C-mediated degradation of cell cycle proteins | 86 | 1.99e-04 | 0.232000 | 7.01e-04 |
Regulation of mitotic cell cycle | 86 | 1.99e-04 | 0.232000 | 7.01e-04 |
PRC2 methylates histones and DNA | 35 | 1.76e-02 | 0.232000 | 3.55e-02 |
RNA Polymerase II Transcription Termination | 65 | 1.24e-03 | 0.232000 | 3.52e-03 |
Removal of the Flap Intermediate | 14 | 1.34e-01 | 0.231000 | 2.02e-01 |
Adaptive Immune System | 649 | 6.04e-24 | -0.231000 | 3.44e-22 |
Condensation of Prophase Chromosomes | 35 | 1.79e-02 | 0.231000 | 3.61e-02 |
FRS-mediated FGFR3 signaling | 18 | 8.97e-02 | -0.231000 | 1.44e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 49 | 5.23e-03 | -0.231000 | 1.23e-02 |
Nuclear events stimulated by ALK signaling in cancer | 19 | 8.27e-02 | -0.230000 | 1.36e-01 |
NOD1/2 Signaling Pathway | 31 | 2.71e-02 | -0.229000 | 5.14e-02 |
Peptide hormone metabolism | 69 | 1.07e-03 | -0.228000 | 3.10e-03 |
Downstream signaling of activated FGFR4 | 24 | 5.52e-02 | -0.226000 | 9.56e-02 |
Degradation of DVL | 55 | 3.73e-03 | 0.226000 | 9.31e-03 |
p53-Dependent G1 DNA Damage Response | 62 | 2.17e-03 | 0.225000 | 5.74e-03 |
p53-Dependent G1/S DNA damage checkpoint | 62 | 2.17e-03 | 0.225000 | 5.74e-03 |
PI-3K cascade:FGFR2 | 20 | 8.15e-02 | -0.225000 | 1.34e-01 |
SIRT1 negatively regulates rRNA expression | 30 | 3.31e-02 | 0.225000 | 6.09e-02 |
Metabolism of amino acids and derivatives | 341 | 9.19e-13 | 0.225000 | 1.68e-11 |
Transport of vitamins, nucleosides, and related molecules | 35 | 2.15e-02 | -0.225000 | 4.24e-02 |
SUMOylation of DNA replication proteins | 46 | 8.50e-03 | -0.224000 | 1.88e-02 |
Glycogen metabolism | 26 | 4.80e-02 | -0.224000 | 8.43e-02 |
RHOBTB2 GTPase cycle | 23 | 6.32e-02 | -0.224000 | 1.07e-01 |
Diseases of glycosylation | 131 | 9.71e-06 | -0.224000 | 4.63e-05 |
RAS processing | 19 | 9.27e-02 | -0.223000 | 1.49e-01 |
Regulation of APC/C activators between G1/S and early anaphase | 79 | 6.18e-04 | 0.223000 | 1.93e-03 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 1.03e-01 | 0.222000 | 1.62e-01 |
Protein ubiquitination | 73 | 1.05e-03 | -0.222000 | 3.04e-03 |
Regulation of ornithine decarboxylase (ODC) | 49 | 7.28e-03 | 0.222000 | 1.66e-02 |
SUMO E3 ligases SUMOylate target proteins | 164 | 9.64e-07 | -0.222000 | 6.07e-06 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 3.02e-02 | 0.221000 | 5.63e-02 |
G1/S DNA Damage Checkpoints | 64 | 2.20e-03 | 0.221000 | 5.80e-03 |
MTOR signalling | 40 | 1.55e-02 | -0.221000 | 3.19e-02 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 4.32e-02 | -0.221000 | 7.67e-02 |
RNA Polymerase I Promoter Escape | 53 | 5.49e-03 | 0.220000 | 1.29e-02 |
Neuronal System | 331 | 5.79e-12 | -0.220000 | 9.01e-11 |
ROS sensing by NFE2L2 | 55 | 4.91e-03 | 0.219000 | 1.17e-02 |
Signaling by CSF3 (G-CSF) | 30 | 3.85e-02 | -0.218000 | 6.93e-02 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 1.31e-01 | -0.218000 | 1.98e-01 |
STING mediated induction of host immune responses | 15 | 1.43e-01 | -0.218000 | 2.15e-01 |
Signaling by Insulin receptor | 73 | 1.27e-03 | -0.218000 | 3.58e-03 |
SLC transporter disorders | 84 | 5.48e-04 | -0.218000 | 1.74e-03 |
Regulation of PTEN gene transcription | 61 | 3.38e-03 | -0.217000 | 8.56e-03 |
Metabolism of steroids | 138 | 1.09e-05 | -0.217000 | 5.07e-05 |
Polo-like kinase mediated events | 16 | 1.33e-01 | 0.217000 | 2.02e-01 |
Glycosphingolipid metabolism | 42 | 1.53e-02 | -0.216000 | 3.16e-02 |
Selective autophagy | 58 | 4.55e-03 | -0.215000 | 1.09e-02 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 1.50e-01 | -0.215000 | 2.22e-01 |
Sensory processing of sound by inner hair cells of the cochlea | 58 | 4.68e-03 | -0.215000 | 1.12e-02 |
TNFR1-induced NFkappaB signaling pathway | 26 | 5.82e-02 | -0.215000 | 1.00e-01 |
G alpha (q) signalling events | 157 | 3.53e-06 | -0.214000 | 1.88e-05 |
Class I MHC mediated antigen processing & presentation | 354 | 4.00e-12 | -0.214000 | 6.58e-11 |
Inflammasomes | 19 | 1.07e-01 | -0.214000 | 1.68e-01 |
SUMOylation of RNA binding proteins | 47 | 1.12e-02 | -0.214000 | 2.40e-02 |
Translation of Structural Proteins | 29 | 4.71e-02 | -0.213000 | 8.28e-02 |
Signaling by ERBB2 TMD/JMD mutants | 21 | 9.13e-02 | -0.213000 | 1.47e-01 |
Signaling by ROBO receptors | 210 | 1.13e-07 | 0.212000 | 8.98e-07 |
Antigen processing: Ubiquitination & Proteasome degradation | 292 | 4.38e-10 | -0.212000 | 4.94e-09 |
MAPK1/MAPK3 signaling | 260 | 5.09e-09 | -0.210000 | 5.08e-08 |
Activation of ATR in response to replication stress | 37 | 2.73e-02 | 0.210000 | 5.15e-02 |
PI-3K cascade:FGFR4 | 17 | 1.35e-01 | -0.210000 | 2.03e-01 |
RAF/MAP kinase cascade | 254 | 8.86e-09 | -0.209000 | 8.67e-08 |
Reactions specific to the complex N-glycan synthesis pathway | 10 | 2.53e-01 | -0.209000 | 3.48e-01 |
Transmission across Chemical Synapses | 216 | 1.23e-07 | -0.209000 | 9.74e-07 |
SCF(Skp2)-mediated degradation of p27/p21 | 60 | 5.41e-03 | 0.208000 | 1.27e-02 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 1.08e-01 | -0.207000 | 1.70e-01 |
RHOBTB3 ATPase cycle | 10 | 2.57e-01 | -0.207000 | 3.53e-01 |
Hh mutants abrogate ligand secretion | 57 | 6.87e-03 | 0.207000 | 1.57e-02 |
SHC-mediated cascade:FGFR1 | 19 | 1.21e-01 | -0.206000 | 1.85e-01 |
Immune System | 1645 | 1.70e-44 | -0.205000 | 3.15e-42 |
Cytochrome c-mediated apoptotic response | 13 | 2.00e-01 | -0.205000 | 2.87e-01 |
Purine salvage | 12 | 2.18e-01 | -0.205000 | 3.07e-01 |
Degradation of cysteine and homocysteine | 11 | 2.39e-01 | 0.205000 | 3.32e-01 |
Metabolism of lipids | 661 | 2.49e-19 | -0.204000 | 8.02e-18 |
NIK–>noncanonical NF-kB signaling | 57 | 7.77e-03 | 0.204000 | 1.74e-02 |
Meiotic recombination | 46 | 1.72e-02 | 0.203000 | 3.49e-02 |
IRAK2 mediated activation of TAK1 complex | 10 | 2.67e-01 | -0.203000 | 3.62e-01 |
Signaling by FGFR in disease | 60 | 6.69e-03 | -0.202000 | 1.53e-02 |
Chromosome Maintenance | 110 | 2.56e-04 | 0.202000 | 8.84e-04 |
Synthesis of PA | 33 | 4.51e-02 | -0.202000 | 7.96e-02 |
CASP8 activity is inhibited | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
Dimerization of procaspase-8 | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
Regulation by c-FLIP | 10 | 2.70e-01 | -0.202000 | 3.63e-01 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 1.19e-01 | -0.201000 | 1.82e-01 |
Neurodegenerative Diseases | 20 | 1.19e-01 | -0.201000 | 1.82e-01 |
MyD88 deficiency (TLR2/4) | 15 | 1.77e-01 | 0.201000 | 2.57e-01 |
Degradation of AXIN | 53 | 1.12e-02 | 0.201000 | 2.40e-02 |
SLC-mediated transmembrane transport | 200 | 9.27e-07 | -0.201000 | 5.86e-06 |
Phospholipase C-mediated cascade; FGFR4 | 12 | 2.28e-01 | 0.201000 | 3.20e-01 |
Signaling by GPCR | 486 | 3.00e-14 | -0.201000 | 6.42e-13 |
Triglyceride catabolism | 18 | 1.40e-01 | -0.201000 | 2.11e-01 |
Sensory processing of sound | 63 | 5.89e-03 | -0.201000 | 1.37e-02 |
PERK regulates gene expression | 31 | 5.41e-02 | 0.200000 | 9.39e-02 |
GPCR downstream signalling | 431 | 1.03e-12 | -0.200000 | 1.86e-11 |
Activation of GABAB receptors | 36 | 3.81e-02 | -0.200000 | 6.88e-02 |
GABA B receptor activation | 36 | 3.81e-02 | -0.200000 | 6.88e-02 |
Interaction between L1 and Ankyrins | 26 | 7.87e-02 | -0.199000 | 1.30e-01 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 2.53e-01 | -0.199000 | 3.48e-01 |
Degradation of GLI2 by the proteasome | 57 | 9.49e-03 | 0.199000 | 2.07e-02 |
RHO GTPases Activate NADPH Oxidases | 21 | 1.15e-01 | -0.198000 | 1.78e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 15 | 1.84e-01 | -0.198000 | 2.65e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 89 | 1.24e-03 | 0.198000 | 3.53e-03 |
Pyrimidine salvage | 10 | 2.80e-01 | 0.197000 | 3.75e-01 |
Pexophagy | 11 | 2.57e-01 | -0.197000 | 3.53e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 82 | 2.02e-03 | -0.197000 | 5.42e-03 |
mRNA 3’-end processing | 56 | 1.09e-02 | 0.197000 | 2.35e-02 |
G-protein activation | 18 | 1.49e-01 | -0.196000 | 2.21e-01 |
Degradation of GLI1 by the proteasome | 57 | 1.04e-02 | 0.196000 | 2.24e-02 |
SHC-mediated cascade:FGFR3 | 16 | 1.75e-01 | -0.196000 | 2.54e-01 |
Antimicrobial peptides | 26 | 8.43e-02 | 0.196000 | 1.38e-01 |
HCMV Infection | 106 | 5.13e-04 | -0.195000 | 1.65e-03 |
Negative regulation of FGFR2 signaling | 31 | 6.01e-02 | -0.195000 | 1.03e-01 |
Methylation | 14 | 2.07e-01 | 0.195000 | 2.95e-01 |
Chemokine receptors bind chemokines | 25 | 9.22e-02 | 0.195000 | 1.48e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.54e-02 | -0.194000 | 3.16e-02 |
mTORC1-mediated signalling | 24 | 1.00e-01 | -0.194000 | 1.59e-01 |
Detoxification of Reactive Oxygen Species | 31 | 6.26e-02 | 0.193000 | 1.07e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 1.45e-01 | -0.193000 | 2.17e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 1.45e-01 | -0.193000 | 2.17e-01 |
Intrinsic Pathway for Apoptosis | 53 | 1.55e-02 | -0.192000 | 3.19e-02 |
BBSome-mediated cargo-targeting to cilium | 21 | 1.28e-01 | -0.192000 | 1.94e-01 |
Regulation of IFNG signaling | 13 | 2.31e-01 | -0.192000 | 3.23e-01 |
Nuclear signaling by ERBB4 | 27 | 8.49e-02 | -0.192000 | 1.38e-01 |
HDR through Homologous Recombination (HRR) | 66 | 7.28e-03 | 0.191000 | 1.66e-02 |
Basigin interactions | 23 | 1.14e-01 | -0.190000 | 1.76e-01 |
G1/S-Specific Transcription | 29 | 7.62e-02 | 0.190000 | 1.26e-01 |
RHO GTPase Effectors | 257 | 1.55e-07 | -0.190000 | 1.17e-06 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 13 | 2.36e-01 | 0.190000 | 3.29e-01 |
Cell recruitment (pro-inflammatory response) | 23 | 1.15e-01 | -0.190000 | 1.78e-01 |
Purinergic signaling in leishmaniasis infection | 23 | 1.15e-01 | -0.190000 | 1.78e-01 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 11 | 2.76e-01 | -0.190000 | 3.71e-01 |
Protein methylation | 15 | 2.04e-01 | -0.190000 | 2.92e-01 |
p38MAPK events | 13 | 2.38e-01 | -0.189000 | 3.31e-01 |
Defective GALNT3 causes HFTC | 12 | 2.58e-01 | 0.188000 | 3.53e-01 |
Peroxisomal protein import | 59 | 1.24e-02 | -0.188000 | 2.63e-02 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 33 | 6.16e-02 | -0.188000 | 1.06e-01 |
Dectin-1 mediated noncanonical NF-kB signaling | 59 | 1.27e-02 | 0.188000 | 2.67e-02 |
HCMV Early Events | 82 | 3.35e-03 | -0.187000 | 8.50e-03 |
Telomere Maintenance | 85 | 2.87e-03 | 0.187000 | 7.34e-03 |
Metabolism of cofactors | 19 | 1.60e-01 | 0.186000 | 2.35e-01 |
mRNA Splicing | 187 | 1.11e-05 | 0.186000 | 5.15e-05 |
Innate Immune System | 861 | 2.29e-20 | -0.185000 | 7.88e-19 |
O-glycosylation of TSR domain-containing proteins | 37 | 5.18e-02 | -0.185000 | 9.04e-02 |
Neutrophil degranulation | 415 | 1.07e-10 | -0.184000 | 1.32e-09 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 76 | 5.44e-03 | -0.184000 | 1.28e-02 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 1.12e-01 | 0.184000 | 1.74e-01 |
Neurotransmitter release cycle | 47 | 3.00e-02 | -0.183000 | 5.59e-02 |
Negative regulation of FGFR4 signaling | 28 | 9.45e-02 | -0.183000 | 1.51e-01 |
NoRC negatively regulates rRNA expression | 68 | 9.31e-03 | 0.182000 | 2.03e-02 |
Response of Mtb to phagocytosis | 22 | 1.39e-01 | -0.182000 | 2.10e-01 |
GABA receptor activation | 48 | 2.92e-02 | -0.182000 | 5.47e-02 |
Sema4D in semaphorin signaling | 24 | 1.23e-01 | -0.182000 | 1.88e-01 |
Activation of Matrix Metalloproteinases | 26 | 1.09e-01 | -0.181000 | 1.71e-01 |
G1/S Transition | 131 | 3.41e-04 | 0.181000 | 1.14e-03 |
G alpha (s) signalling events | 93 | 2.57e-03 | -0.181000 | 6.66e-03 |
Resolution of Abasic Sites (AP sites) | 38 | 5.39e-02 | 0.181000 | 9.36e-02 |
Adrenaline,noradrenaline inhibits insulin secretion | 23 | 1.34e-01 | -0.181000 | 2.02e-01 |
Assembly of the ORC complex at the origin of replication | 31 | 8.18e-02 | 0.181000 | 1.35e-01 |
Estrogen-dependent gene expression | 109 | 1.14e-03 | -0.180000 | 3.26e-03 |
p75NTR signals via NF-kB | 16 | 2.12e-01 | -0.180000 | 3.00e-01 |
Acetylcholine binding and downstream events | 10 | 3.24e-01 | 0.180000 | 4.24e-01 |
Postsynaptic nicotinic acetylcholine receptors | 10 | 3.24e-01 | 0.180000 | 4.24e-01 |
Chromatin modifying enzymes | 224 | 3.39e-06 | -0.180000 | 1.81e-05 |
Chromatin organization | 224 | 3.39e-06 | -0.180000 | 1.81e-05 |
Termination of translesion DNA synthesis | 32 | 7.86e-02 | 0.180000 | 1.30e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 8.85e-02 | -0.180000 | 1.43e-01 |
Metabolism of amine-derived hormones | 12 | 2.82e-01 | 0.179000 | 3.77e-01 |
tRNA modification in the nucleus and cytosol | 43 | 4.28e-02 | 0.179000 | 7.62e-02 |
Biosynthesis of DHA-derived SPMs | 14 | 2.48e-01 | 0.178000 | 3.43e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 8.69e-02 | -0.178000 | 1.41e-01 |
Branched-chain amino acid catabolism | 21 | 1.59e-01 | -0.178000 | 2.34e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 1.27e-02 | -0.177000 | 2.67e-02 |
Amino acid transport across the plasma membrane | 31 | 8.76e-02 | -0.177000 | 1.42e-01 |
Deubiquitination | 248 | 1.63e-06 | -0.177000 | 9.51e-06 |
mRNA Splicing - Major Pathway | 179 | 4.61e-05 | 0.176000 | 1.84e-04 |
Interleukin-37 signaling | 21 | 1.63e-01 | -0.176000 | 2.39e-01 |
Neurotoxicity of clostridium toxins | 10 | 3.36e-01 | 0.176000 | 4.34e-01 |
Defective B3GALTL causes PpS | 36 | 6.83e-02 | -0.176000 | 1.15e-01 |
Regulation of RUNX3 expression and activity | 54 | 2.61e-02 | 0.175000 | 4.97e-02 |
G2/M Checkpoints | 140 | 3.57e-04 | 0.175000 | 1.19e-03 |
Signaling by Interleukins | 388 | 3.45e-09 | -0.174000 | 3.55e-08 |
Mitochondrial tRNA aminoacylation | 21 | 1.66e-01 | -0.174000 | 2.43e-01 |
Mitotic Prophase | 104 | 2.13e-03 | -0.174000 | 5.66e-03 |
GLI3 is processed to GLI3R by the proteasome | 57 | 2.34e-02 | 0.174000 | 4.57e-02 |
Transcriptional regulation of testis differentiation | 11 | 3.19e-01 | -0.174000 | 4.17e-01 |
Cholesterol biosynthesis | 24 | 1.42e-01 | -0.173000 | 2.12e-01 |
FRS-mediated FGFR2 signaling | 22 | 1.59e-01 | -0.173000 | 2.35e-01 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 3.44e-01 | -0.173000 | 4.41e-01 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 1.61e-01 | -0.173000 | 2.36e-01 |
E3 ubiquitin ligases ubiquitinate target proteins | 53 | 2.98e-02 | -0.173000 | 5.57e-02 |
Nonhomologous End-Joining (NHEJ) | 43 | 5.04e-02 | -0.172000 | 8.81e-02 |
Metabolism of polyamines | 57 | 2.47e-02 | 0.172000 | 4.74e-02 |
Infection with Mycobacterium tuberculosis | 24 | 1.45e-01 | -0.172000 | 2.17e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 3.05e-01 | 0.171000 | 4.01e-01 |
Budding and maturation of HIV virion | 28 | 1.19e-01 | -0.170000 | 1.82e-01 |
Vitamin D (calciferol) metabolism | 10 | 3.51e-01 | -0.170000 | 4.50e-01 |
tRNA Aminoacylation | 42 | 5.82e-02 | -0.169000 | 1.00e-01 |
Disease | 1461 | 1.66e-27 | -0.169000 | 1.22e-25 |
Beta-catenin independent WNT signaling | 138 | 6.38e-04 | -0.168000 | 1.98e-03 |
ZBP1(DAI) mediated induction of type I IFNs | 19 | 2.04e-01 | -0.168000 | 2.92e-01 |
Cardiac conduction | 109 | 2.41e-03 | -0.168000 | 6.34e-03 |
Response of EIF2AK1 (HRI) to heme deficiency | 15 | 2.62e-01 | 0.167000 | 3.55e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 97 | 4.49e-03 | -0.167000 | 1.08e-02 |
Class B/2 (Secretin family receptors) | 71 | 1.53e-02 | -0.166000 | 3.16e-02 |
RIP-mediated NFkB activation via ZBP1 | 16 | 2.51e-01 | -0.166000 | 3.47e-01 |
Cytosolic tRNA aminoacylation | 24 | 1.61e-01 | -0.165000 | 2.36e-01 |
Developmental Biology | 851 | 2.55e-16 | -0.165000 | 6.19e-15 |
PD-1 signaling | 18 | 2.29e-01 | 0.164000 | 3.21e-01 |
tRNA processing | 124 | 1.64e-03 | 0.164000 | 4.49e-03 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 10 | 3.71e-01 | -0.164000 | 4.69e-01 |
Diseases of hemostasis | 10 | 3.71e-01 | -0.164000 | 4.69e-01 |
Pentose phosphate pathway | 13 | 3.07e-01 | -0.163000 | 4.03e-01 |
Post-chaperonin tubulin folding pathway | 20 | 2.07e-01 | 0.163000 | 2.94e-01 |
Defective CFTR causes cystic fibrosis | 58 | 3.21e-02 | 0.163000 | 5.93e-02 |
Post-translational protein phosphorylation | 87 | 8.83e-03 | -0.162000 | 1.94e-02 |
Collagen formation | 83 | 1.10e-02 | -0.161000 | 2.36e-02 |
Negative epigenetic regulation of rRNA expression | 71 | 1.88e-02 | 0.161000 | 3.77e-02 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 92 | 7.56e-03 | -0.161000 | 1.71e-02 |
Unfolded Protein Response (UPR) | 90 | 8.54e-03 | -0.160000 | 1.88e-02 |
Signaling by EGFR in Cancer | 25 | 1.66e-01 | -0.160000 | 2.42e-01 |
Nuclear Envelope (NE) Reassembly | 73 | 1.83e-02 | -0.160000 | 3.68e-02 |
Nervous system development | 524 | 3.70e-10 | -0.160000 | 4.27e-09 |
Oncogene Induced Senescence | 31 | 1.25e-01 | -0.159000 | 1.91e-01 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 16 | 2.70e-01 | -0.159000 | 3.64e-01 |
Cytokine Signaling in Immune system | 605 | 2.12e-11 | -0.159000 | 3.05e-10 |
Inhibition of DNA recombination at telomere | 40 | 8.32e-02 | 0.158000 | 1.37e-01 |
Voltage gated Potassium channels | 33 | 1.16e-01 | -0.158000 | 1.79e-01 |
Purine catabolism | 17 | 2.60e-01 | 0.158000 | 3.53e-01 |
Defective C1GALT1C1 causes TNPS | 13 | 3.26e-01 | 0.157000 | 4.25e-01 |
Regulation of TP53 Activity | 155 | 7.20e-04 | -0.157000 | 2.20e-03 |
Fc epsilon receptor (FCERI) signaling | 128 | 2.12e-03 | -0.157000 | 5.65e-03 |
Viral Messenger RNA Synthesis | 44 | 7.15e-02 | -0.157000 | 1.20e-01 |
The phototransduction cascade | 27 | 1.59e-01 | -0.156000 | 2.35e-01 |
Transcriptional regulation by RUNX3 | 94 | 8.71e-03 | -0.156000 | 1.91e-02 |
Telomere C-strand synthesis initiation | 13 | 3.29e-01 | -0.156000 | 4.28e-01 |
Hedgehog ligand biogenesis | 63 | 3.18e-02 | 0.156000 | 5.88e-02 |
Metabolism of RNA | 677 | 4.23e-12 | 0.156000 | 6.87e-11 |
Phosphorylation of CD3 and TCR zeta chains | 17 | 2.66e-01 | 0.156000 | 3.61e-01 |
Transport of small molecules | 608 | 4.96e-11 | -0.156000 | 6.49e-10 |
Removal of the Flap Intermediate from the C-strand | 17 | 2.68e-01 | -0.155000 | 3.62e-01 |
Base Excision Repair | 64 | 3.22e-02 | 0.155000 | 5.93e-02 |
Diseases of metabolism | 218 | 8.06e-05 | -0.155000 | 3.05e-04 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 27 | 1.64e-01 | 0.155000 | 2.40e-01 |
TCF dependent signaling in response to WNT | 187 | 2.61e-04 | -0.155000 | 8.96e-04 |
Phase II - Conjugation of compounds | 76 | 2.00e-02 | 0.154000 | 3.97e-02 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 2.88e-01 | -0.153000 | 3.83e-01 |
IRAK4 deficiency (TLR2/4) | 16 | 2.90e-01 | 0.153000 | 3.85e-01 |
Heme degradation | 12 | 3.62e-01 | 0.152000 | 4.60e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 36 | 1.15e-01 | -0.152000 | 1.78e-01 |
rRNA modification in the nucleus and cytosol | 60 | 4.21e-02 | 0.152000 | 7.52e-02 |
Plasma lipoprotein assembly | 13 | 3.44e-01 | 0.152000 | 4.41e-01 |
FRS-mediated FGFR4 signaling | 19 | 2.53e-01 | -0.151000 | 3.48e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 26 | 1.83e-01 | -0.151000 | 2.65e-01 |
UCH proteinases | 92 | 1.26e-02 | 0.150000 | 2.67e-02 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 38 | 1.10e-01 | 0.150000 | 1.73e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 3.87e-02 | 0.149000 | 6.95e-02 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 3.06e-01 | -0.148000 | 4.02e-01 |
FGFR2 alternative splicing | 25 | 2.03e-01 | 0.147000 | 2.91e-01 |
Visual phototransduction | 73 | 2.99e-02 | -0.147000 | 5.58e-02 |
Deadenylation-dependent mRNA decay | 53 | 6.55e-02 | -0.146000 | 1.11e-01 |
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 25 | 2.06e-01 | -0.146000 | 2.94e-01 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 3.28e-01 | -0.146000 | 4.27e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 3.28e-01 | -0.146000 | 4.27e-01 |
Scavenging by Class A Receptors | 17 | 2.98e-01 | 0.146000 | 3.94e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 1.99e-01 | 0.145000 | 2.86e-01 |
Signaling by FGFR | 80 | 2.46e-02 | -0.145000 | 4.72e-02 |
Regulation of TP53 Activity through Methylation | 19 | 2.75e-01 | 0.145000 | 3.70e-01 |
FGFR4 ligand binding and activation | 11 | 4.06e-01 | 0.145000 | 5.03e-01 |
TNFR2 non-canonical NF-kB pathway | 91 | 1.73e-02 | 0.144000 | 3.51e-02 |
Activation of kainate receptors upon glutamate binding | 24 | 2.22e-01 | -0.144000 | 3.11e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 2.90e-01 | -0.144000 | 3.86e-01 |
Glycerophospholipid biosynthesis | 116 | 7.46e-03 | -0.144000 | 1.69e-02 |
Transcriptional regulation of pluripotent stem cells | 30 | 1.74e-01 | -0.143000 | 2.53e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 4.33e-01 | 0.143000 | 5.28e-01 |
Phenylalanine and tyrosine metabolism | 10 | 4.33e-01 | 0.143000 | 5.28e-01 |
RNA Polymerase I Promoter Clearance | 72 | 3.57e-02 | 0.143000 | 6.49e-02 |
RNA Polymerase I Transcription | 72 | 3.57e-02 | 0.143000 | 6.49e-02 |
Formation of the beta-catenin:TCF transactivating complex | 53 | 7.15e-02 | -0.143000 | 1.20e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 34 | 1.49e-01 | -0.143000 | 2.21e-01 |
Sema4D induced cell migration and growth-cone collapse | 20 | 2.69e-01 | -0.143000 | 3.63e-01 |
G alpha (i) signalling events | 199 | 5.22e-04 | -0.143000 | 1.67e-03 |
Axon guidance | 502 | 4.28e-08 | -0.143000 | 3.70e-07 |
Late Phase of HIV Life Cycle | 135 | 4.27e-03 | -0.142000 | 1.04e-02 |
Tight junction interactions | 22 | 2.48e-01 | -0.142000 | 3.43e-01 |
Regulation of TP53 Activity through Association with Co-factors | 12 | 3.99e-01 | -0.141000 | 4.97e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 2.53e-01 | -0.141000 | 3.48e-01 |
IRF3-mediated induction of type I IFN | 12 | 4.00e-01 | -0.140000 | 4.97e-01 |
HCMV Late Events | 78 | 3.23e-02 | -0.140000 | 5.95e-02 |
Programmed Cell Death | 195 | 7.38e-04 | -0.140000 | 2.25e-03 |
Regulation of FZD by ubiquitination | 21 | 2.68e-01 | -0.140000 | 3.63e-01 |
The canonical retinoid cycle in rods (twilight vision) | 18 | 3.06e-01 | 0.139000 | 4.02e-01 |
SHC-mediated cascade:FGFR2 | 20 | 2.81e-01 | -0.139000 | 3.76e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 3.84e-01 | -0.139000 | 4.84e-01 |
Synthesis, secretion, and deacylation of Ghrelin | 13 | 3.88e-01 | 0.138000 | 4.86e-01 |
Metabolism of proteins | 1745 | 4.58e-22 | -0.138000 | 2.26e-20 |
Synthesis of bile acids and bile salts | 30 | 1.93e-01 | -0.137000 | 2.77e-01 |
Metabolism of non-coding RNA | 53 | 8.38e-02 | -0.137000 | 1.37e-01 |
snRNP Assembly | 53 | 8.38e-02 | -0.137000 | 1.37e-01 |
Regulation of RUNX2 expression and activity | 70 | 4.71e-02 | 0.137000 | 8.28e-02 |
IL-6-type cytokine receptor ligand interactions | 16 | 3.43e-01 | -0.137000 | 4.41e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 18 | 3.20e-01 | -0.135000 | 4.18e-01 |
HIV Life Cycle | 147 | 4.65e-03 | -0.135000 | 1.11e-02 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 6.18e-02 | 0.135000 | 1.06e-01 |
Cleavage of the damaged purine | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
Depurination | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 29 | 2.10e-01 | 0.135000 | 2.97e-01 |
Pyruvate metabolism | 28 | 2.18e-01 | -0.134000 | 3.07e-01 |
Dual incision in TC-NER | 65 | 6.25e-02 | 0.134000 | 1.07e-01 |
RNA Polymerase I Transcription Termination | 30 | 2.06e-01 | 0.133000 | 2.94e-01 |
Interferon Signaling | 174 | 2.49e-03 | -0.133000 | 6.49e-03 |
Peroxisomal lipid metabolism | 27 | 2.32e-01 | -0.133000 | 3.25e-01 |
Mitotic G1 phase and G1/S transition | 147 | 5.67e-03 | 0.132000 | 1.32e-02 |
Activation of SMO | 18 | 3.35e-01 | -0.131000 | 4.34e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 26 | 2.47e-01 | -0.131000 | 3.42e-01 |
S Phase | 160 | 4.57e-03 | 0.130000 | 1.09e-02 |
cGMP effects | 14 | 4.02e-01 | -0.129000 | 4.99e-01 |
Pre-NOTCH Expression and Processing | 71 | 5.93e-02 | -0.129000 | 1.02e-01 |
Presynaptic depolarization and calcium channel opening | 11 | 4.58e-01 | 0.129000 | 5.52e-01 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 3.57e-01 | -0.129000 | 4.55e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 3.57e-01 | -0.129000 | 4.55e-01 |
Processing of Intronless Pre-mRNAs | 19 | 3.30e-01 | -0.129000 | 4.28e-01 |
Cytosolic sensors of pathogen-associated DNA | 61 | 8.24e-02 | -0.129000 | 1.36e-01 |
Hyaluronan metabolism | 14 | 4.05e-01 | -0.128000 | 5.02e-01 |
Assembly of collagen fibrils and other multimeric structures | 52 | 1.10e-01 | -0.128000 | 1.72e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 105 | 2.35e-02 | 0.128000 | 4.57e-02 |
Apoptosis | 169 | 4.13e-03 | -0.128000 | 1.01e-02 |
Signaling by FGFR2 IIIa TM | 19 | 3.35e-01 | 0.128000 | 4.34e-01 |
Regulation of HMOX1 expression and activity | 63 | 8.05e-02 | 0.127000 | 1.33e-01 |
Gluconeogenesis | 29 | 2.36e-01 | -0.127000 | 3.29e-01 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 4.12e-01 | -0.127000 | 5.09e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 3.97e-01 | -0.126000 | 4.96e-01 |
Caspase activation via Death Receptors in the presence of ligand | 15 | 4.00e-01 | -0.125000 | 4.98e-01 |
ABC transporter disorders | 73 | 6.45e-02 | 0.125000 | 1.09e-01 |
Cyclin D associated events in G1 | 45 | 1.47e-01 | -0.125000 | 2.19e-01 |
G1 Phase | 45 | 1.47e-01 | -0.125000 | 2.19e-01 |
Dual Incision in GG-NER | 41 | 1.67e-01 | 0.125000 | 2.44e-01 |
Muscle contraction | 164 | 5.87e-03 | -0.125000 | 1.36e-02 |
Base-Excision Repair, AP Site Formation | 36 | 1.98e-01 | 0.124000 | 2.84e-01 |
PIWI-interacting RNA (piRNA) biogenesis | 25 | 2.83e-01 | 0.124000 | 3.78e-01 |
Triglyceride metabolism | 28 | 2.58e-01 | -0.123000 | 3.53e-01 |
Arachidonic acid metabolism | 44 | 1.58e-01 | 0.123000 | 2.34e-01 |
Generic Transcription Pathway | 1126 | 2.84e-12 | -0.123000 | 4.82e-11 |
Recognition of DNA damage by PCNA-containing replication complex | 30 | 2.44e-01 | 0.123000 | 3.39e-01 |
Chaperonin-mediated protein folding | 83 | 5.34e-02 | -0.123000 | 9.30e-02 |
Ion channel transport | 152 | 9.72e-03 | -0.121000 | 2.11e-02 |
Neddylation | 222 | 1.83e-03 | -0.121000 | 4.93e-03 |
Cyclin E associated events during G1/S transition | 83 | 5.73e-02 | 0.121000 | 9.91e-02 |
Asymmetric localization of PCP proteins | 62 | 1.01e-01 | 0.121000 | 1.60e-01 |
Common Pathway of Fibrin Clot Formation | 15 | 4.23e-01 | -0.120000 | 5.19e-01 |
Regulation of gene expression in beta cells | 14 | 4.38e-01 | -0.120000 | 5.32e-01 |
TNF signaling | 44 | 1.71e-01 | -0.119000 | 2.49e-01 |
ER-Phagosome pathway | 87 | 5.45e-02 | 0.119000 | 9.45e-02 |
Gene expression (Transcription) | 1379 | 8.57e-14 | -0.119000 | 1.74e-12 |
Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 4.28e-01 | 0.118000 | 5.25e-01 |
Homology Directed Repair | 111 | 3.16e-02 | 0.118000 | 5.84e-02 |
Nitric oxide stimulates guanylate cyclase | 18 | 3.87e-01 | -0.118000 | 4.86e-01 |
PTEN Regulation | 140 | 1.69e-02 | -0.117000 | 3.44e-02 |
Extension of Telomeres | 51 | 1.50e-01 | 0.117000 | 2.22e-01 |
Sensory Perception | 181 | 7.27e-03 | -0.116000 | 1.66e-02 |
DNA Damage Recognition in GG-NER | 38 | 2.18e-01 | 0.115000 | 3.07e-01 |
Ub-specific processing proteases | 177 | 8.15e-03 | -0.115000 | 1.81e-02 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 4.42e-01 | -0.115000 | 5.35e-01 |
Synthesis of PC | 27 | 3.04e-01 | -0.114000 | 4.01e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 238 | 2.42e-03 | 0.114000 | 6.35e-03 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 3.07e-01 | 0.114000 | 4.02e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 3.07e-01 | 0.114000 | 4.02e-01 |
Signaling by the B Cell Receptor (BCR) | 106 | 4.32e-02 | -0.114000 | 7.67e-02 |
FGFR2 mutant receptor activation | 30 | 2.82e-01 | 0.113000 | 3.77e-01 |
Metabolism of Angiotensinogen to Angiotensins | 13 | 4.79e-01 | -0.113000 | 5.75e-01 |
E2F mediated regulation of DNA replication | 22 | 3.60e-01 | 0.113000 | 4.59e-01 |
Dopamine Neurotransmitter Release Cycle | 22 | 3.60e-01 | -0.113000 | 4.59e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 4.36e-01 | 0.113000 | 5.31e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 20 | 3.85e-01 | -0.112000 | 4.84e-01 |
Cell Cycle Checkpoints | 260 | 1.94e-03 | 0.112000 | 5.20e-03 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 2.47e-01 | 0.111000 | 3.42e-01 |
Signaling by NOTCH | 194 | 7.72e-03 | -0.111000 | 1.74e-02 |
TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 5.27e-01 | -0.110000 | 6.15e-01 |
RNA Polymerase II Transcription | 1244 | 5.24e-11 | -0.110000 | 6.80e-10 |
Surfactant metabolism | 20 | 3.96e-01 | -0.110000 | 4.96e-01 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 5.11e-01 | -0.110000 | 6.01e-01 |
SHC-mediated cascade:FGFR4 | 17 | 4.37e-01 | -0.109000 | 5.31e-01 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 4.39e-01 | 0.109000 | 5.32e-01 |
Cyclin A:Cdk2-associated events at S phase entry | 85 | 8.49e-02 | 0.108000 | 1.38e-01 |
Diseases associated with O-glycosylation of proteins | 62 | 1.42e-01 | -0.108000 | 2.13e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 1.01e-01 | 0.107000 | 1.60e-01 |
Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 3.35e-01 | 0.107000 | 4.34e-01 |
Defective Intrinsic Pathway for Apoptosis | 22 | 3.86e-01 | -0.107000 | 4.85e-01 |
Apoptosis induced DNA fragmentation | 12 | 5.23e-01 | 0.107000 | 6.11e-01 |
Tryptophan catabolism | 13 | 5.07e-01 | 0.106000 | 5.99e-01 |
Homologous DNA Pairing and Strand Exchange | 42 | 2.33e-01 | 0.106000 | 3.26e-01 |
Infectious disease | 740 | 8.00e-07 | -0.106000 | 5.10e-06 |
Diseases of programmed cell death | 62 | 1.48e-01 | 0.106000 | 2.21e-01 |
Activation of NF-kappaB in B cells | 65 | 1.41e-01 | 0.106000 | 2.11e-01 |
Packaging Of Telomere Ends | 25 | 3.61e-01 | 0.105000 | 4.60e-01 |
Biological oxidations | 157 | 2.26e-02 | 0.105000 | 4.44e-02 |
Stimuli-sensing channels | 84 | 9.56e-02 | -0.105000 | 1.53e-01 |
RHO GTPases Activate Formins | 118 | 4.96e-02 | -0.105000 | 8.68e-02 |
Metabolism of vitamins and cofactors | 171 | 1.86e-02 | -0.104000 | 3.73e-02 |
Formation of apoptosome | 11 | 5.50e-01 | -0.104000 | 6.37e-01 |
Regulation of the apoptosome activity | 11 | 5.50e-01 | -0.104000 | 6.37e-01 |
Smooth Muscle Contraction | 34 | 2.94e-01 | -0.104000 | 3.90e-01 |
Downregulation of ERBB2:ERBB3 signaling | 13 | 5.17e-01 | -0.104000 | 6.07e-01 |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 11 | 5.52e-01 | 0.103000 | 6.39e-01 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 15 | 4.88e-01 | -0.103000 | 5.83e-01 |
Phospholipase C-mediated cascade; FGFR3 | 11 | 5.56e-01 | 0.103000 | 6.41e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 29 | 3.39e-01 | -0.103000 | 4.38e-01 |
Cleavage of the damaged pyrimidine | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
Depyrimidination | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 34 | 3.05e-01 | 0.102000 | 4.01e-01 |
Glutamate Neurotransmitter Release Cycle | 23 | 4.00e-01 | -0.101000 | 4.97e-01 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 1.02e-01 | 0.101000 | 1.61e-01 |
Hedgehog ‘on’ state | 84 | 1.11e-01 | 0.100000 | 1.74e-01 |
Pyroptosis | 24 | 3.98e-01 | -0.099700 | 4.97e-01 |
G beta:gamma signalling through BTK | 14 | 5.19e-01 | -0.099500 | 6.08e-01 |
Regulated Necrosis | 51 | 2.21e-01 | -0.099100 | 3.10e-01 |
Cellular response to chemical stress | 150 | 3.65e-02 | 0.098900 | 6.60e-02 |
Mitochondrial calcium ion transport | 22 | 4.22e-01 | -0.098900 | 5.19e-01 |
RIPK1-mediated regulated necrosis | 27 | 3.76e-01 | -0.098500 | 4.74e-01 |
Regulation of necroptotic cell death | 27 | 3.76e-01 | -0.098500 | 4.74e-01 |
Phospholipase C-mediated cascade; FGFR2 | 15 | 5.09e-01 | 0.098400 | 6.00e-01 |
TP53 Regulates Transcription of Cell Cycle Genes | 48 | 2.39e-01 | -0.098200 | 3.32e-01 |
B-WICH complex positively regulates rRNA expression | 53 | 2.17e-01 | 0.097900 | 3.07e-01 |
Aggrephagy | 21 | 4.37e-01 | 0.097900 | 5.31e-01 |
Formation of tubulin folding intermediates by CCT/TriC | 23 | 4.24e-01 | -0.096400 | 5.20e-01 |
Fertilization | 16 | 5.05e-01 | 0.096400 | 5.97e-01 |
FGFR2 ligand binding and activation | 15 | 5.21e-01 | 0.095700 | 6.10e-01 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 12 | 5.67e-01 | 0.095400 | 6.52e-01 |
RHO GTPases activate PKNs | 53 | 2.30e-01 | -0.095300 | 3.22e-01 |
Formation of the Early Elongation Complex | 33 | 3.44e-01 | 0.095200 | 4.41e-01 |
Formation of the HIV-1 Early Elongation Complex | 33 | 3.44e-01 | 0.095200 | 4.41e-01 |
Dectin-2 family | 18 | 4.85e-01 | 0.095100 | 5.80e-01 |
HIV Transcription Initiation | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
RNA Polymerase II HIV Promoter Escape | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
RNA Polymerase II Promoter Escape | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
RNA Polymerase II Transcription Initiation | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 47 | 2.59e-01 | 0.095100 | 3.53e-01 |
Separation of Sister Chromatids | 168 | 3.51e-02 | 0.094200 | 6.41e-02 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 1.36e-01 | 0.094000 | 2.05e-01 |
Mitochondrial biogenesis | 91 | 1.21e-01 | -0.093900 | 1.86e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.09e-01 | 0.092600 | 6.00e-01 |
GABA synthesis, release, reuptake and degradation | 18 | 4.97e-01 | -0.092500 | 5.91e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 72 | 1.77e-01 | 0.092000 | 2.57e-01 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 30 | 3.83e-01 | 0.092000 | 4.83e-01 |
Collagen biosynthesis and modifying enzymes | 61 | 2.14e-01 | -0.091900 | 3.03e-01 |
Pre-NOTCH Transcription and Translation | 55 | 2.40e-01 | -0.091500 | 3.34e-01 |
Inactivation of CSF3 (G-CSF) signaling | 25 | 4.29e-01 | -0.091400 | 5.25e-01 |
RNA polymerase II transcribes snRNA genes | 71 | 1.84e-01 | -0.091200 | 2.65e-01 |
Telomere C-strand (Lagging Strand) Synthesis | 34 | 3.62e-01 | 0.090300 | 4.60e-01 |
TRAF6 mediated NF-kB activation | 23 | 4.55e-01 | -0.090000 | 5.50e-01 |
Maturation of nucleoprotein | 11 | 6.06e-01 | -0.089800 | 6.86e-01 |
Metabolism of porphyrins | 23 | 4.57e-01 | 0.089700 | 5.51e-01 |
Translesion Synthesis by POLH | 18 | 5.11e-01 | 0.089500 | 6.01e-01 |
Alpha-protein kinase 1 signaling pathway | 11 | 6.07e-01 | -0.089500 | 6.87e-01 |
Metabolism of water-soluble vitamins and cofactors | 117 | 9.51e-02 | -0.089300 | 1.52e-01 |
Transcription of E2F targets under negative control by DREAM complex | 19 | 5.02e-01 | 0.089000 | 5.95e-01 |
Signaling by FGFR2 | 67 | 2.07e-01 | -0.089000 | 2.95e-01 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 6.11e-01 | 0.088600 | 6.89e-01 |
ROS and RNS production in phagocytes | 32 | 3.86e-01 | 0.088500 | 4.85e-01 |
Complement cascade | 37 | 3.52e-01 | 0.088400 | 4.50e-01 |
Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.41e-01 | 0.088100 | 4.40e-01 |
Plasma lipoprotein assembly, remodeling, and clearance | 56 | 2.54e-01 | -0.088000 | 3.49e-01 |
Cytosolic sulfonation of small molecules | 21 | 4.88e-01 | -0.087500 | 5.82e-01 |
Formation of TC-NER Pre-Incision Complex | 53 | 2.73e-01 | 0.087000 | 3.67e-01 |
HIV Infection | 223 | 2.58e-02 | -0.086600 | 4.92e-02 |
Late endosomal microautophagy | 30 | 4.12e-01 | -0.086400 | 5.09e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.18e-01 | -0.085700 | 6.07e-01 |
Cellular Senescence | 153 | 6.85e-02 | -0.085300 | 1.15e-01 |
Transcriptional regulation of granulopoiesis | 52 | 2.93e-01 | -0.084300 | 3.89e-01 |
Nucleotide Excision Repair | 110 | 1.27e-01 | 0.084200 | 1.93e-01 |
Interconversion of nucleotide di- and triphosphates | 29 | 4.32e-01 | 0.084200 | 5.28e-01 |
Potassium Channels | 83 | 1.86e-01 | -0.084000 | 2.67e-01 |
Acyl chain remodelling of PI | 13 | 6.05e-01 | -0.083000 | 6.86e-01 |
Negative regulation of FLT3 | 14 | 5.93e-01 | -0.082600 | 6.76e-01 |
NGF-stimulated transcription | 40 | 3.69e-01 | -0.082100 | 4.68e-01 |
Processing of DNA double-strand break ends | 72 | 2.29e-01 | 0.082000 | 3.21e-01 |
Intraflagellar transport | 39 | 3.77e-01 | 0.081800 | 4.75e-01 |
G0 and Early G1 | 27 | 4.63e-01 | 0.081700 | 5.56e-01 |
IKK complex recruitment mediated by RIP1 | 22 | 5.08e-01 | -0.081500 | 6.00e-01 |
G beta:gamma signalling through PLC beta | 15 | 5.85e-01 | -0.081400 | 6.69e-01 |
Presynaptic function of Kainate receptors | 15 | 5.85e-01 | -0.081400 | 6.69e-01 |
Regulation of Complement cascade | 29 | 4.51e-01 | 0.080900 | 5.45e-01 |
Aspartate and asparagine metabolism | 10 | 6.59e-01 | 0.080500 | 7.33e-01 |
Cytoprotection by HMOX1 | 120 | 1.29e-01 | 0.080300 | 1.95e-01 |
TRP channels | 18 | 5.56e-01 | -0.080200 | 6.41e-01 |
Formation of RNA Pol II elongation complex | 57 | 2.96e-01 | -0.080000 | 3.92e-01 |
RNA Polymerase II Transcription Elongation | 57 | 2.96e-01 | -0.080000 | 3.92e-01 |
Plasma lipoprotein clearance | 29 | 4.58e-01 | -0.079700 | 5.52e-01 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
Diseases of DNA Double-Strand Break Repair | 24 | 5.03e-01 | 0.079000 | 5.95e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 51 | 3.29e-01 | -0.079000 | 4.28e-01 |
Antigen processing-Cross presentation | 98 | 1.78e-01 | 0.078700 | 2.58e-01 |
Downregulation of ERBB2 signaling | 28 | 4.72e-01 | -0.078600 | 5.67e-01 |
RA biosynthesis pathway | 17 | 5.78e-01 | 0.077900 | 6.64e-01 |
Interleukin-12 family signaling | 51 | 3.40e-01 | -0.077200 | 4.39e-01 |
Diseases of mitotic cell cycle | 38 | 4.24e-01 | 0.074900 | 5.20e-01 |
NF-kB is activated and signals survival | 13 | 6.40e-01 | -0.074800 | 7.17e-01 |
Cellular hexose transport | 17 | 5.94e-01 | 0.074700 | 6.77e-01 |
Termination of O-glycan biosynthesis | 19 | 5.74e-01 | -0.074500 | 6.60e-01 |
Gene Silencing by RNA | 97 | 2.06e-01 | -0.074300 | 2.94e-01 |
Killing mechanisms | 11 | 6.70e-01 | -0.074100 | 7.41e-01 |
WNT5:FZD7-mediated leishmania damping | 11 | 6.70e-01 | -0.074100 | 7.41e-01 |
Regulation of RAS by GAPs | 64 | 3.05e-01 | 0.074100 | 4.01e-01 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 5.22e-01 | -0.073900 | 6.11e-01 |
Transcriptional Regulation by TP53 | 356 | 1.74e-02 | -0.073300 | 3.51e-02 |
Acetylcholine Neurotransmitter Release Cycle | 15 | 6.23e-01 | -0.073300 | 7.01e-01 |
Collagen chain trimerization | 39 | 4.29e-01 | -0.073200 | 5.25e-01 |
Butyrophilin (BTN) family interactions | 10 | 6.91e-01 | 0.072700 | 7.60e-01 |
Apoptotic factor-mediated response | 19 | 5.88e-01 | -0.071800 | 6.72e-01 |
Striated Muscle Contraction | 27 | 5.20e-01 | 0.071500 | 6.09e-01 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 6.98e-01 | -0.070800 | 7.64e-01 |
p75NTR recruits signalling complexes | 13 | 6.61e-01 | -0.070300 | 7.33e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.16e-01 | 0.070300 | 6.94e-01 |
RNA Polymerase II Pre-transcription Events | 80 | 2.78e-01 | -0.070100 | 3.73e-01 |
Sensory perception of sweet, bitter, and umami (glutamate) taste | 20 | 5.89e-01 | -0.069800 | 6.73e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 4.59e-01 | 0.069400 | 5.53e-01 |
C-type lectin receptors (CLRs) | 128 | 1.76e-01 | -0.069300 | 2.55e-01 |
Mitotic G2-G2/M phases | 183 | 1.12e-01 | 0.068100 | 1.74e-01 |
Advanced glycosylation endproduct receptor signaling | 11 | 6.96e-01 | -0.068100 | 7.63e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 5.42e-01 | -0.067800 | 6.30e-01 |
NCAM1 interactions | 35 | 4.88e-01 | -0.067700 | 5.82e-01 |
Norepinephrine Neurotransmitter Release Cycle | 16 | 6.40e-01 | -0.067500 | 7.17e-01 |
Transcriptional regulation by RUNX1 | 187 | 1.12e-01 | -0.067300 | 1.75e-01 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 5.81e-01 | 0.066500 | 6.66e-01 |
HDR through Single Strand Annealing (SSA) | 37 | 4.85e-01 | 0.066300 | 5.80e-01 |
Mismatch Repair | 15 | 6.57e-01 | -0.066200 | 7.32e-01 |
Glycogen storage diseases | 14 | 6.69e-01 | 0.066000 | 7.41e-01 |
mRNA Capping | 29 | 5.39e-01 | 0.065900 | 6.27e-01 |
ERBB2 Activates PTK6 Signaling | 12 | 6.93e-01 | -0.065800 | 7.62e-01 |
Protein folding | 89 | 2.85e-01 | -0.065500 | 3.80e-01 |
G2/M Transition | 181 | 1.28e-01 | 0.065500 | 1.95e-01 |
Acyl chain remodelling of PC | 22 | 5.95e-01 | 0.065400 | 6.78e-01 |
MASTL Facilitates Mitotic Progression | 10 | 7.20e-01 | 0.065400 | 7.82e-01 |
Organelle biogenesis and maintenance | 272 | 6.94e-02 | -0.063900 | 1.17e-01 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 18 | 6.40e-01 | -0.063700 | 7.17e-01 |
TNFs bind their physiological receptors | 21 | 6.17e-01 | 0.063100 | 6.95e-01 |
GPCR ligand binding | 273 | 7.36e-02 | -0.062800 | 1.23e-01 |
Prostacyclin signalling through prostacyclin receptor | 15 | 6.74e-01 | -0.062700 | 7.44e-01 |
Acyl chain remodelling of PE | 23 | 6.04e-01 | 0.062400 | 6.86e-01 |
DNA Double Strand Break Response | 52 | 4.37e-01 | -0.062300 | 5.31e-01 |
Interferon gamma signaling | 80 | 3.37e-01 | -0.062100 | 4.35e-01 |
HATs acetylate histones | 101 | 2.83e-01 | -0.061800 | 3.78e-01 |
Serotonin Neurotransmitter Release Cycle | 17 | 6.60e-01 | -0.061600 | 7.33e-01 |
Nucleotide catabolism | 31 | 5.54e-01 | 0.061400 | 6.40e-01 |
TP53 Regulates Transcription of Cell Death Genes | 43 | 4.93e-01 | -0.060500 | 5.87e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 5.44e-01 | 0.060200 | 6.31e-01 |
Na+/Cl- dependent neurotransmitter transporters | 13 | 7.13e-01 | -0.059000 | 7.75e-01 |
Disorders of transmembrane transporters | 157 | 2.05e-01 | -0.058600 | 2.92e-01 |
tRNA processing in the nucleus | 59 | 4.36e-01 | -0.058600 | 5.31e-01 |
Signaling by NOTCH4 | 81 | 3.64e-01 | 0.058300 | 4.63e-01 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 15 | 6.98e-01 | 0.057900 | 7.64e-01 |
Fatty acid metabolism | 153 | 2.18e-01 | -0.057700 | 3.07e-01 |
RNA Polymerase I Transcription Initiation | 47 | 4.97e-01 | 0.057300 | 5.91e-01 |
HDR through MMEJ (alt-NHEJ) | 10 | 7.54e-01 | -0.057200 | 8.10e-01 |
ABC-family proteins mediated transport | 97 | 3.32e-01 | 0.057000 | 4.31e-01 |
Recycling of bile acids and salts | 13 | 7.22e-01 | 0.056900 | 7.84e-01 |
Activation of HOX genes during differentiation | 82 | 3.74e-01 | -0.056800 | 4.73e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 82 | 3.74e-01 | -0.056800 | 4.73e-01 |
Glyoxylate metabolism and glycine degradation | 25 | 6.24e-01 | -0.056600 | 7.02e-01 |
Processing of Capped Intronless Pre-mRNA | 28 | 6.05e-01 | 0.056400 | 6.86e-01 |
Regulation of PTEN stability and activity | 67 | 4.27e-01 | 0.056100 | 5.24e-01 |
Mitophagy | 28 | 6.08e-01 | -0.055900 | 6.87e-01 |
Positive epigenetic regulation of rRNA expression | 68 | 4.30e-01 | 0.055400 | 5.25e-01 |
Diseases of DNA repair | 34 | 5.83e-01 | 0.054500 | 6.68e-01 |
Phase 2 - plateau phase | 14 | 7.28e-01 | 0.053700 | 7.89e-01 |
Incretin synthesis, secretion, and inactivation | 18 | 6.94e-01 | -0.053600 | 7.62e-01 |
Chaperone Mediated Autophagy | 18 | 6.96e-01 | -0.053300 | 7.63e-01 |
MAPK6/MAPK4 signaling | 87 | 3.97e-01 | -0.052600 | 4.96e-01 |
DNA Damage/Telomere Stress Induced Senescence | 52 | 5.16e-01 | -0.052100 | 6.06e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 33 | 6.05e-01 | 0.052100 | 6.86e-01 |
Trafficking and processing of endosomal TLR | 11 | 7.66e-01 | -0.051900 | 8.18e-01 |
Bile acid and bile salt metabolism | 37 | 5.85e-01 | -0.051800 | 6.69e-01 |
Plasma lipoprotein remodeling | 23 | 6.69e-01 | -0.051400 | 7.41e-01 |
Degradation of beta-catenin by the destruction complex | 83 | 4.18e-01 | -0.051400 | 5.16e-01 |
Mitotic Spindle Checkpoint | 109 | 3.56e-01 | 0.051100 | 4.55e-01 |
Downstream TCR signaling | 90 | 4.07e-01 | 0.050500 | 5.04e-01 |
ABC transporters in lipid homeostasis | 15 | 7.37e-01 | 0.050100 | 7.97e-01 |
CLEC7A (Dectin-1) signaling | 97 | 4.05e-01 | -0.048900 | 5.02e-01 |
Hedgehog ‘off’ state | 95 | 4.14e-01 | 0.048500 | 5.11e-01 |
Metabolic disorders of biological oxidation enzymes | 30 | 6.46e-01 | 0.048400 | 7.21e-01 |
Cilium Assembly | 181 | 2.62e-01 | -0.048300 | 3.55e-01 |
Cellular response to hypoxia | 73 | 4.78e-01 | 0.048000 | 5.74e-01 |
Interferon alpha/beta signaling | 57 | 5.33e-01 | 0.047700 | 6.21e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 27 | 6.68e-01 | -0.047700 | 7.41e-01 |
Amyloid fiber formation | 60 | 5.25e-01 | 0.047400 | 6.12e-01 |
Inwardly rectifying K+ channels | 29 | 6.60e-01 | 0.047300 | 7.33e-01 |
LGI-ADAM interactions | 12 | 7.77e-01 | -0.047200 | 8.28e-01 |
Diseases associated with N-glycosylation of proteins | 17 | 7.38e-01 | -0.046900 | 7.97e-01 |
Xenobiotics | 15 | 7.53e-01 | -0.046800 | 8.10e-01 |
Activated point mutants of FGFR2 | 14 | 7.62e-01 | 0.046800 | 8.16e-01 |
Cyclin A/B1/B2 associated events during G2/M transition | 25 | 6.88e-01 | 0.046300 | 7.58e-01 |
Insulin receptor recycling | 24 | 6.96e-01 | 0.046100 | 7.63e-01 |
Signaling by Retinoic Acid | 37 | 6.31e-01 | -0.045600 | 7.10e-01 |
FGFR2c ligand binding and activation | 10 | 8.03e-01 | 0.045500 | 8.48e-01 |
PCP/CE pathway | 90 | 4.59e-01 | -0.045100 | 5.53e-01 |
RNA Polymerase III Chain Elongation | 18 | 7.41e-01 | 0.045000 | 7.99e-01 |
TP53 Regulates Metabolic Genes | 85 | 4.80e-01 | -0.044300 | 5.75e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 7.39e-01 | -0.044200 | 7.98e-01 |
Activation of G protein gated Potassium channels | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
G protein gated Potassium channels | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 24 | 7.11e-01 | 0.043700 | 7.74e-01 |
Membrane binding and targetting of GAG proteins | 14 | 7.80e-01 | -0.043000 | 8.30e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 7.80e-01 | -0.043000 | 8.30e-01 |
Signaling by FGFR2 in disease | 40 | 6.39e-01 | -0.042900 | 7.17e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 64 | 5.57e-01 | -0.042400 | 6.42e-01 |
FCERI mediated NF-kB activation | 76 | 5.38e-01 | 0.040900 | 6.26e-01 |
Cytochrome P450 - arranged by substrate type | 46 | 6.34e-01 | -0.040600 | 7.12e-01 |
Glucagon-type ligand receptors | 23 | 7.42e-01 | -0.039700 | 8.00e-01 |
Phase I - Functionalization of compounds | 76 | 5.53e-01 | 0.039400 | 6.39e-01 |
Carboxyterminal post-translational modifications of tubulin | 37 | 6.79e-01 | -0.039300 | 7.49e-01 |
Diseases of carbohydrate metabolism | 30 | 7.13e-01 | -0.038800 | 7.75e-01 |
Lysine catabolism | 12 | 8.17e-01 | -0.038700 | 8.58e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 16 | 7.89e-01 | -0.038600 | 8.37e-01 |
Regulation of BACH1 activity | 11 | 8.25e-01 | 0.038600 | 8.65e-01 |
Suppression of phagosomal maturation | 13 | 8.11e-01 | 0.038300 | 8.53e-01 |
Assembly Of The HIV Virion | 16 | 7.93e-01 | -0.037900 | 8.40e-01 |
SUMOylation of DNA methylation proteins | 16 | 7.94e-01 | 0.037700 | 8.40e-01 |
Transcriptional Regulation by E2F6 | 34 | 7.05e-01 | -0.037500 | 7.70e-01 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 7.96e-01 | 0.037400 | 8.41e-01 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 8.39e-01 | 0.037100 | 8.78e-01 |
FGFR3 ligand binding and activation | 11 | 8.32e-01 | -0.037000 | 8.71e-01 |
FGFR3c ligand binding and activation | 11 | 8.32e-01 | -0.037000 | 8.71e-01 |
Amino acids regulate mTORC1 | 51 | 6.49e-01 | -0.036900 | 7.23e-01 |
Resolution of Sister Chromatid Cohesion | 105 | 5.14e-01 | -0.036900 | 6.04e-01 |
Olfactory Signaling Pathway | 24 | 7.55e-01 | 0.036700 | 8.11e-01 |
Regulation of TP53 Activity through Phosphorylation | 91 | 5.45e-01 | -0.036700 | 6.32e-01 |
Epigenetic regulation of gene expression | 110 | 5.07e-01 | 0.036600 | 5.99e-01 |
Metabolism | 1881 | 8.46e-03 | -0.036400 | 1.87e-02 |
Polymerase switching on the C-strand of the telomere | 26 | 7.49e-01 | 0.036200 | 8.07e-01 |
Host Interactions of HIV factors | 125 | 4.86e-01 | -0.036100 | 5.81e-01 |
Nicotinamide salvaging | 18 | 7.91e-01 | -0.036100 | 8.39e-01 |
Regulation of innate immune responses to cytosolic DNA | 14 | 8.16e-01 | 0.035800 | 8.58e-01 |
Peptide ligand-binding receptors | 106 | 5.24e-01 | 0.035800 | 6.12e-01 |
FGFR1 ligand binding and activation | 13 | 8.24e-01 | -0.035700 | 8.65e-01 |
Beta-oxidation of very long chain fatty acids | 10 | 8.46e-01 | 0.035600 | 8.83e-01 |
Metabolism of folate and pterines | 16 | 8.06e-01 | -0.035500 | 8.50e-01 |
Reproduction | 92 | 5.60e-01 | 0.035100 | 6.45e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 6.06e-01 | 0.035100 | 6.86e-01 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 7.04e-01 | -0.034300 | 7.70e-01 |
RNA Polymerase III Transcription | 41 | 7.04e-01 | -0.034300 | 7.70e-01 |
EML4 and NUDC in mitotic spindle formation | 96 | 5.64e-01 | -0.034000 | 6.50e-01 |
Metabolism of steroid hormones | 30 | 7.50e-01 | -0.033600 | 8.08e-01 |
Regulation of TNFR1 signaling | 35 | 7.31e-01 | -0.033600 | 7.92e-01 |
Class A/1 (Rhodopsin-like receptors) | 187 | 4.41e-01 | -0.032700 | 5.34e-01 |
Transcription of the HIV genome | 69 | 6.49e-01 | -0.031700 | 7.23e-01 |
Mitotic Metaphase and Anaphase | 229 | 4.12e-01 | 0.031500 | 5.09e-01 |
Telomere Extension By Telomerase | 23 | 7.94e-01 | -0.031500 | 8.40e-01 |
Defects in cobalamin (B12) metabolism | 13 | 8.45e-01 | -0.031300 | 8.82e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 8.47e-01 | -0.031000 | 8.83e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 7.77e-01 | -0.030900 | 8.28e-01 |
Mitotic Anaphase | 228 | 4.21e-01 | 0.030900 | 5.18e-01 |
FGFR3 mutant receptor activation | 10 | 8.66e-01 | 0.030800 | 8.95e-01 |
Signaling by activated point mutants of FGFR3 | 10 | 8.66e-01 | 0.030800 | 8.95e-01 |
Folding of actin by CCT/TriC | 10 | 8.71e-01 | -0.029800 | 8.97e-01 |
Oxidative Stress Induced Senescence | 83 | 6.43e-01 | -0.029400 | 7.20e-01 |
SUMOylation of immune response proteins | 11 | 8.66e-01 | -0.029300 | 8.95e-01 |
Iron uptake and transport | 56 | 7.08e-01 | -0.028900 | 7.73e-01 |
Heme biosynthesis | 13 | 8.57e-01 | 0.028900 | 8.91e-01 |
DNA Repair | 298 | 4.02e-01 | 0.028200 | 4.99e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 8.33e-01 | -0.028000 | 8.72e-01 |
PINK1-PRKN Mediated Mitophagy | 21 | 8.25e-01 | 0.027900 | 8.65e-01 |
Downstream signaling events of B Cell Receptor (BCR) | 79 | 6.73e-01 | 0.027500 | 7.44e-01 |
Interleukin-1 family signaling | 126 | 5.96e-01 | -0.027300 | 6.78e-01 |
Early Phase of HIV Life Cycle | 13 | 8.65e-01 | 0.027200 | 8.95e-01 |
Acyl chain remodelling of PG | 13 | 8.66e-01 | -0.027000 | 8.95e-01 |
Transport of Mature Transcript to Cytoplasm | 81 | 6.83e-01 | 0.026200 | 7.53e-01 |
Generation of second messenger molecules | 29 | 8.07e-01 | 0.026100 | 8.51e-01 |
Interleukin-12 signaling | 43 | 7.68e-01 | -0.026000 | 8.20e-01 |
RMTs methylate histone arginines | 44 | 7.65e-01 | 0.026000 | 8.18e-01 |
Signaling by Hedgehog | 132 | 6.08e-01 | -0.025800 | 6.87e-01 |
DNA Double-Strand Break Repair | 140 | 5.98e-01 | 0.025800 | 6.80e-01 |
Phospholipase C-mediated cascade: FGFR1 | 14 | 8.69e-01 | 0.025400 | 8.97e-01 |
Transcriptional regulation by small RNAs | 69 | 7.19e-01 | -0.025000 | 7.81e-01 |
Transcriptional regulation by RUNX2 | 116 | 6.46e-01 | -0.024700 | 7.21e-01 |
Anchoring of the basal body to the plasma membrane | 97 | 6.74e-01 | 0.024700 | 7.44e-01 |
Protein localization | 158 | 5.95e-01 | 0.024500 | 6.78e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
HIV Transcription Elongation | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 7.85e-01 | 0.024300 | 8.33e-01 |
NRIF signals cell death from the nucleus | 16 | 8.70e-01 | 0.023700 | 8.97e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 57 | 7.62e-01 | -0.023200 | 8.16e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 8.81e-01 | -0.023100 | 9.08e-01 |
Meiosis | 76 | 7.38e-01 | 0.022200 | 7.97e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.04e-01 | 0.022100 | 9.26e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 81 | 7.32e-01 | -0.022000 | 7.92e-01 |
Cell Cycle, Mitotic | 513 | 3.96e-01 | 0.021800 | 4.96e-01 |
Cell Cycle | 637 | 3.52e-01 | 0.021600 | 4.50e-01 |
Other interleukin signaling | 22 | 8.65e-01 | -0.020900 | 8.95e-01 |
AURKA Activation by TPX2 | 72 | 7.65e-01 | 0.020400 | 8.18e-01 |
G2/M DNA damage checkpoint | 69 | 7.70e-01 | 0.020400 | 8.21e-01 |
Meiotic synapsis | 50 | 8.04e-01 | -0.020300 | 8.49e-01 |
Centrosome maturation | 81 | 7.59e-01 | 0.019800 | 8.14e-01 |
Recruitment of mitotic centrosome proteins and complexes | 81 | 7.59e-01 | 0.019800 | 8.14e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 8.58e-01 | 0.018900 | 8.91e-01 |
Tat-mediated HIV elongation arrest and recovery | 30 | 8.58e-01 | 0.018900 | 8.91e-01 |
Synthesis of PE | 13 | 9.11e-01 | 0.017800 | 9.32e-01 |
RNA Polymerase III Transcription Initiation | 36 | 8.60e-01 | -0.017000 | 8.93e-01 |
Eicosanoid ligand-binding receptors | 12 | 9.21e-01 | -0.016600 | 9.40e-01 |
Vitamin B5 (pantothenate) metabolism | 17 | 9.08e-01 | 0.016200 | 9.29e-01 |
Triglyceride biosynthesis | 10 | 9.31e-01 | 0.015700 | 9.49e-01 |
Transferrin endocytosis and recycling | 30 | 8.82e-01 | 0.015600 | 9.08e-01 |
HDACs deacetylate histones | 54 | 8.43e-01 | 0.015500 | 8.82e-01 |
Metabolism of nucleotides | 90 | 8.07e-01 | 0.014900 | 8.50e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 8.65e-01 | 0.014800 | 8.95e-01 |
Interleukin-10 signaling | 33 | 8.88e-01 | -0.014200 | 9.12e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 9.04e-01 | -0.013200 | 9.26e-01 |
Formation of Incision Complex in GG-NER | 43 | 8.82e-01 | -0.013000 | 9.08e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 9.34e-01 | -0.012800 | 9.51e-01 |
Nucleotide salvage | 21 | 9.26e-01 | 0.011700 | 9.45e-01 |
Cellular responses to stress | 677 | 6.45e-01 | -0.010400 | 7.21e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 8.91e-01 | 0.010100 | 9.15e-01 |
TCR signaling | 110 | 8.55e-01 | -0.010100 | 8.91e-01 |
Nicotinate metabolism | 29 | 9.27e-01 | -0.009790 | 9.46e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 14 | 9.58e-01 | -0.008170 | 9.70e-01 |
Interleukin-1 signaling | 96 | 8.94e-01 | -0.007870 | 9.17e-01 |
Mitotic Prometaphase | 186 | 8.56e-01 | -0.007690 | 8.91e-01 |
Regulation of PLK1 Activity at G2/M Transition | 87 | 9.12e-01 | -0.006820 | 9.33e-01 |
Hyaluronan uptake and degradation | 10 | 9.71e-01 | 0.006590 | 9.82e-01 |
MicroRNA (miRNA) biogenesis | 24 | 9.57e-01 | 0.006350 | 9.70e-01 |
Diseases associated with the TLR signaling cascade | 28 | 9.55e-01 | 0.006170 | 9.69e-01 |
Diseases of Immune System | 28 | 9.55e-01 | 0.006170 | 9.69e-01 |
HIV elongation arrest and recovery | 32 | 9.52e-01 | 0.006160 | 9.67e-01 |
Pausing and recovery of HIV elongation | 32 | 9.52e-01 | 0.006160 | 9.67e-01 |
M Phase | 371 | 8.65e-01 | 0.005140 | 8.95e-01 |
Phase 0 - rapid depolarisation | 29 | 9.64e-01 | 0.004900 | 9.75e-01 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 92 | 9.41e-01 | -0.004450 | 9.57e-01 |
Amplification of signal from the kinetochores | 92 | 9.41e-01 | -0.004450 | 9.57e-01 |
Metalloprotease DUBs | 26 | 9.70e-01 | 0.004320 | 9.81e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 9.83e-01 | 0.003460 | 9.89e-01 |
Acyl chain remodelling of PS | 18 | 9.81e-01 | -0.003310 | 9.87e-01 |
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 13 | 9.84e-01 | -0.003180 | 9.89e-01 |
Cellular responses to stimuli | 687 | 8.94e-01 | -0.002970 | 9.17e-01 |
Transcriptional Regulation by VENTX | 38 | 9.76e-01 | -0.002800 | 9.84e-01 |
DNA Damage Bypass | 47 | 9.74e-01 | -0.002720 | 9.84e-01 |
Keratinization | 47 | 9.77e-01 | 0.002400 | 9.85e-01 |
Nucleotide-like (purinergic) receptors | 12 | 9.89e-01 | -0.002400 | 9.93e-01 |
Sensory perception of taste | 25 | 9.84e-01 | 0.002380 | 9.89e-01 |
Loss of Nlp from mitotic centrosomes | 69 | 9.76e-01 | 0.002060 | 9.84e-01 |
Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 9.76e-01 | 0.002060 | 9.84e-01 |
Processing of SMDT1 | 15 | 9.95e-01 | 0.000943 | 9.98e-01 |
RNA Polymerase III Transcription Termination | 23 | 9.95e-01 | 0.000788 | 9.98e-01 |
Pregnenolone biosynthesis | 11 | 9.97e-01 | 0.000640 | 9.98e-01 |
Crosslinking of collagen fibrils | 10 | 9.98e-01 | -0.000505 | 9.98e-01 |
Recruitment of NuMA to mitotic centrosomes | 80 | 9.96e-01 | 0.000343 | 9.98e-01 |
Josephin domain DUBs | 10 | 9.99e-01 | -0.000291 | 9.99e-01 |
CLEC7A (Dectin-1) induces NFAT activation
134 | |
---|---|
set | CLEC7A (Dectin-1) induces NFAT activation |
setSize | 11 |
pANOVA | 9.68e-07 |
s.dist | -0.853 |
p.adjustANOVA | 6.07e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITPR1 | -11377 |
ITPR3 | -10980 |
AHCYL1 | -10915 |
PPP3CA | -10754 |
ITPR2 | -10484 |
PPP3R1 | -10098 |
NFATC3 | -9412 |
NFATC1 | -9330 |
PPP3CB | -7240 |
CALM1 | -7050 |
NFATC2 | -6401 |
GeneID | Gene Rank |
---|---|
ITPR1 | -11377 |
ITPR3 | -10980 |
AHCYL1 | -10915 |
PPP3CA | -10754 |
ITPR2 | -10484 |
PPP3R1 | -10098 |
NFATC3 | -9412 |
NFATC1 | -9330 |
PPP3CB | -7240 |
CALM1 | -7050 |
NFATC2 | -6401 |
Cohesin Loading onto Chromatin
203 | |
---|---|
set | Cohesin Loading onto Chromatin |
setSize | 10 |
pANOVA | 3.04e-06 |
s.dist | -0.852 |
p.adjustANOVA | 1.63e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WAPL | -10914 |
NIPBL | -10299 |
RAD21 | -10290 |
PDS5A | -10246 |
STAG2 | -10214 |
SMC1A | -9265 |
PDS5B | -9064 |
STAG1 | -8365 |
MAU2 | -8358 |
SMC3 | -7530 |
GeneID | Gene Rank |
---|---|
WAPL | -10914 |
NIPBL | -10299 |
RAD21 | -10290 |
PDS5A | -10246 |
STAG2 | -10214 |
SMC1A | -9265 |
PDS5B | -9064 |
STAG1 | -8365 |
MAU2 | -8358 |
SMC3 | -7530 |
Laminin interactions
630 | |
---|---|
set | Laminin interactions |
setSize | 23 |
pANOVA | 4.4e-11 |
s.dist | -0.793 |
p.adjustANOVA | 5.87e-10 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
ITGA6 | -11286 |
NID1 | -11180 |
ITGAV | -11113 |
LAMB2 | -10934 |
ITGA1 | -10654 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
LAMA1 | -10193 |
HSPG2 | -9870 |
ITGA3 | -9698 |
ITGB4 | -8554 |
ITGA7 | -7619 |
NID2 | -7130 |
LAMC2 | -6635 |
COL18A1 | -6473 |
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
ITGA6 | -11286 |
NID1 | -11180 |
ITGAV | -11113 |
LAMB2 | -10934 |
ITGA1 | -10654 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
LAMA1 | -10193 |
HSPG2 | -9870 |
ITGA3 | -9698 |
ITGB4 | -8554 |
ITGA7 | -7619 |
NID2 | -7130 |
LAMC2 | -6635 |
COL18A1 | -6473 |
LAMA2 | -4266 |
LAMC3 | -2462 |
LAMA3 | 5212 |
S33 mutants of beta-catenin aren’t phosphorylated
1103 | |
---|---|
set | S33 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
S37 mutants of beta-catenin aren’t phosphorylated
1104 | |
---|---|
set | S37 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
S45 mutants of beta-catenin aren’t phosphorylated
1105 | |
---|---|
set | S45 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by CTNNB1 phospho-site mutants
1175 | |
---|---|
set | Signaling by CTNNB1 phospho-site mutants |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by GSK3beta mutants
1202 | |
---|---|
set | Signaling by GSK3beta mutants |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
T41 mutants of beta-catenin aren’t phosphorylated
1293 | |
---|---|
set | T41 mutants of beta-catenin aren’t phosphorylated |
setSize | 15 |
pANOVA | 1.53e-07 |
s.dist | -0.783 |
p.adjustANOVA | 1.16e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by Hippo
1204 | |
---|---|
set | Signaling by Hippo |
setSize | 20 |
pANOVA | 1.64e-09 |
s.dist | -0.779 |
p.adjustANOVA | 1.78e-08 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AMOTL1 | -11249 |
YAP1 | -11062 |
TJP1 | -10967 |
WWTR1 | -10838 |
AMOT | -10567 |
LATS1 | -10224 |
TJP2 | -10124 |
SAV1 | -9569 |
LATS2 | -9336 |
MOB1A | -9309 |
STK4 | -9279 |
AMOTL2 | -9241 |
MOB1B | -8267 |
CASP3 | -8212 |
STK3 | -7927 |
DVL2 | -7004 |
YWHAB | -6645 |
NPHP4 | -6309 |
WWC1 | -5132 |
YWHAE | 1543 |
GeneID | Gene Rank |
---|---|
AMOTL1 | -11249 |
YAP1 | -11062 |
TJP1 | -10967 |
WWTR1 | -10838 |
AMOT | -10567 |
LATS1 | -10224 |
TJP2 | -10124 |
SAV1 | -9569 |
LATS2 | -9336 |
MOB1A | -9309 |
STK4 | -9279 |
AMOTL2 | -9241 |
MOB1B | -8267 |
CASP3 | -8212 |
STK3 | -7927 |
DVL2 | -7004 |
YWHAB | -6645 |
NPHP4 | -6309 |
WWC1 | -5132 |
YWHAE | 1543 |
Syndecan interactions
1268 | |
---|---|
set | Syndecan interactions |
setSize | 20 |
pANOVA | 1.76e-09 |
s.dist | -0.777 |
p.adjustANOVA | 1.88e-08 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITGB3 | -11388 |
ITGB1 | -11317 |
ITGA2 | -11315 |
ITGA6 | -11286 |
ITGAV | -11113 |
TNC | -10940 |
ACTN1 | -10918 |
SDC4 | -10735 |
PRKCA | -10498 |
ITGB5 | -10206 |
TGFB1 | -8918 |
CASK | -8743 |
ITGB4 | -8554 |
THBS1 | -7620 |
SDC1 | -7206 |
SDC3 | -6862 |
SDC2 | -5839 |
FGF2 | -5306 |
TRAPPC4 | -4762 |
VTN | 4190 |
GeneID | Gene Rank |
---|---|
ITGB3 | -11388 |
ITGB1 | -11317 |
ITGA2 | -11315 |
ITGA6 | -11286 |
ITGAV | -11113 |
TNC | -10940 |
ACTN1 | -10918 |
SDC4 | -10735 |
PRKCA | -10498 |
ITGB5 | -10206 |
TGFB1 | -8918 |
CASK | -8743 |
ITGB4 | -8554 |
THBS1 | -7620 |
SDC1 | -7206 |
SDC3 | -6862 |
SDC2 | -5839 |
FGF2 | -5306 |
TRAPPC4 | -4762 |
VTN | 4190 |
MET activates RAP1 and RAC1
658 | |
---|---|
set | MET activates RAP1 and RAC1 |
setSize | 11 |
pANOVA | 8.89e-06 |
s.dist | -0.773 |
p.adjustANOVA | 4.31e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MET | -11149 |
DOCK7 | -10847 |
GRB2 | -10626 |
CRKL | -10083 |
RAPGEF1 | -9150 |
RAP1B | -9004 |
CRK | -8881 |
GAB1 | -8325 |
RAP1A | -6474 |
HGF | -4279 |
RAC1 | -3826 |
GeneID | Gene Rank |
---|---|
MET | -11149 |
DOCK7 | -10847 |
GRB2 | -10626 |
CRKL | -10083 |
RAPGEF1 | -9150 |
RAP1B | -9004 |
CRK | -8881 |
GAB1 | -8325 |
RAP1A | -6474 |
HGF | -4279 |
RAC1 | -3826 |
APC truncation mutants have impaired AXIN binding
11 | |
---|---|
set | APC truncation mutants have impaired AXIN binding |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
AXIN missense mutants destabilize the destruction complex
24 | |
---|---|
set | AXIN missense mutants destabilize the destruction complex |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by AMER1 mutants
1168 | |
---|---|
set | Signaling by AMER1 mutants |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by APC mutants
1169 | |
---|---|
set | Signaling by APC mutants |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Signaling by AXIN mutants
1170 | |
---|---|
set | Signaling by AXIN mutants |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
Truncations of AMER1 destabilize the destruction complex
1410 | |
---|---|
set | Truncations of AMER1 destabilize the destruction complex |
setSize | 14 |
pANOVA | 6.48e-07 |
s.dist | -0.768 |
p.adjustANOVA | 4.24e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
ERKs are inactivated
357 | |
---|---|
set | ERKs are inactivated |
setSize | 13 |
pANOVA | 1.68e-06 |
s.dist | -0.767 |
p.adjustANOVA | 9.67e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DUSP4 | -11285 |
PPP2R5D | -11215 |
MAPK1 | -11008 |
DUSP7 | -10143 |
PPP2CB | -10130 |
DUSP3 | -9469 |
MAPK3 | -9373 |
PPP2CA | -7327 |
VRK3 | -7235 |
DUSP6 | -6006 |
PPP2R1B | -5567 |
PPP2R1A | -4930 |
MAPK7 | -4670 |
GeneID | Gene Rank |
---|---|
DUSP4 | -11285 |
PPP2R5D | -11215 |
MAPK1 | -11008 |
DUSP7 | -10143 |
PPP2CB | -10130 |
DUSP3 | -9469 |
MAPK3 | -9373 |
PPP2CA | -7327 |
VRK3 | -7235 |
DUSP6 | -6006 |
PPP2R1B | -5567 |
PPP2R1A | -4930 |
MAPK7 | -4670 |
MET activates PTK2 signaling
657 | |
---|---|
set | MET activates PTK2 signaling |
setSize | 18 |
pANOVA | 2.19e-08 |
s.dist | -0.762 |
p.adjustANOVA | 2.01e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
MET | -11149 |
LAMB2 | -10934 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
PTK2 | -10250 |
LAMA1 | -10193 |
ITGA3 | -9698 |
SRC | -7386 |
LAMC2 | -6635 |
HGF | -4279 |
LAMA2 | -4266 |
LAMC3 | -2462 |
LAMA3 | 5212 |
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
MET | -11149 |
LAMB2 | -10934 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
PTK2 | -10250 |
LAMA1 | -10193 |
ITGA3 | -9698 |
SRC | -7386 |
LAMC2 | -6635 |
HGF | -4279 |
LAMA2 | -4266 |
LAMC3 | -2462 |
LAMA3 | 5212 |
Establishment of Sister Chromatid Cohesion
372 | |
---|---|
set | Establishment of Sister Chromatid Cohesion |
setSize | 11 |
pANOVA | 1.5e-05 |
s.dist | -0.754 |
p.adjustANOVA | 6.74e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WAPL | -10914 |
RAD21 | -10290 |
PDS5A | -10246 |
STAG2 | -10214 |
ESCO1 | -9347 |
SMC1A | -9265 |
PDS5B | -9064 |
STAG1 | -8365 |
SMC3 | -7530 |
ESCO2 | -3964 |
CDCA5 | -597 |
GeneID | Gene Rank |
---|---|
WAPL | -10914 |
RAD21 | -10290 |
PDS5A | -10246 |
STAG2 | -10214 |
ESCO1 | -9347 |
SMC1A | -9265 |
PDS5B | -9064 |
STAG1 | -8365 |
SMC3 | -7530 |
ESCO2 | -3964 |
CDCA5 | -597 |
MET promotes cell motility
660 | |
---|---|
set | MET promotes cell motility |
setSize | 29 |
pANOVA | 5.6e-12 |
s.dist | -0.739 |
p.adjustANOVA | 8.81e-11 |
Top enriched genes
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
MET | -11149 |
LAMB2 | -10934 |
DOCK7 | -10847 |
GRB2 | -10626 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
PTK2 | -10250 |
LAMA1 | -10193 |
CRKL | -10083 |
ITGA3 | -9698 |
RAPGEF1 | -9150 |
RAP1B | -9004 |
TNS3 | -8959 |
CRK | -8881 |
GAB1 | -8325 |
GeneID | Gene Rank |
---|---|
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
MET | -11149 |
LAMB2 | -10934 |
DOCK7 | -10847 |
GRB2 | -10626 |
LAMA5 | -10549 |
LAMA4 | -10450 |
LAMB1 | -10431 |
PTK2 | -10250 |
LAMA1 | -10193 |
CRKL | -10083 |
ITGA3 | -9698 |
RAPGEF1 | -9150 |
RAP1B | -9004 |
TNS3 | -8959 |
CRK | -8881 |
GAB1 | -8325 |
SRC | -7386 |
LAMC2 | -6635 |
RAP1A | -6474 |
HGF | -4279 |
LAMA2 | -4266 |
RAC1 | -3826 |
LAMC3 | -2462 |
TNS4 | 4061 |
LAMA3 | 5212 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS
270 | |
---|---|
set | Defective EXT1 causes exostoses 1, TRPS2 and CHDS |
setSize | 13 |
pANOVA | 4.77e-06 |
s.dist | -0.733 |
p.adjustANOVA | 2.44e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
EXT2 | -9326 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
EXT1 | -6377 |
SDC2 | -5839 |
GPC2 | -3380 |
GPC5 | -3235 |
GeneID | Gene Rank |
---|---|
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
EXT2 | -9326 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
EXT1 | -6377 |
SDC2 | -5839 |
GPC2 | -3380 |
GPC5 | -3235 |
Defective EXT2 causes exostoses 2
271 | |
---|---|
set | Defective EXT2 causes exostoses 2 |
setSize | 13 |
pANOVA | 4.77e-06 |
s.dist | -0.733 |
p.adjustANOVA | 2.44e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
EXT2 | -9326 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
EXT1 | -6377 |
SDC2 | -5839 |
GPC2 | -3380 |
GPC5 | -3235 |
GeneID | Gene Rank |
---|---|
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
EXT2 | -9326 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
EXT1 | -6377 |
SDC2 | -5839 |
GPC2 | -3380 |
GPC5 | -3235 |
tRNA processing in the mitochondrion
1477 | |
---|---|
set | tRNA processing in the mitochondrion |
setSize | 20 |
pANOVA | 1.43e-08 |
s.dist | 0.732 |
p.adjustANOVA | 1.35e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-CYB | 14772 |
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-CO2 | 14768 |
MT-CO1 | 14766 |
MT-ND1 | 14765 |
MT-CO3 | 14764 |
MT-ND4 | 14762 |
MT-ND4L | 14760 |
MT-RNR1 | 14757 |
MT-RNR2 | 14756 |
MT-ND6 | 14633 |
MT-ATP6 | 14606 |
MT-ND5 | 14600 |
MT-ATP8 | 14192 |
HSD17B10 | 13513 |
TRMT10C | 4645 |
ELAC2 | -1278 |
TRNT1 | -3642 |
PRORP | -8469 |
GeneID | Gene Rank |
---|---|
MT-CYB | 14772 |
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-CO2 | 14768 |
MT-CO1 | 14766 |
MT-ND1 | 14765 |
MT-CO3 | 14764 |
MT-ND4 | 14762 |
MT-ND4L | 14760 |
MT-RNR1 | 14757 |
MT-RNR2 | 14756 |
MT-ND6 | 14633 |
MT-ATP6 | 14606 |
MT-ND5 | 14600 |
MT-ATP8 | 14192 |
HSD17B10 | 13513 |
TRMT10C | 4645 |
ELAC2 | -1278 |
TRNT1 | -3642 |
PRORP | -8469 |
Synthesis of PIPs at the early endosome membrane
1278 | |
---|---|
set | Synthesis of PIPs at the early endosome membrane |
setSize | 16 |
pANOVA | 4.19e-07 |
s.dist | -0.73 |
p.adjustANOVA | 2.92e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MTMR12 | -11240 |
PIKFYVE | -10408 |
PIK3C2A | -9621 |
PIK3R4 | -9524 |
MTMR2 | -9438 |
INPP4A | -8999 |
MTMR4 | -8979 |
INPP5F | -8487 |
PIK3C3 | -7967 |
MTM1 | -7910 |
VAC14 | -7876 |
PI4K2B | -7570 |
PI4K2A | -6857 |
MTMR10 | -6497 |
FIG4 | -5627 |
INPP4B | 1266 |
GeneID | Gene Rank |
---|---|
MTMR12 | -11240 |
PIKFYVE | -10408 |
PIK3C2A | -9621 |
PIK3R4 | -9524 |
MTMR2 | -9438 |
INPP4A | -8999 |
MTMR4 | -8979 |
INPP5F | -8487 |
PIK3C3 | -7967 |
MTM1 | -7910 |
VAC14 | -7876 |
PI4K2B | -7570 |
PI4K2A | -6857 |
MTMR10 | -6497 |
FIG4 | -5627 |
INPP4B | 1266 |
Complex I biogenesis
211 | |
---|---|
set | Complex I biogenesis |
setSize | 57 |
pANOVA | 1.31e-21 |
s.dist | 0.73 |
p.adjustANOVA | 5.88e-20 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-ND1 | 14765 |
MT-ND4 | 14762 |
NDUFB1 | 14751 |
NDUFV2 | 14736 |
NDUFS5 | 14733 |
NDUFA7 | 14731 |
NDUFA1 | 14715 |
NDUFA2 | 14713 |
NDUFAF3 | 14700 |
NDUFA3 | 14672 |
NDUFA12 | 14637 |
MT-ND6 | 14633 |
NDUFB8 | 14627 |
MT-ND5 | 14600 |
NDUFB4 | 14596 |
NDUFA13 | 14559 |
NDUFA6 | 14489 |
NDUFA8 | 14488 |
GeneID | Gene Rank |
---|---|
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-ND1 | 14765 |
MT-ND4 | 14762 |
NDUFB1 | 14751 |
NDUFV2 | 14736 |
NDUFS5 | 14733 |
NDUFA7 | 14731 |
NDUFA1 | 14715 |
NDUFA2 | 14713 |
NDUFAF3 | 14700 |
NDUFA3 | 14672 |
NDUFA12 | 14637 |
MT-ND6 | 14633 |
NDUFB8 | 14627 |
MT-ND5 | 14600 |
NDUFB4 | 14596 |
NDUFA13 | 14559 |
NDUFA6 | 14489 |
NDUFA8 | 14488 |
NDUFA11 | 14439 |
NDUFB9 | 14393 |
NDUFS8 | 14361 |
NDUFS3 | 14313 |
NDUFB10 | 14169 |
NDUFAF2 | 14161 |
NDUFB2 | 14098 |
NDUFB7 | 14030 |
NDUFC1 | 14023 |
NDUFS7 | 13997 |
NDUFV3 | 13890 |
COA1 | 13884 |
NDUFB6 | 13749 |
NDUFS6 | 13691 |
NDUFB3 | 13629 |
NDUFB11 | 13161 |
NDUFC2 | 12983 |
ACAD9 | 12951 |
NDUFA5 | 12663 |
NDUFAF6 | 12067 |
NDUFA9 | 11918 |
ECSIT | 11669 |
TMEM126B | 11368 |
NDUFAF5 | 11271 |
NDUFAF4 | 11158 |
NDUFAF1 | 11010 |
NDUFV1 | 10505 |
NDUFAF7 | 10405 |
NDUFAB1 | 10262 |
TMEM186 | 6002 |
NDUFS4 | 4585 |
TIMMDC1 | -3430 |
NDUFA10 | -4388 |
NDUFB5 | -5177 |
NDUFS1 | -7143 |
NUBPL | -8112 |
NDUFS2 | -10170 |
Beta-catenin phosphorylation cascade
111 | |
---|---|
set | Beta-catenin phosphorylation cascade |
setSize | 17 |
pANOVA | 1.86e-07 |
s.dist | -0.73 |
p.adjustANOVA | 1.37e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
FRAT2 | -2944 |
FRAT1 | -2426 |
GeneID | Gene Rank |
---|---|
CTNNB1 | -11218 |
PPP2R5D | -11215 |
CSNK1A1 | -10939 |
GSK3B | -10857 |
PPP2R5E | -10593 |
APC | -10339 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
AMER1 | -8228 |
AXIN1 | -7360 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
FRAT2 | -2944 |
FRAT1 | -2426 |
Signaling by PDGFRA extracellular domain mutants
1229 | |
---|---|
set | Signaling by PDGFRA extracellular domain mutants |
setSize | 12 |
pANOVA | 1.41e-05 |
s.dist | -0.724 |
p.adjustANOVA | 6.37e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
PIK3CB | -10352 |
STAT1 | -10345 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
PIK3R2 | -5950 |
HRAS | 13906 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
PIK3CB | -10352 |
STAT1 | -10345 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
PIK3R2 | -5950 |
HRAS | 13906 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
1230 | |
---|---|
set | Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants |
setSize | 12 |
pANOVA | 1.41e-05 |
s.dist | -0.724 |
p.adjustANOVA | 6.37e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
PIK3CB | -10352 |
STAT1 | -10345 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
PIK3R2 | -5950 |
HRAS | 13906 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
PIK3CB | -10352 |
STAT1 | -10345 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
PIK3R2 | -5950 |
HRAS | 13906 |
Non-integrin membrane-ECM interactions
782 | |
---|---|
set | Non-integrin membrane-ECM interactions |
setSize | 42 |
pANOVA | 8.66e-16 |
s.dist | -0.717 |
p.adjustANOVA | 2e-14 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ITGB3 | -11388 |
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
AGRN | -11307 |
ITGA6 | -11286 |
PDGFB | -11280 |
ITGAV | -11113 |
TNC | -10940 |
LAMB2 | -10934 |
ACTN1 | -10918 |
SDC4 | -10735 |
LAMA5 | -10549 |
PRKCA | -10498 |
LAMA4 | -10450 |
LAMB1 | -10431 |
ITGB5 | -10206 |
LAMA1 | -10193 |
HSPG2 | -9870 |
GeneID | Gene Rank |
---|---|
ITGB3 | -11388 |
LAMB3 | -11357 |
LAMC1 | -11329 |
ITGB1 | -11317 |
ITGA2 | -11315 |
AGRN | -11307 |
ITGA6 | -11286 |
PDGFB | -11280 |
ITGAV | -11113 |
TNC | -10940 |
LAMB2 | -10934 |
ACTN1 | -10918 |
SDC4 | -10735 |
LAMA5 | -10549 |
PRKCA | -10498 |
LAMA4 | -10450 |
LAMB1 | -10431 |
ITGB5 | -10206 |
LAMA1 | -10193 |
HSPG2 | -9870 |
TGFB1 | -8918 |
CASK | -8743 |
DAG1 | -8675 |
ITGB4 | -8554 |
DDR1 | -8308 |
DDR2 | -8017 |
NTN4 | -7805 |
THBS1 | -7620 |
PDGFA | -7510 |
SDC1 | -7206 |
SDC3 | -6862 |
LAMC2 | -6635 |
SDC2 | -5839 |
FGF2 | -5306 |
TRAPPC4 | -4762 |
LAMA2 | -4266 |
LAMC3 | -2462 |
NRXN1 | 150 |
DMD | 994 |
TTR | 2169 |
VTN | 4190 |
LAMA3 | 5212 |
Viral mRNA Translation
1429 | |
---|---|
set | Viral mRNA Translation |
setSize | 87 |
pANOVA | 6.88e-31 |
s.dist | 0.716 |
p.adjustANOVA | 8.48e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
RPL28 | 14550 |
RPS16 | 14529 |
RPS11 | 14523 |
RPL23 | 14510 |
RPL29 | 14503 |
RPL19 | 14499 |
RPL17 | 14497 |
RPS15 | 14496 |
RPS19 | 14476 |
RPL36 | 14456 |
RPL9 | 14394 |
RPL18 | 14388 |
RPL35A | 14377 |
RPL26L1 | 14358 |
RPS27L | 14338 |
RPS8 | 14333 |
RPLP1 | 14319 |
RPL6 | 14318 |
RPL36AL | 14290 |
RPS25 | 14278 |
RPL37A | 14263 |
RPL26 | 14246 |
RPS13 | 14240 |
RPL13 | 14186 |
RPL4 | 14145 |
RPS28 | 14071 |
RPS14 | 14014 |
RPS6 | 13991 |
RPL11 | 13968 |
RPS4X | 13824 |
RPL22L1 | 13806 |
RPL15 | 13737 |
RPS3 | 13719 |
RPL5 | 13658 |
RPL39 | 13544 |
RPL18A | 13507 |
RPS23 | 13488 |
RPL7A | 13286 |
UBA52 | 13217 |
RPS17 | 13209 |
RPL27 | 13203 |
RPS12 | 13178 |
RPSA | 13154 |
RPS27 | 12843 |
RPL30 | 12665 |
RPS10 | 12226 |
RPL8 | 11881 |
RPS9 | 11743 |
RPL22 | 11069 |
RPS29 | 10608 |
RPS2 | 10438 |
RPL3L | 9364 |
RPL13A | 8281 |
RPS27A | 7697 |
RPS3A | 6206 |
RPL21 | 6069 |
RPL10 | 1775 |
RPL3 | -4638 |
RPL23A | -5359 |
RPL41 | -6177 |
RPL39L | -6371 |
RPLP0 | -7433 |
DNAJC3 | -7651 |
GRSF1 | -7945 |
RPS5 | -8067 |
RPL10A | -8314 |
RPL7 | -8891 |
Peptide chain elongation
852 | |
---|---|
set | Peptide chain elongation |
setSize | 87 |
pANOVA | 7.93e-31 |
s.dist | 0.715 |
p.adjustANOVA | 9.02e-29 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
RPL28 | 14550 |
RPS16 | 14529 |
RPS11 | 14523 |
RPL23 | 14510 |
RPL29 | 14503 |
RPL19 | 14499 |
RPL17 | 14497 |
RPS15 | 14496 |
RPS19 | 14476 |
RPL36 | 14456 |
RPL9 | 14394 |
RPL18 | 14388 |
RPL35A | 14377 |
RPL26L1 | 14358 |
RPS27L | 14338 |
RPS8 | 14333 |
RPLP1 | 14319 |
RPL6 | 14318 |
RPL36AL | 14290 |
RPS25 | 14278 |
RPL37A | 14263 |
RPL26 | 14246 |
RPS13 | 14240 |
RPL13 | 14186 |
RPL4 | 14145 |
RPS28 | 14071 |
RPS14 | 14014 |
RPS6 | 13991 |
RPL11 | 13968 |
RPS4X | 13824 |
RPL22L1 | 13806 |
RPL15 | 13737 |
RPS3 | 13719 |
RPL5 | 13658 |
RPL39 | 13544 |
RPL18A | 13507 |
RPS23 | 13488 |
RPL7A | 13286 |
UBA52 | 13217 |
RPS17 | 13209 |
RPL27 | 13203 |
RPS12 | 13178 |
RPSA | 13154 |
RPS27 | 12843 |
RPL30 | 12665 |
RPS10 | 12226 |
RPL8 | 11881 |
RPS9 | 11743 |
RPL22 | 11069 |
RPS29 | 10608 |
RPS2 | 10438 |
RPL3L | 9364 |
RPL13A | 8281 |
RPS27A | 7697 |
RPS3A | 6206 |
RPL21 | 6069 |
RPL10 | 1775 |
RPL3 | -4638 |
RPL23A | -5359 |
RPL41 | -6177 |
RPL39L | -6371 |
RPLP0 | -7433 |
EEF1A1 | -7541 |
RPS5 | -8067 |
RPL10A | -8314 |
RPL7 | -8891 |
EEF2 | -8912 |
Signaling by PDGFR in disease
1228 | |
---|---|
set | Signaling by PDGFR in disease |
setSize | 19 |
pANOVA | 8.03e-08 |
s.dist | -0.711 |
p.adjustANOVA | 6.49e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
GOLGA4 | -10362 |
PIK3CB | -10352 |
STAT1 | -10345 |
STRN | -10181 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
KANK1 | -8588 |
WDR48 | -7167 |
PIK3R2 | -5950 |
ETV6 | -5676 |
KDR | -4602 |
FIP1L1 | -4599 |
HRAS | 13906 |
GeneID | Gene Rank |
---|---|
PDGFRA | -11184 |
STAT3 | -10772 |
GRB2 | -10626 |
GOLGA4 | -10362 |
PIK3CB | -10352 |
STAT1 | -10345 |
STRN | -10181 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
KRAS | -8721 |
KANK1 | -8588 |
WDR48 | -7167 |
PIK3R2 | -5950 |
ETV6 | -5676 |
KDR | -4602 |
FIP1L1 | -4599 |
HRAS | 13906 |
DCC mediated attractive signaling
245 | |
---|---|
set | DCC mediated attractive signaling |
setSize | 14 |
pANOVA | 4.24e-06 |
s.dist | -0.71 |
p.adjustANOVA | 2.22e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DOCK1 | -10879 |
PTK2 | -10250 |
NCK1 | -10095 |
NTN1 | -9908 |
ABLIM3 | -9474 |
DCC | -9460 |
WASL | -8689 |
CDC42 | -8552 |
SRC | -7386 |
TRIO | -6874 |
ABLIM1 | -5575 |
RAC1 | -3826 |
FYN | -3672 |
ABLIM2 | -1605 |
GeneID | Gene Rank |
---|---|
DOCK1 | -10879 |
PTK2 | -10250 |
NCK1 | -10095 |
NTN1 | -9908 |
ABLIM3 | -9474 |
DCC | -9460 |
WASL | -8689 |
CDC42 | -8552 |
SRC | -7386 |
TRIO | -6874 |
ABLIM1 | -5575 |
RAC1 | -3826 |
FYN | -3672 |
ABLIM2 | -1605 |
Activation of RAC1
46 | |
---|---|
set | Activation of RAC1 |
setSize | 13 |
pANOVA | 9.42e-06 |
s.dist | -0.709 |
p.adjustANOVA | 4.53e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ROBO1 | -10780 |
PAK2 | -10387 |
NCK1 | -10095 |
SOS1 | -10023 |
PAK1 | -9837 |
SOS2 | -9419 |
SLIT2 | -9320 |
PAK3 | -7519 |
PAK4 | -6964 |
NCK2 | -6728 |
PAK5 | -4128 |
RAC1 | -3826 |
PAK6 | 418 |
GeneID | Gene Rank |
---|---|
ROBO1 | -10780 |
PAK2 | -10387 |
NCK1 | -10095 |
SOS1 | -10023 |
PAK1 | -9837 |
SOS2 | -9419 |
SLIT2 | -9320 |
PAK3 | -7519 |
PAK4 | -6964 |
NCK2 | -6728 |
PAK5 | -4128 |
RAC1 | -3826 |
PAK6 | 418 |
FOXO-mediated transcription of cell cycle genes
402 | |
---|---|
set | FOXO-mediated transcription of cell cycle genes |
setSize | 15 |
pANOVA | 2.13e-06 |
s.dist | -0.707 |
p.adjustANOVA | 1.19e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CAV1 | -11260 |
CDKN1A | -11157 |
RBL2 | -11019 |
FOXO3 | -10708 |
SMAD4 | -10684 |
FOXO1 | -10285 |
CDKN1B | -9434 |
SMAD2 | -9233 |
BTG1 | -8909 |
CCNG2 | -8722 |
SMAD3 | -8597 |
FOXO4 | -7482 |
KLF4 | -7151 |
GADD45A | -1324 |
PCBP4 | 12731 |
GeneID | Gene Rank |
---|---|
CAV1 | -11260 |
CDKN1A | -11157 |
RBL2 | -11019 |
FOXO3 | -10708 |
SMAD4 | -10684 |
FOXO1 | -10285 |
CDKN1B | -9434 |
SMAD2 | -9233 |
BTG1 | -8909 |
CCNG2 | -8722 |
SMAD3 | -8597 |
FOXO4 | -7482 |
KLF4 | -7151 |
GADD45A | -1324 |
PCBP4 | 12731 |
HDMs demethylate histones
509 | |
---|---|
set | HDMs demethylate histones |
setSize | 22 |
pANOVA | 1.56e-08 |
s.dist | -0.696 |
p.adjustANOVA | 1.46e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KDM5B | -11193 |
KDM1B | -10910 |
KDM4C | -10902 |
KDM5A | -10282 |
KDM7A | -10275 |
KDM4B | -10186 |
KDM3B | -10032 |
KDM5C | -9480 |
KDM1A | -9433 |
KDM6A | -9040 |
KDM4A | -8582 |
JMJD6 | -8560 |
KDM6B | -8163 |
KDM2B | -8140 |
KDM2A | -7781 |
PHF8 | -7730 |
KDM3A | -7043 |
ARID5B | -6158 |
PHF2 | -5878 |
KDM4D | -5486 |
GeneID | Gene Rank |
---|---|
KDM5B | -11193.0 |
KDM1B | -10910.0 |
KDM4C | -10902.0 |
KDM5A | -10282.0 |
KDM7A | -10275.0 |
KDM4B | -10186.0 |
KDM3B | -10032.0 |
KDM5C | -9480.0 |
KDM1A | -9433.0 |
KDM6A | -9040.0 |
KDM4A | -8582.0 |
JMJD6 | -8560.0 |
KDM6B | -8163.0 |
KDM2B | -8140.0 |
KDM2A | -7781.0 |
PHF8 | -7730.0 |
KDM3A | -7043.0 |
ARID5B | -6158.0 |
PHF2 | -5878.0 |
KDM4D | -5486.0 |
H3C1 | 3171.0 |
H3C15 | 9115.5 |
Adenylate cyclase inhibitory pathway
61 | |
---|---|
set | Adenylate cyclase inhibitory pathway |
setSize | 12 |
pANOVA | 3.89e-05 |
s.dist | -0.686 |
p.adjustANOVA | 0.000158 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ADCY1 | -11110 |
GNAI3 | -10973 |
ADCY6 | -10943 |
ADCY7 | -10524 |
ADCY9 | -9337 |
GNAI1 | -9293 |
ADCY3 | -7605 |
ADCY5 | -6394 |
GNAL | -3771 |
GNAI2 | -3728 |
ADCY2 | -3004 |
ADCY4 | -619 |
GeneID | Gene Rank |
---|---|
ADCY1 | -11110 |
GNAI3 | -10973 |
ADCY6 | -10943 |
ADCY7 | -10524 |
ADCY9 | -9337 |
GNAI1 | -9293 |
ADCY3 | -7605 |
ADCY5 | -6394 |
GNAL | -3771 |
GNAI2 | -3728 |
ADCY2 | -3004 |
ADCY4 | -619 |
Eukaryotic Translation Termination
377 | |
---|---|
set | Eukaryotic Translation Termination |
setSize | 91 |
pANOVA | 1.29e-29 |
s.dist | 0.684 |
p.adjustANOVA | 1.27e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
TRMT112 | 14645 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
TRMT112 | 14645 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
RPL28 | 14550 |
RPS16 | 14529 |
RPS11 | 14523 |
RPL23 | 14510 |
RPL29 | 14503 |
RPL19 | 14499 |
RPL17 | 14497 |
RPS15 | 14496 |
RPS19 | 14476 |
RPL36 | 14456 |
RPL9 | 14394 |
RPL18 | 14388 |
RPL35A | 14377 |
RPL26L1 | 14358 |
RPS27L | 14338 |
RPS8 | 14333 |
RPLP1 | 14319 |
RPL6 | 14318 |
RPL36AL | 14290 |
RPS25 | 14278 |
RPL37A | 14263 |
RPL26 | 14246 |
RPS13 | 14240 |
RPL13 | 14186 |
RPL4 | 14145 |
RPS28 | 14071 |
RPS14 | 14014 |
RPS6 | 13991 |
RPL11 | 13968 |
RPS4X | 13824 |
RPL22L1 | 13806 |
RPL15 | 13737 |
RPS3 | 13719 |
RPL5 | 13658 |
RPL39 | 13544 |
RPL18A | 13507 |
RPS23 | 13488 |
RPL7A | 13286 |
UBA52 | 13217 |
RPS17 | 13209 |
RPL27 | 13203 |
RPS12 | 13178 |
RPSA | 13154 |
RPS27 | 12843 |
RPL30 | 12665 |
RPS10 | 12226 |
N6AMT1 | 12141 |
RPL8 | 11881 |
RPS9 | 11743 |
RPL22 | 11069 |
RPS29 | 10608 |
RPS2 | 10438 |
RPL3L | 9364 |
RPL13A | 8281 |
RPS27A | 7697 |
RPS3A | 6206 |
RPL21 | 6069 |
RPL10 | 1775 |
RPL3 | -4638 |
RPL23A | -5359 |
RPL41 | -6177 |
RPL39L | -6371 |
GSPT2 | -6829 |
RPLP0 | -7433 |
RPS5 | -8067 |
RPL10A | -8314 |
APEH | -8673 |
RPL7 | -8891 |
ETF1 | -9598 |
GSPT1 | -10363 |
Synthesis of PIPs at the late endosome membrane
1279 | |
---|---|
set | Synthesis of PIPs at the late endosome membrane |
setSize | 11 |
pANOVA | 8.49e-05 |
s.dist | -0.684 |
p.adjustANOVA | 0.000319 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PIKFYVE | -10408 |
PIK3C2A | -9621 |
PIK3R4 | -9524 |
MTMR2 | -9438 |
MTMR4 | -8979 |
MTMR9 | -8214 |
PIK3C3 | -7967 |
MTM1 | -7910 |
VAC14 | -7876 |
FIG4 | -5627 |
MTMR7 | 5748 |
GeneID | Gene Rank |
---|---|
PIKFYVE | -10408 |
PIK3C2A | -9621 |
PIK3R4 | -9524 |
MTMR2 | -9438 |
MTMR4 | -8979 |
MTMR9 | -8214 |
PIK3C3 | -7967 |
MTM1 | -7910 |
VAC14 | -7876 |
FIG4 | -5627 |
MTMR7 | 5748 |
ERK/MAPK targets
356 | |
---|---|
set | ERK/MAPK targets |
setSize | 22 |
pANOVA | 2.97e-08 |
s.dist | -0.682 |
p.adjustANOVA | 2.66e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DUSP4 | -11285 |
PPP2R5D | -11215 |
MAPK1 | -11008 |
DUSP7 | -10143 |
PPP2CB | -10130 |
RPS6KA3 | -9604 |
DUSP3 | -9469 |
MAPK3 | -9373 |
RPS6KA2 | -9203 |
RPS6KA1 | -7863 |
MAPK14 | -7640 |
PPP2CA | -7327 |
VRK3 | -7235 |
RPS6KA5 | -7165 |
DUSP6 | -6006 |
MEF2A | -5794 |
PPP2R1B | -5567 |
PPP2R1A | -4930 |
MAPK7 | -4670 |
MEF2C | -4363 |
GeneID | Gene Rank |
---|---|
DUSP4 | -11285 |
PPP2R5D | -11215 |
MAPK1 | -11008 |
DUSP7 | -10143 |
PPP2CB | -10130 |
RPS6KA3 | -9604 |
DUSP3 | -9469 |
MAPK3 | -9373 |
RPS6KA2 | -9203 |
RPS6KA1 | -7863 |
MAPK14 | -7640 |
PPP2CA | -7327 |
VRK3 | -7235 |
RPS6KA5 | -7165 |
DUSP6 | -6006 |
MEF2A | -5794 |
PPP2R1B | -5567 |
PPP2R1A | -4930 |
MAPK7 | -4670 |
MEF2C | -4363 |
ELK1 | -3995 |
MAPK11 | 4949 |
Selenocysteine synthesis
1146 | |
---|---|
set | Selenocysteine synthesis |
setSize | 91 |
pANOVA | 3.21e-29 |
s.dist | 0.68 |
p.adjustANOVA | 2.97e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
RPL28 | 14550 |
RPS16 | 14529 |
RPS11 | 14523 |
RPL23 | 14510 |
RPL29 | 14503 |
RPL19 | 14499 |
RPL17 | 14497 |
RPS15 | 14496 |
RPS19 | 14476 |
RPL36 | 14456 |
RPL9 | 14394 |
RPL18 | 14388 |
RPL35A | 14377 |
RPL26L1 | 14358 |
RPS27L | 14338 |
RPS8 | 14333 |
RPLP1 | 14319 |
RPL6 | 14318 |
RPL36AL | 14290 |
RPS25 | 14278 |
RPL37A | 14263 |
RPL26 | 14246 |
RPS13 | 14240 |
RPL13 | 14186 |
RPL4 | 14145 |
RPS28 | 14071 |
RPS14 | 14014 |
RPS6 | 13991 |
RPL11 | 13968 |
RPS4X | 13824 |
RPL22L1 | 13806 |
RPL15 | 13737 |
RPS3 | 13719 |
RPL5 | 13658 |
RPL39 | 13544 |
RPL18A | 13507 |
RPS23 | 13488 |
RPL7A | 13286 |
UBA52 | 13217 |
RPS17 | 13209 |
RPL27 | 13203 |
RPS12 | 13178 |
RPSA | 13154 |
RPS27 | 12843 |
RPL30 | 12665 |
RPS10 | 12226 |
RPL8 | 11881 |
RPS9 | 11743 |
RPL22 | 11069 |
PSTK | 10855 |
RPS29 | 10608 |
RPS2 | 10438 |
RPL3L | 9364 |
RPL13A | 8281 |
RPS27A | 7697 |
RPS3A | 6206 |
RPL21 | 6069 |
RPL10 | 1775 |
SEPHS2 | -372 |
EEFSEC | -3593 |
RPL3 | -4638 |
SEPSECS | -5198 |
RPL23A | -5359 |
RPL41 | -6177 |
RPL39L | -6371 |
SECISBP2 | -6619 |
RPLP0 | -7433 |
RPS5 | -8067 |
RPL10A | -8314 |
RPL7 | -8891 |
SARS1 | -9523 |
Eukaryotic Translation Elongation
375 | |
---|---|
set | Eukaryotic Translation Elongation |
setSize | 92 |
pANOVA | 5.39e-29 |
s.dist | 0.673 |
p.adjustANOVA | 4.43e-27 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
GeneID | Gene Rank |
---|---|
RPL38 | 14728 |
RPL14 | 14725 |
RPL37 | 14722 |
RPL31 | 14719 |
RPS26 | 14702 |
FAU | 14690 |
RPL35 | 14685 |
RPS20 | 14683 |
RPL27A | 14639 |
RPS24 | 14622 |
RPS21 | 14610 |
RPL36A | 14598 |
RPLP2 | 14587 |
RPL34 | 14584 |
RPL24 | 14583 |
RPL12 | 14580 |
RPS15A | 14577 |
RPS18 | 14572 |
RPL32 | 14571 |
RPS7 | 14564 |
RPL28 | 14550 |
RPS16 | 14529 |
RPS11 | 14523 |
RPL23 | 14510 |
RPL29 | 14503 |
RPL19 | 14499 |
RPL17 | 14497 |
RPS15 | 14496 |
RPS19 | 14476 |
RPL36 | 14456 |
RPL9 | 14394 |
RPL18 | 14388 |
RPL35A | 14377 |
RPL26L1 | 14358 |
RPS27L | 14338 |
RPS8 | 14333 |
RPLP1 | 14319 |
RPL6 | 14318 |
RPL36AL | 14290 |
RPS25 | 14278 |
RPL37A | 14263 |
RPL26 | 14246 |
RPS13 | 14240 |
RPL13 | 14186 |
RPL4 | 14145 |
RPS28 | 14071 |
RPS14 | 14014 |
RPS6 | 13991 |
RPL11 | 13968 |
RPS4X | 13824 |
RPL22L1 | 13806 |
RPL15 | 13737 |
RPS3 | 13719 |
RPL5 | 13658 |
RPL39 | 13544 |
RPL18A | 13507 |
RPS23 | 13488 |
RPL7A | 13286 |
UBA52 | 13217 |
RPS17 | 13209 |
RPL27 | 13203 |
RPS12 | 13178 |
RPSA | 13154 |
RPS27 | 12843 |
RPL30 | 12665 |
EEF1D | 12605 |
RPS10 | 12226 |
RPL8 | 11881 |
RPS9 | 11743 |
RPL22 | 11069 |
RPS29 | 10608 |
RPS2 | 10438 |
EEF1B2 | 9965 |
RPL3L | 9364 |
RPL13A | 8281 |
RPS27A | 7697 |
RPS3A | 6206 |
RPL21 | 6069 |
RPL10 | 1775 |
EEF1A2 | -3550 |
RPL3 | -4638 |
RPL23A | -5359 |
EEF1G | -5887 |
RPL41 | -6177 |
RPL39L | -6371 |
RPLP0 | -7433 |
EEF1A1 | -7541 |
RPS5 | -8067 |
RPL10A | -8314 |
EEF1A1P5 | -8339 |
RPL7 | -8891 |
EEF2 | -8912 |
Platelet sensitization by LDL
883 | |
---|---|
set | Platelet sensitization by LDL |
setSize | 15 |
pANOVA | 6.79e-06 |
s.dist | -0.671 |
p.adjustANOVA | 3.36e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
PPP2R5E | -10593 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
PTPN11 | -9492 |
PLA2G4A | -9352 |
LRP8 | -9305 |
PECAM1 | -7865 |
MAPK14 | -7640 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
PTPN6 | 6610 |
GeneID | Gene Rank |
---|---|
PPP2R5D | -11215 |
PPP2R5E | -10593 |
PPP2CB | -10130 |
PPP2R5A | -9682 |
PTPN11 | -9492 |
PLA2G4A | -9352 |
LRP8 | -9305 |
PECAM1 | -7865 |
MAPK14 | -7640 |
PPP2CA | -7327 |
PPP2R1B | -5567 |
PPP2R5C | -5404 |
PPP2R1A | -4930 |
PPP2R5B | -4321 |
PTPN6 | 6610 |
rRNA processing in the mitochondrion
1471 | |
---|---|
set | rRNA processing in the mitochondrion |
setSize | 24 |
pANOVA | 1.27e-08 |
s.dist | 0.671 |
p.adjustANOVA | 1.21e-07 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-CYB | 14772 |
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-CO2 | 14768 |
MT-CO1 | 14766 |
MT-ND1 | 14765 |
MT-CO3 | 14764 |
MT-ND4 | 14762 |
MT-ND4L | 14760 |
MT-RNR1 | 14757 |
MT-RNR2 | 14756 |
MT-ATP6 | 14606 |
MT-ND5 | 14600 |
MT-ATP8 | 14192 |
HSD17B10 | 13513 |
MRM2 | 12429 |
MTERF4 | 11344 |
MRM3 | 8243 |
MRM1 | 8199 |
TFB1M | 5669 |
GeneID | Gene Rank |
---|---|
MT-CYB | 14772 |
MT-ND2 | 14771 |
MT-ND3 | 14769 |
MT-CO2 | 14768 |
MT-CO1 | 14766 |
MT-ND1 | 14765 |
MT-CO3 | 14764 |
MT-ND4 | 14762 |
MT-ND4L | 14760 |
MT-RNR1 | 14757 |
MT-RNR2 | 14756 |
MT-ATP6 | 14606 |
MT-ND5 | 14600 |
MT-ATP8 | 14192 |
HSD17B10 | 13513 |
MRM2 | 12429 |
MTERF4 | 11344 |
MRM3 | 8243 |
MRM1 | 8199 |
TFB1M | 5669 |
TRMT10C | 4645 |
ELAC2 | -1278 |
PRORP | -8469 |
NSUN4 | -9122 |
Signaling by FLT3 fusion proteins
1200 | |
---|---|
set | Signaling by FLT3 fusion proteins |
setSize | 19 |
pANOVA | 4.21e-07 |
s.dist | -0.67 |
p.adjustANOVA | 2.92e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CDKN1A | -11157 |
SPTBN1 | -11088 |
GRB2 | -10626 |
TRIP11 | -10478 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
STAT5B | -9035 |
GOLGB1 | -8910 |
GAB2 | -8835 |
KRAS | -8721 |
ZMYM2 | -6904 |
PIM1 | -6662 |
ETV6 | -5676 |
MYO18A | -4059 |
NOX4 | -3988 |
STAT5A | -2885 |
HRAS | 13906 |
GeneID | Gene Rank |
---|---|
CDKN1A | -11157 |
SPTBN1 | -11088 |
GRB2 | -10626 |
TRIP11 | -10478 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
STAT5B | -9035 |
GOLGB1 | -8910 |
GAB2 | -8835 |
KRAS | -8721 |
ZMYM2 | -6904 |
PIM1 | -6662 |
ETV6 | -5676 |
MYO18A | -4059 |
NOX4 | -3988 |
STAT5A | -2885 |
HRAS | 13906 |
Signaling by FGFR3 fusions in cancer
1194 | |
---|---|
set | Signaling by FGFR3 fusions in cancer |
setSize | 10 |
pANOVA | 0.000258 |
s.dist | -0.667 |
p.adjustANOVA | 0.000889 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GRB2 | -10626 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
FRS2 | -9420 |
KRAS | -8721 |
GAB1 | -8325 |
FGFR3 | -7938 |
HRAS | 13906 |
GeneID | Gene Rank |
---|---|
GRB2 | -10626 |
SOS1 | -10023 |
NRAS | -9826 |
PIK3CA | -9701 |
PIK3R1 | -9670 |
FRS2 | -9420 |
KRAS | -8721 |
GAB1 | -8325 |
FGFR3 | -7938 |
HRAS | 13906 |
Defective B4GALT7 causes EDS, progeroid type
267 | |
---|---|
set | Defective B4GALT7 causes EDS, progeroid type |
setSize | 18 |
pANOVA | 1.16e-06 |
s.dist | -0.662 |
p.adjustANOVA | 7.07e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CSPG4 | -11375 |
VCAN | -11365 |
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
SDC2 | -5839 |
B4GALT7 | -5082 |
BCAN | -4115 |
GPC2 | -3380 |
CSPG5 | -3264 |
GPC5 | -3235 |
NCAN | -1857 |
BGN | -1384 |
GeneID | Gene Rank |
---|---|
CSPG4 | -11375 |
VCAN | -11365 |
GPC6 | -11331 |
AGRN | -11307 |
SDC4 | -10735 |
HSPG2 | -9870 |
GPC4 | -9044 |
GPC1 | -8024 |
SDC1 | -7206 |
SDC3 | -6862 |
SDC2 | -5839 |
B4GALT7 | -5082 |
BCAN | -4115 |
GPC2 | -3380 |
CSPG5 | -3264 |
GPC5 | -3235 |
NCAN | -1857 |
BGN | -1384 |
ALK mutants bind TKIs
10 | |
---|---|
set | ALK mutants bind TKIs |
setSize | 12 |
pANOVA | 7.86e-05 |
s.dist | -0.658 |
p.adjustANOVA | 0.000299 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CLTC | -11303 |
EIF2AK3 | -11053 |
BIRC6 | -10900 |
PRKAR1A | -10732 |
STRN | -10181 |
FN1 | -9930 |
PPM1B | -8702 |
HIP1 | -8158 |
ALK | -6779 |
EML4 | -5902 |
BCL11A | -2682 |
NPM1 | 13339 |
GeneID | Gene Rank |
---|---|
CLTC | -11303 |
EIF2AK3 | -11053 |
BIRC6 | -10900 |
PRKAR1A | -10732 |
STRN | -10181 |
FN1 | -9930 |
PPM1B | -8702 |
HIP1 | -8158 |
ALK | -6779 |
EML4 | -5902 |
BCL11A | -2682 |
NPM1 | 13339 |
Interleukin-6 signaling
604 | |
---|---|
set | Interleukin-6 signaling |
setSize | 11 |
pANOVA | 0.000174 |
s.dist | -0.654 |
p.adjustANOVA | 0.00062 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IL6R | -11298 |
CBL | -11081 |
IL6ST | -10890 |
STAT3 | -10772 |
STAT1 | -10345 |
JAK1 | -9971 |
PTPN11 | -9492 |
JAK2 | -6732 |
SOCS3 | -3875 |
TYK2 | -2862 |
IL6 | 11896 |
GeneID | Gene Rank |
---|---|
IL6R | -11298 |
CBL | -11081 |
IL6ST | -10890 |
STAT3 | -10772 |
STAT1 | -10345 |
JAK1 | -9971 |
PTPN11 | -9492 |
JAK2 | -6732 |
SOCS3 | -3875 |
TYK2 | -2862 |
IL6 | 11896 |
Cell-extracellular matrix interactions
171 | |
---|---|
set | Cell-extracellular matrix interactions |
setSize | 16 |
pANOVA | 6.27e-06 |
s.dist | -0.652 |
p.adjustANOVA | 3.11e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FLNA | -11346 |
FLNC | -11326 |
ITGB1 | -11317 |
FERMT2 | -11153 |
ACTN1 | -10918 |
LIMS1 | -10700 |
FBLIM1 | -9992 |
PARVB | -8860 |
PXN | -8213 |
ARHGEF6 | -7685 |
PARVA | -6809 |
ILK | -6798 |
VASP | -6675 |
LIMS2 | -4619 |
RSU1 | 6816 |
TESK1 | 10249 |
GeneID | Gene Rank |
---|---|
FLNA | -11346 |
FLNC | -11326 |
ITGB1 | -11317 |
FERMT2 | -11153 |
ACTN1 | -10918 |
LIMS1 | -10700 |
FBLIM1 | -9992 |
PARVB | -8860 |
PXN | -8213 |
ARHGEF6 | -7685 |
PARVA | -6809 |
ILK | -6798 |
VASP | -6675 |
LIMS2 | -4619 |
RSU1 | 6816 |
TESK1 | 10249 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.1 (2022-06-23)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.1 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] stats4 stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.3.0 GGally_2.1.2
## [3] gtools_3.9.2.2 echarts4r_0.4.4
## [5] beeswarm_0.4.0 vioplot_0.3.7
## [7] sm_2.2-5.7 kableExtra_1.3.4
## [9] topconfects_1.12.0 limma_3.52.1
## [11] eulerr_6.1.1 mitch_1.8.0
## [13] MASS_7.3-58 fgsea_1.22.0
## [15] gplots_3.1.3 DESeq2_1.36.0
## [17] SummarizedExperiment_1.26.1 Biobase_2.56.0
## [19] MatrixGenerics_1.8.0 matrixStats_0.62.0
## [21] GenomicRanges_1.48.0 GenomeInfoDb_1.32.2
## [23] IRanges_2.30.0 S4Vectors_0.34.0
## [25] BiocGenerics_0.42.0 reshape2_1.4.4
## [27] forcats_0.5.1 stringr_1.4.0
## [29] dplyr_1.0.9 purrr_0.3.4
## [31] readr_2.1.2 tidyr_1.2.0
## [33] tibble_3.1.7 ggplot2_3.3.6
## [35] tidyverse_1.3.1 zoo_1.8-10
##
## loaded via a namespace (and not attached):
## [1] readxl_1.4.0 backports_1.4.1 fastmatch_1.1-3
## [4] systemfonts_1.0.4 plyr_1.8.7 polylabelr_0.2.0
## [7] splines_4.2.1 BiocParallel_1.30.3 digest_0.6.29
## [10] htmltools_0.5.2 fansi_1.0.3 magrittr_2.0.3
## [13] memoise_2.0.1 tzdb_0.3.0 Biostrings_2.64.0
## [16] annotate_1.74.0 modelr_0.1.8 svglite_2.1.0
## [19] colorspace_2.0-3 blob_1.2.3 rvest_1.0.2
## [22] haven_2.5.0 xfun_0.31 crayon_1.5.1
## [25] RCurl_1.98-1.7 jsonlite_1.8.0 genefilter_1.78.0
## [28] survival_3.4-0 glue_1.6.2 polyclip_1.10-0
## [31] gtable_0.3.0 zlibbioc_1.42.0 XVector_0.36.0
## [34] webshot_0.5.3 DelayedArray_0.22.0 scales_1.2.0
## [37] DBI_1.1.3 Rcpp_1.0.8.3 viridisLite_0.4.0
## [40] xtable_1.8-4 bit_4.0.4 htmlwidgets_1.5.4
## [43] httr_1.4.3 RColorBrewer_1.1-3 ellipsis_0.3.2
## [46] pkgconfig_2.0.3 reshape_0.8.9 XML_3.99-0.10
## [49] sass_0.4.1 dbplyr_2.2.1 locfit_1.5-9.5
## [52] utf8_1.2.2 tidyselect_1.1.2 rlang_1.0.3
## [55] later_1.3.0 AnnotationDbi_1.58.0 munsell_0.5.0
## [58] cellranger_1.1.0 tools_4.2.1 cachem_1.0.6
## [61] cli_3.3.0 generics_0.1.2 RSQLite_2.2.14
## [64] broom_0.8.0 evaluate_0.15 fastmap_1.1.0
## [67] yaml_2.3.5 knitr_1.39 bit64_4.0.5
## [70] fs_1.5.2 caTools_1.18.2 KEGGREST_1.36.2
## [73] mime_0.12 xml2_1.3.3 compiler_4.2.1
## [76] rstudioapi_0.13 png_0.1-7 reprex_2.0.1
## [79] geneplotter_1.74.0 bslib_0.3.1 stringi_1.7.6
## [82] highr_0.9 lattice_0.20-45 Matrix_1.4-1
## [85] vctrs_0.4.1 pillar_1.7.0 lifecycle_1.0.1
## [88] jquerylib_0.1.4 data.table_1.14.2 bitops_1.0-7
## [91] httpuv_1.6.5 R6_2.5.1 promises_1.2.0.1
## [94] KernSmooth_2.23-20 gridExtra_2.3 codetools_0.2-18
## [97] assertthat_0.2.1 withr_2.5.0 GenomeInfoDbData_1.2.8
## [100] parallel_4.2.1 hms_1.1.1 grid_4.2.1
## [103] rmarkdown_2.14 shiny_1.7.1 lubridate_1.8.0
END of report